

1 fair extent as to again if the indication is going after
2 drug treatment experience, drug resistant population, the
3 bar is a lot higher than if you are doing a general
4 "population" and then perhaps retrospectively looking at
5 subgroups.

6 Would anyone like to sort of describe this
7 further? I am not sure we really can.

8 Dr. Charache.

9 DR. CHARACHE: I would say it depends.

10 DR. HAMMER: And we all concur with that, I think.

11 I think we have given you guidance on this. If we
12 can move on.

13 Question 3. What type of in vitro and clinical
14 data should be provided by drug sponsors to characterize an
15 antiretroviral's ability to induce resistance and cross-
16 resistance?

17 In your discussion, please include details such as
18 methods, patient subsets, number of patients, number of
19 isolates, duration of treatment, number of drugs,
20 definitions for assessing treatment response, etc.

21 We also touched upon this I think in the scenarios
22 about resistance and cross-resistance.

23 Would anyone like to add to this, because we have
24 really talked about this. Certainly, I think everyone is in
25 agreement that the lack of ability to induce resistance or

1 cross-resistance, the bar for that claim is very, very high.
2 The issue of a little more slowly developing resistance, I
3 think can be made based on genetic barriers and the
4 mutations that come in, in vitro and in clinical isolates.

5 The clinical trials have to be well designed to
6 really assess failures on treatment when they are in salvage
7 regimens to really start looking at the issue of cross-
8 resistance to other agents in the class.

9 I am not sure we can be more specific.

10 Dr. Pettinelli.

11 DR. PETTINELLI: Just as a general statement,
12 however, I think it will be important to be able to evaluate
13 all the drug available in the specific class. The
14 recommendation will be really to look in terms of cross-
15 resistance all the available agent.

16 DR. HAMMER: I was looking at Dr. Stanley's
17 comments to me to see if there was something to add.

18 Did anyone else want to add to Question 3?

19 Dr. Mayers.

20 DR. MAYERS: I think that the in vitro data can
21 clearly can tell you drugs you don't want to randomize to
22 the patient the next time around, but I don't think in vitro
23 data necessarily helps you for activity, so that I think
24 that it would be very useful if there could be some
25 mechanism developed for the companies, where there appears

1 not to be cross-resistance, to arrange to randomize the next
2 round off their large Phase II's into those classes of drugs
3 to get that answer, because right now we are really not
4 getting the randomization until the next round of the
5 patients, and the next round cleanly for these drugs, so
6 that there is a lot of claims based on in vitro data, and
7 that there is very little true efficacy data, which I think
8 is the gold standard here.

9 DR. HAMMER: Although there is sequential
10 selection bias in such studies.

11 Dr. Mathews.

12 DR. MATHEWS: One thing that we haven't really
13 emphasized as much, although Trip made a comment that I
14 think is important, is that the resistance and cross-
15 resistance information I don't think can be a substitute for
16 the treatment history, the previous treatment history,
17 because of all of the problems, and cross-sectional looks at
18 resistance.

19 So, collecting and analyzing the treatment history
20 in conjunction with the resistance data, I think until we
21 get further information validating the resistance data, it
22 is going to be very important.

23 DR. HAMMER: Although I would mention one. It is
24 only one study, and it was a relatively small study of Mike
25 Saag at ICAC, 71 patients -- and I think the resistance

1 testing was done retrospectively, but in a multi-variant
2 analysis, phenotypic testing, when that was included,
3 antiretroviral treatment history was no longer a significant
4 predictor. However, it was just a single study, and it was
5 only 71 subjects. I think the point is very well taken.

6 The next question, we really should try to spend
7 some time on, because this is important. It has come up,
8 and it is really where many of the issues of resistance and
9 cross-resistance have come out in academic and company
10 studies.

11 The fourth question is: What types of
12 postmarketing evaluations regarding drug resistance/cross
13 resistance should be conducted?

14 This, we really haven't wrestled with, and it is
15 an important issue because that is where the larger numbers
16 are treated, and these issues come out.

17 Dr. Pettinelli.

18 DR. PETTINELLI: Just one comment. After
19 accelerated approval, I think that some of the patients are
20 being followed up for a longer term, and I believe it will
21 be essential to also evaluate those patients in terms of
22 their genotypic/phenotypic profile.

23 DR. HAMMER: Also, I would like to read into the
24 record Dr. Stanley's comment on Question 4.

25 "There should be a plan up-front to continue to

1 monitor certain subsets of patients for development of
2 resistance or cross-resistance. For instance, a sponsor
3 could establish an agreement with certain clinicians to
4 perform genotyping and phenotyping on any of their patients
5 who go on the drug and who then fail."

6 I think there are a number of research groups,
7 practice research groups and academic research groups and
8 others who would be even more than happy to participate in
9 such studies.

10 That last comment is my editorial comment.

11 Dr. Charache.

12 DR. CHARACHE: It would probably be important to
13 also test a subset of those who did not fail, so you can
14 better interpret some of the changes.

15 DR. HAMMER: You mean at baseline, because at
16 least with the current techniques, we can't amplify the
17 virus in those who succeed by our most critical definitions
18 of success.

19 DR. CHARACHE: You are absolutely right. Take it
20 back.

21 DR. MURRAY: I have a question regarding maybe --
22 well, I don't know, since Dr. Stanley made it, I don't know
23 if anybody can answer this -- so, a company does some
24 postmarketing surveillance, it is not going to be
25 controlled, what do we do with the information? What can

1 they say about it?

2 DR. HAMMER: I don't have Dr. Stanley's cell phone
3 number. In Phase IV data, I think what you can try to do,
4 and I think what she has indicating, is to really set up a
5 number of cohorts of reasonable sizes where although it is
6 uncontrolled information, you have got data on treatment
7 experience, treatment history, follow-up information, and
8 marker data, and try to make thoughts about really, and then
9 be able to grab the isolates and study them.

10 So, I think that the cohort information that one
11 could develop through these sorts of things, it wouldn't
12 take more than perhaps several hundreds of patients really,
13 can be quite valuable.

14 So, it is uncontrolled, but it is really the
15 length the follow-up and the completeness of the dataset and
16 the virology analyses that can correlate, that would be of
17 greatest use.

18 DR. MURRAY: And label-worthy?

19 DR. HAMMER: Potentially label-worthy, but we
20 would already be in Phase IV, so this would be an amendment
21 to the label rather than a primary indication. I would
22 think that that kind of data would be supportive
23 information, and, yes, could be label-worthy because it may
24 be supportive of the smaller dataset that says a drug is
25 helpful in a certain population, or it may actually modify

1 the label to back off.

2 Dr. Yogev.

3 DR. YOGEV: I was just wondering if this is not
4 the time to think about the clearinghouse, like we have
5 immunization, an agency, you said. Because we are going to
6 do more and more often, as clinician, to identify for
7 ourself why the patient failed, we should have a place where
8 we can send those results to be verified or whatever, and
9 that is how you can collect them there.

10 A company now, for example, are following pregnant
11 women who are receiving their drug to see if there are any
12 side effects, and that is how they will change or at least
13 inform the rest of us. I think because it is so
14 complicated, and because we are individually doing it, we
15 need a place maybe to think about it, it will be part of the
16 postmarketing, to have a place to send those, which we
17 identify resistant as the reason for the failure, to send
18 over the accumulated data.

19 DR. HAMMER: It is a good idea, but it just seems
20 like an overwhelming undertaking if we have 30, 40,
21 sometimes, in some populations, 50 percent failures of
22 treated patients. The sheer numbers are extraordinary, and
23 if one doesn't control for the data that is given, and it's
24 passive acquisition, I would be concerned about really what
25 conclusions could be drawn outside of the kinds of cohort

1 populations that are being described now. The numbers are
2 just overwhelming as far as failures in this country on
3 antiretroviral therapy.

4 DR. YOGEV: I was not talking about the failure
5 per se, I was talking about an investigator tested, found
6 out they are resistant, to have a place that will collect
7 them, because then you find out suddenly that there are 300
8 cases, nobody knows how much, because the cohort might be
9 very difficult to follow, because over there they
10 investigate all the failures. All I am talking about is
11 collect the resistance, verify them, and then you know what
12 you have.

13 DR. HAMMER: That is a good point. I think we
14 have actually a little bit of handle on that from the two
15 commercial groups that are doing phenotyping, have put out
16 some very impressive information that have helped evaluate,
17 that is selected by obviously what they receive, but it
18 gives you an indication at least in patients who are failing
19 and getting resistance testing what it looks like. So, that
20 could be taken further in a more independent fashion I think
21 is what you are suggesting.

22 Other comments on Question 4?

23 Question 5, which I think we can deal with very
24 quickly, is: Please comment on the feasibility and
25 limitations of incorporating "real-time" HIV resistance

1 testing in clinical protocols.

2 I will ask Dr. Mayers to answer this in three
3 words.

4 DR. MAYERS: It is doable. I think that actually
5 real-time resistance testing costs the same amount as post-
6 hoc resistance testing, if you define what you want to test,
7 and I think that actually there is a real utility to the
8 industry to collect baseline samples to look at the
9 resistance in their failure patients in their early studies
10 to understand whether their drug is working and how it fails
11 to tailor and design their Phase III studies.

12 So, I think it is of great utility to the company,
13 and it is a reason for the patient to stay in the study
14 because they are going to get some data back that is
15 potentially of use to them.

16 So, I think that this has real utility in
17 understanding your drug's success and failure and designing
18 your Phase III studies and helping to manage your patients
19 when they fail the study. I personally don't see a drawback
20 to introducing this if you have a plan set up of evaluations
21 for your drug. Doing it real-time just gives real-time data
22 rather than data a year down the road.

23 DR. HAMMER: Dr. Mathews.

24 DR. MATHEWS: Several times this issue has come up
25 about doing resistance testing in people that are succeeding

1 on therapy and how it is not feasible. I just wonder what
2 your thoughts are on looking at the idea of periodically
3 withdrawing therapy even on trials to sample rebound virus,
4 and see what the mutational patterns are.

5 DR. HAMMER: It certainly is feasible to do. I
6 think there are issues of safety. One has to decide what
7 you are doing that for, and to me, there are issues still of
8 safety. Within a clinical protocol, it is not unreasonable,
9 but given the fact that you are re-seeding targets and you
10 may drop your CD4 count, it is a bit problematic to me,
11 although obviously, it needs to be studied further.

12 Mr. Harrington.

13 MR. HARRINGTON: TAG co-sponsored a workshop on
14 this topic in the summer, and Dr. Miller was there. I think
15 there is going to be plenty of protocols that are going to
16 be looking at structured treatment interruptions in the
17 suppressed and unsuppressed, and first line and salvage
18 population.

19 I think we might get some answers out of that, and
20 I would think it probably wouldn't be clinically ready for
21 prime time other than in the context of a study that had a
22 good hypothesis behind it.

23 DR. HAMMER: I think Chris's point is it is a good
24 way to get an isolate approximate to the regimen to see what
25 it looks like. I think we will get information about this

1 at the Retrovirus Conference and subsequently.

2 Other comments?

3 Dr. Gulick.

4 DR. GULICK: One thing that has been said before
5 should be restated is that the use of resistance testing on
6 study should, at the very least, be up to where the level of
7 where clinical care is, as we have learned from viral load
8 and the use of real-time viral load testing, which suddenly
9 became really the only way to do it, because that is what
10 was being done in the community. The same principle
11 probably needs to be applied here.

12 DR. HAMMER: Does anyone on the committee see that
13 there is a real block to the feasibility of real-time
14 testing in the setting of drug development and clinical
15 protocols?

16 Dr. Jackson.

17 DR. JACKSON: Maybe Doug could comment, but I
18 agree the utility is clearly there for a number of reasons,
19 out in terms of the feasibility, obviously, you need to get
20 a viral load, as well, at the same time before you waste
21 your time trying to amplify something that isn't there, but
22 what has sort of been the range of turn-around times that
23 you have been able to achieve in real-time for these
24 protocols?

25 DR. MAYERS: We are turning them around in about

1 10 days right now on average.

2 DR. JACKSON: On average.

3 DR. MAYERS: On average. The problem is if
4 everything amplifies right for you the first time, it's a
5 three to five day procedure.

6 DR. JACKSON: But when they don't --

7 DR. MAYERS: It can be ugly, and we do go to back-
8 up primers and back-up to get sequence.

9 I think that the way we are doing it in the CPCRA,
10 which I think is reasonable, is we bring the sample in, we
11 do a viral load. As soon as the viral load hits the cut
12 point, you send the sample in for sequencing. Since it is
13 the same labs, that is a fairly rapid process, and it can be
14 done out of the same vial of plasma.

15 It is feasible if you are set up to do it. I
16 think that the new technologies, especially the rapidly
17 improving ability to put it all together quickly and check
18 it, what used to be eight hours of somebody's day is now
19 significantly shortened.

20 But the turn-around times, I think in the next
21 year are going to be 96 hours, you know, five to seven days
22 is going to be expectation, five to seven working days will
23 be the expectation of getting this data back. It is getting
24 faster and faster. The technology is getting better.

25 DR. JACKSON: Although obviously, there are always

1 problems that take sometimes longer, two to three weeks
2 even, and, of course, that is in the laboratory. Our
3 experience with viral load testing, of course, the real
4 delay is getting the specimens from the sites with the
5 correct labeling and everything else.

6 So, I think it is important for sponsors or
7 investigators, in designing trials with real-time testing,
8 that if there are randomization points, that we have to be
9 very realistic in terms of how much time is really necessary
10 to do real-time testing, taking into account all these
11 factors.

12 DR. MAYERS: If you are asking from when the blood
13 is drawn to when the result goes out to the field, right now
14 it is taking us -- because we ship weekly and there is an
15 average of six days between the blood draw and actually
16 getting it to the lab -- it is a 13-day turn-around time
17 from the shipment of the sample coming in to it going back
18 out to the field, and it is probably on the order of 21 to
19 24 days between the sample being drawn, the viral load and
20 the genotype getting back in the current system.

21 I think that you may not, people may not be
22 willing to wait that long, you are right. On the other
23 hand, I think that if the issue is, is it worth the company
24 getting the data on a real-time basis, I think it actually
25 has pragmatic utility to the companies.

1 I have a little more concern actually about the
2 issue of doing genotyping on the way in for a drug where I
3 don't know what its responses are going to be, because you
4 are presuming you know how the drug is going to work before
5 you have ever put it into people, and that is a limitation.

6 If you assume that you know what is going to
7 happen before you do the study, you can limit yourself from
8 finding out data that is very useful. So, I think I am a
9 little less comfortable unless there is 100 percent
10 resistance between the two drugs.

11 In my early, first-time failure studies I am going
12 to limit the patients until I get some data to support that
13 knowledge. I think you can prejudge yourself out of utility
14 unless you at least do a little clinical data to make your
15 decisions.

16 DR. HAMMER: I think we can rely on the sponsors
17 not to do that. We will have their drugs before they have
18 adequately tested them.

19 Dr. Jolson.

20 DR. JOLSON: I had another feasibility question.
21 Maybe Doug could answer it.

22 We are often criticized that our requirements are
23 burdensome, financially burdensome, particularly for smaller
24 companies. What we are talking about I think at this
25 meeting involves more testing than is currently being done

1 in clinical trials.

2 What would you -- and this is just an estimate --
3 the incremental cost is when you consider doing at least
4 baseline resistance testing on most trial participants, and
5 then resampling again at the time of failure, how much
6 additional cost should we be anticipating that will be
7 incurred?

8 DR. MAYERS: Phenotype and genotype together?

9 DR. JOLSON: Well, maybe you can tell me for each
10 one.

11 DR. MAYERS: It is running about \$385 to 400 --
12 around \$400 a sample, a little bit less, for genotyping of
13 the protease and RT gene. The companies are just
14 establishing pricings for phenotyping, but my understanding
15 is it is going to be in \$750 to \$900 range.

16 So, you are probably adding about \$2,500 to that
17 company for that patient who fails. For the ones who don't
18 fail, obviously, not as much money. On the other hand, my
19 counter to that would be that if you don't do this testing,
20 and you go into your Phase III program, you are going into
21 your Phase III program blind, and what is the cost of doing
22 1,000-patient trial in the wrong patient group because you
23 didn't have the data to select the right patients for your
24 large studies.

25 By investing up-front in your Phase I/II program,

1 and looking at where does my drug work best in experienced
2 patients, how does my drug fail in inexperienced patients,
3 that allows you to design a Phase II/III program that
4 efficiently targets your drug to the right patient groups.

5 DR. YOGEV: Do you really need both of them? We
6 just thought that it's so nicely correlated, it would be
7 enough, the genotype only, for example, in Phase I/II.

8 DR. MAYERS: I think in Phase I/II, you are going
9 to have to get both data, because it's a new drug. You
10 don't know what the relationships are.

11 I think that you can then, once you have enough
12 Phase I/II data, make an efficient strategy as to how you
13 are going to go beyond that, but I really do think, in Phase
14 I and II, it pays off to invest the money in those patients.

15 DR. HAMMER: I would agree.

16 Dr. Jackson.

17 DR. JACKSON: Getting back, if a company is going
18 to make a claim about resistance, and efficacy against
19 resistance, I think you have to have phenotypic resistance
20 data.

21 DR. HAMMER: That makes sense, internally logical.

22 Are there other comments on Question 5?

23 Since we are running ahead, I have been asked to
24 recap this meeting, which I think is just a slightly
25 daunting request, but at lunchtime I put a few slides

1 together and I will try quickly to do that. I think this is
2 intended really for the potential sponsors in the audience.
3 I would say that, in advance, that any comment I am going to
4 make has not been vetted with my colleagues here, it is
5 really personal sense of this, and is somewhat generic. The
6 details need to be worked out, I think, as each drug comes
7 through development, but maybe it will create a summation
8 for this meeting.

9 Recap and Summation of the Meeting

10 [Slide.1

11 DR. HAMMER: First, I think the first important
12 thing at the recap is I think thanks should go to Heidi
13 Jolson and Jeff Murray and their colleagues for putting this
14 meeting together.

15 I think I can speak for the committee that it has
16 been a privilege to participate and particularly to hear the
17 wealth of data that has been presented, some of it, and a
18 fair amount of it, for the first time in this venue.

19 I think and I hope that we can look back at this
20 as a turning point, if you will, in the resistance field in
21 HIV drug development, much as the RNA Symposium was the
22 turning point for drug development in clinical trials, as
23 well.

24 [Slide.]

25 So, I started the meeting recap with a non-

1 controversial question and answer, which I think is at least
2 where we should start.

3 Does resistance testing have a role in drug
4 development?

5 I think the consistent message from the group
6 subject to disagreement here is an emphatic yes. It not
7 only does, but should have a role.

8 [Slide.]

9 I think there is also general agreement that both
10 genotypic and phenotypic testing are important. I think it
11 is also well to remember that we get wound up in specific
12 assays, but that no single assay, genotypic or phenotypic,
13 has been individually discussed or should or can be
14 recommended.

15 I think there are pros and cons to each of the
16 assay and the formats. The technical and interpretive
17 limitations have been well outlined, particularly in Doug
18 Richman's talk, and that, as everything else in science and
19 development, you need to choose which assay is most
20 appropriate to answer the question that is at hand.

21 I think whether you are doing genotyping or
22 phenotyping and which platform you are using and which assay
23 you are using, you need to think about what question you are
24 asking and what answers you want.

25 I also think in relation to NDAs that come in, and

1 certainly data that is seen by this committee, that
2 validation data for any assay that is used needs to be
3 provided. This can be more easily done, obviously, if there
4 is a well validated commercial assay, but I think for in-
5 house assays, we need to know really what their performance
6 characteristics are.

7 I think the agency will demand that, and as we
8 have talked about, standardization is going to be increasing
9 important. It may be externally imposed, as well.

10 [Slide.]

11 So, yes, I think NDAs should include resistance
12 data. They already do essentially, at least the ones that
13 this committee has seen in the more recent times, and that
14 is not going to change.

15 There is an issue of what level, I think, and it
16 is termed at sort of the minimal level, and again I say this
17 as personal. This is not committee-wide, this is not the
18 agency, this is just me from this meeting.

19 At the preclinical level, I think we have talked
20 about this, that at the minimum, we want to see drug passage
21 studies where passage in the presence of drug with genotypic
22 and phenotypic characterization of mutants is performed, and
23 then the testing of the significance of those mutations,
24 there would be a site-directed mutagenesis.

25 For companies that have been well involved in

1 this, this is old hat. For companies that are thinking
2 about getting into this area, this may not be so old. But I
3 think it is important, and again, in the era of non-
4 monotherapy, the in vitro data and trying to characterize
5 mutations and what they do in vitro, and potentially, as we
6 talked about in some animal studies, but certainly in vitro,
7 it is going to be important because the clinical data will
8 be increasingly complex.

9 The second minimum characteristic is to test the
10 drug against a panel of well-characterized isolates. We
11 talked about this a lot. What we haven't really wrestled
12 with is what the size of that panel should be. I threw out
13 a number, I think somewhere between 50 and 100 isolates is
14 what we should think about, laboratory and clinical strains,
15 and certainly if you are looking at an agent against drug
16 resistant mutants, you are looking at a panel closer to 100
17 or more.

18 I think in the open public hearing, the data on
19 tipranavir is sort of an illustration of sort of what a
20 panel of 100 or 100 isolates can tell you of highly
21 resistant isolates against a new drug.

22 [Slide.]

23 On the clinical side, minimally, one needs to
24 characterize the escape mutants on therapy, and the group
25 lacked a lot of consensus on this, it is the issue that

1 resistance is not the sole reason for drug failure, and to
2 make sure that the confounders of failure are taken into
3 account when looking at the escape mutants on therapy.

4 So, PK substudies and adherent substudies within
5 larger trials are important to try to pin down what is the
6 cause of the failure, and it may not be just one issue. It
7 may be more than one issue.

8 The other issue, at the minimum, is depending upon
9 the prevalence of drug resistance in the population, and
10 this drives to Susan Little's presentation. You may need
11 baseline characterization of the population that you are
12 studying even if you are not particularly going after a drug
13 resistant population as an indication, if you are testing
14 that drug in New York, San Diego, San Francisco, et cetera,
15 you may in the next few years need to really at least sample
16 that population to know what you are doing.

17 Retrospective resistant studies, I think are still
18 acceptable, but obviously, our notions are changing, and
19 there will be an increasing emphasis on pressure to look at
20 prospectively designed studies that bring in resistance
21 testing even in drug development that it not going after a
22 specific indication for an experienced population, because
23 even in naive populations, this will have, in areas where
24 there is a lot of drug penetration, will have an impact on
25 response.

1 [Slide.]

2 At the next level, not the minimalistic level, but
3 the next level, for drugs with potential activity versus
4 drug resistant virus and for which a primary indication for
5 treatment of patients with resistant virus is sought,
6 characterization of those patient up-front, genotypically
7 and/or phenotypically, is important, and then to test for
8 activity in combination regimens.

9 This slide was made at lunchtime, before the
10 afternoon discussion, so this was already covered. This is
11 a question mark because no one really has the answers for
12 what the right comparator regimens are. You can just do
13 your best.

14 I think you do need comparator regimens, and you
15 need to try to control for as many factors as you can
16 virologically and otherwise and regimenwise to try to come
17 up with what those treatment responses are in those patient
18 populations.

19 Again, the confounding issues need to be taken
20 into account. One needs to think about not just up-front,
21 randomizations based on drug resistance, but also strategic
22 trials, i.e., looking at patients who fail on regimen A, and
23 then using a new drug and a new combination to rescue those
24 patients strategically. So, that is the use of resistance
25 testing in the midst of a trial in more of a strategic

1 fashion.

2 Then, the RCG analysis has brought up with us the
3 issue of uniformity of analyses, and this is not for me to
4 really state one way or another, but I think the committee
5 over time is helped by sort of looking at data that is
6 analyzed perhaps primarily in one way, but more uniformly in
7 another way, and it was very helpful to see the RCG
8 analysis, and I imagine discussions will go on with the
9 agency and sponsors about how to sort of put forward their
10 clinical resistance information and drug activity
11 information in the packages that are submitted in much the
12 same way that endpoint issues were discussed when RNA became
13 the primary endpoint, both for accelerated approval and for
14 most traditional approvals.

15 So, I think this needs to be discussed more at the
16 agency sponsor level, but the committee looks at this with
17 interest.

18 [Slide.]

19 There are a number of secondary gains from this
20 meeting, which I hope, in fact, will occur. The first and
21 most important is despite what happened at the beginning of
22 this week, I would hope that there is strong encouragement
23 for the further drug development and treatment-experienced
24 patients, and the presence of drug resistance testing and
25 its prevalence in trials and in clinical practice is going

1 to drive this, and I hope this meeting helps that.

2 We can hopefully facilitate more collaborations
3 among industry, academia, and government. It is the only
4 way we are going to develop the data. We need the drugs, we
5 need the assays, we need the clinical trial design, we need
6 the patient populations that bring all these groups
7 together.

8 The RCG effort, I think was a beautiful example of
9 the way these three groups came together to analyze their
10 data in a record-setting time frame.

11 We talked about standardizations, and we need to
12 move toward that. We are recognizing the issues that are
13 involved in that. It is not antibacterial therapy. I think
14 that helps us strongly to say what might be a reasonable
15 Holy Grail to go after, but we are far from that, but we can
16 standardize in certain areas as far as panels of isolates,
17 the assays that are used, validation criteria, et cetera.

18 Obviously, through all this, we are going to get
19 smarter, and most importantly, this is going to increase the
20 pressure to improve access to resistance testing for
21 populations in this country and elsewhere, a very important
22 side effect.

23 [Slide.]

24 I thought the way to end really was to talk about
25 -- you know, we talked a lot about what we don't know and

1 what we need to know, so I thought it was important actually
2 to try to organize or at least put some thoughts forward
3 about where current research and future research should be
4 going in the resistance field, which directly drive to drug
5 development, as well, although not specifically or uniquely.

6 There are four areas to consider. One is the
7 epidemiologic. I think it is clear from the presentation
8 this morning that we need increasing data and ongoing
9 studies about the prevalence and transmission of resistant
10 virus. There are some, but we need better studies about the
11 cost-benefit of resistance testing to prove to third-party
12 payers that if you stop wasting drugs or expose patients to
13 toxic drugs that they won't succeed with, that, in fact,
14 resistance testing can be cost effective.

15 [Slide.]

16 The long list of current and future areas of
17 research is on the clinical research side, and we saw some
18 of the prospective studies that are currently going on. We
19 need to really think about whether it is phenotypic testing,
20 genotypic testing, or both, the most expensive option, and
21 it won't be this, but whether it be one or the other, or
22 virtual phenotype, so called, or whatever, we will know in
23 the course of the next year, year and a half.

24 The role of resistant testing in primary and
25 established infection and, really, how widespread that

1 should be in our population needs to be determined, and how
2 it improves outcome.

3 The further definition of the role of testing and
4 treatment failure. I mean I think there is still debate
5 despite what recommendations may be forthcoming about
6 whether a physician's best guess and treatment history and
7 RNA trajectories may be just as valuable as an expensive
8 resistance test.

9 We have talked about assessing relative
10 contributions of resistance, adherence, and the
11 pharmacokinetics to treatment failure. The best thing about
12 the attack on resistance is to prevent it in the first
13 place, and this means good drugs, good regimens, intelligent
14 treatment choices, which we don't talk about too much, we
15 assume this probably too often.

16 We talked about this, and this is very important -
17 the long term benefit of resistance testing. Those are data
18 we did not see in the last two days, and hopefully we will
19 see over the next couple of years.

20 We also talked about the fact that we don't know
21 what the relationship of an IC50 or an IC90 or 95 is to the
22 in vivo activity of the drugs, and one clearinghouse we do
23 need is the knowledge base of achievable drug levels and the
24 determination of whether peak trough, area under the curve,
25 or whatever, is the best measurement, the pharmacologic

1 correlate of response.

2 This is going to be helpful particularly if we get
3 into therapeutic drug level monitoring.

4 It has been brought up a couple of times that
5 individual drug susceptibility may not be as helpful as
6 looking at a regimen score of susceptibility at least in
7 clinical trial assessments of success. That is a little bit
8 more difficult on an individual patient basis.

9 [Slide.]

10 The pathogenetic side we didn't talk about too
11 much, but this is going to drive the rest of the field. The
12 dynamics and the relative fitness of viral subpopulations in
13 relation to strategic treatment interruptions and drug
14 recycling will help us, I think, in knowing what to do in
15 salvage therapy, and will also help us in trying to think
16 about interesting trials with new agents for salvage.

17 Rich D'Aquila touched on this, the importance of
18 resistance mutation interactions. We have a number of them.
19 Some have been tried to be exploited in therapeutic
20 interventions, but we really haven't exploited this to the
21 full degree that we can.

22 There is a very important issue about the
23 evolution in latent reservoirs and compartments. The
24 compartment issue was talked about. We know that there is
25 virus in latent reservoirs. Some individuals have evolution

1 in their envelope. To date, there has been very little
2 evidence of evolution in RT and protease, but the numbers of
3 overall patients that have been studied is relatively small,
4 and if you are evolving an envelope, it is I think only a
5 matter of time before there is evolution in RT and protease
6 even in these very low level infected reservoirs.

7 The cellular mechanisms of resistant and
8 particularly the most recently described MRP4 with PMEA and
9 some of the nucleosides is important.

10 The role of protease cleavage site mutations, Doug
11 Mayers brought up, and we have talked about natural
12 polymorphisms and what is a polymorphism and what is a drug
13 resistance mutation, and that debate has been going on for a
14 couple of years, but I think one of the key issues now are
15 these low level changes in susceptibility in recently
16 infected individuals, again Susan Little's data, and really
17 what that means clinically is a 4-fold change or a 6-fold
18 change or an 8-fold change, and susceptibility to an NNRTI
19 in a naive population important, and we honestly don't know
20 the answer to that, and these are recently accrued data that
21 we need to investigate through treatment response studies.

22 [Slide.1

23 Lastly, there are technical issues, and we talked
24 about this, I think on the first day.

25 We need improved detection of mixtures because of

1 the fear that a low level mixture, a low level subpopulation
2 will arise quickly when we start a new regimen. The
3 amplification issues I think are going to take care of
4 themselves. I think we will see technical improvements that
5 will be very consistent at 1,000, increasingly consistent at
6 500, and potentially down to full levels of detection.

7 The different subtype issues has been raised with
8 certain types of assays, for example, the chip technology
9 has not performed particularly well with subtype issues, so
10 this always has to be looked at, particularly as subtypes
11 circulate around the world and as drug hopefully circulate
12 around the world.

13 Then, the data analysis interpretation both at the
14 clinical trial level, cohort study level, and individual
15 patient level is a huge issue in really handling these data,
16 not only in a physician's office, but in a clinical trial's
17 operation, as well, and for the agency.

18 Some of the issues that are going on with
19 relational database development are going to be very helpful
20 there. Again, we talked about we are only as good as the
21 assays. The information that is produced is only as good as
22 the assays that produced them, so the quality assurance
23 issues need to be tackled, and this can be done in a number
24 of ways - through external groups, through quality assurance
25 programs like the BQA program that was mentioned through

1 DAIDS, and others, but that needs to be also brought to
2 play.

3 So, that is sort of the future, and I think a lot
4 of this relates to drug development, so these issues of
5 research are relevant.

6 On that note, those are my recap comments. I
7 would like to actually give the committee a chance to add
8 anything they would like to since I didn't have a chance to
9 vet this with my colleagues except that I think they knew by
10 inference that I was going to make this mercifully brief.

11 Dr. Jolson, is there anything else that the
12 committee needs to tackle?

13 DR. JOLSON: Well, I certainly wouldn't dare ask
14 you any more questions. In fact, the committee has just
15 been incredibly diligent to work through all these
16 questions, and when we started off the meeting, we called it
17 a workshop, and hopefully, you understand why the emphasis
18 was on the work, not on the shopping part of it.

19 I just really want to one more time thank
20 everybody for their thoughtful input. I want to thank the
21 speakers on both days who just did a wonderful job providing
22 really important background information for the committee's
23 deliberation.

24 Yesterday, I acknowledged the RCG, but I would
25 also like to reiterate our commitment to an effort like

1 that, that brings together industry and academia with the
2 government and other interested groups.

3 I want to acknowledge everybody on our side who
4 just did a tremendous job putting this workshop together.
5 We really do see it as a milestone, as you were mentioning,
6 that it really is a very public statement for us that we are
7 seriously concerned about the issue of development of
8 resistance to current and future antivirals, and we do want
9 to see the field move forward, so we can provide better
10 information and product labeling.

11 We saw these two days as an initial step towards
12 those goals. So, I just again want to thank everybody for
13 their hard work and their contribution towards that effort.

14 And thank you for chairing a meeting that ended on
15 time. That really met our goals.

16 DR. HAMMER: Thank you. I would just like to
17 thank my committee members and guests, and thank you and
18 also once again thanks to the audience participation and
19 particularly to the speakers, who I think did a fabulous job
20 in updating us on a state-of-the-art fashion.

21 With that, the meeting is adjourned. Thank you.


22 [Whereupon, at 3:15 p.m., the meeting was
23 adjourned.]

24

- - -

C E R T I F I C A T E

I, **ALICE TOIGO**, the Official Court Reporter for Miller Reporting Company, Inc., hereby certify that I recorded the foregoing proceedings; that the proceedings have been reduced to typewriting by me, or under my direction and that the foregoing transcript is a correct and accurate record of the proceedings to the best of my knowledge, ability and belief.

A handwritten signature in cursive script, reading "Alice Toigo", is written over a horizontal line.**ALICE TOIGO**

Lawyer's Notes

\$	15 17:24; 19:2; 43:17; 45:7; 50:12; 90:8; 134:10; 197:3 150 19:19 151 41:5; 149:13 151-complex 40:18 151M 40:22 16 87:5 18 6:14; 19:20 181 125:11 184 45:12; 75:1; 136:1; 137:s 184V 135:10 19 11:8; 18:6 1989 15:10 199 19:1 1992 9:14; 101:21 1997 15:12 1998 13:9; 15:10, 23; 56:20 1:00 131:21; 132:2	167:22; 176:17; 186:22; 198:13; 199:18 30 20:19; 43:15; 44:22; 142:25; 151:6; 156:21; 163:15; 166:7; 204:20 30-fold 50:4 IO-patient 153:12; 163:6; 164:5; 166:4 300 205:7 3001 130:5 304 138:21 31 17:2 32nd 9:14 33 18:23; 20:19 333 154:15 35,000 138:13 36 14:19 37 20:16 370 19:9 372 37:11; 53:18 378 50:11; 51:3; 52:10; 63:25; 64:24 39 13:2; 14:6 3:15 228:22 3TC 22:8, 15; 54:9, 20, 22; 126:14; 135:11; 174:2	500-patient 185:5 51 20:2 54 20:25; 127:24 6 6 17:9; 18:4, 4; 19:25; 21:10; 24:12, 19, 24; 25:2, 6; 145:16 6-fold 225:17 60 17:15; 43:15 62 40:24; 41:9 65 171:22 67 17:18, 24; 134:10 69 38:22; 41:17 7 7 25:17 70 15:11, 11; 139:14 700-patient 80:5 70R 173:8 71 200:25; 201:5 72 134:10 74v 135:9 75 40:25 765 49:23 77 40:25; 41:9 8 B 17:13, 18; 18:5, 22; 19:13, 13; 20:1, 14; 21:6; 125:9; 140:24 B-fold 50:21; 225:18 B.4-fold 14:24 BO17-9 , 13, 15; 33:2; 46:25; 61:24; 125:11; 134:9; 139:14, 22 BOO34:25 82 19:24; 20:1; 45:11; 46:16; 127:24; 139:13; 173:9 84 20:20; 127:24; 139:13 85 33:2 89 18:7, 12 9 9 12:18; 134:10 90 103:24; 127:19; 134:11; 139:14; 140:19; 154:11 90-fold 139:22 95 18:4; 59:3, 8; 64:2; 140:24; 223:21 96 209:21 138 34:7 138-I 186 22:6 99 18:19; 34:7	A a.m 131:20 Abbott 49: 17 ABI 139:3 ability 47:25; 95:4; 135:3; 153:5; 198:15, 25; 209:17 able 17:17; 25:19; 28:3, 5; 34:9; 44:20; 58:6, 22; 70:8; 81:13; 84:14; 86:25; 88:4; 95:7, 16; 96:7; 111:23; 114:5; 116:21; 121:2; 127:12; 131:2; 133:16, 19; 134:9, 18; 141:25; 155:25; 173:25; 174:17; 175:5, 12; 178:12; 194:12; 199:12; 203:9; 208:23 above 49:14; 99:19 absence 25:14; 55:9; 58:22; 65:19; 124:19 absolute 47:16; 61:7, 20; 62:10, 11 Absolutely 60:17; 81:8; 84:19; 145:23; 202:19 absorbed 148:3, 4, 20 absurd 73:21 ABT 82:5 ABT-378 51:2; 74:7 ABT-378/ritonavir 49:19 ABT378 192:20 academia 221:3; 228:1 academic 42:18; 201:9; 202:7 academics 116:13 accelerate 132:15 accelerated 69:2; 122:4; 127:2; 201:19; 220:13 acceleration 133:21 accept 113:11, 11; 118:6; 146:24 acceptable 167:21; 218:18 accepted 122:3 accepting 170:11 access 18:11; 26:S; 62:2; 68:21; 76:8, 9, 23; 78:12; 185:20; 193:23; 221:20 accomplished 115:21; 121:4 accordance 6:14 according 13:9; 15:9; 50:7; 116:16 account 35:20; 36:7; 40:5, 7; 44:4; 52:22; 58:19; 191:5; 210:10; 218:3; 219:20 accrued 225:20 accumulate 13:24 accumulated 204:18 accumulating 72:16 accumulation 13:16 accurate 101:16, 17; 133:3
0	0.04 46:21 0.2 133:22 0.5 24:21 0.75 37: 11 035 54:24; 174:1			
1	1 8:15; 12:8, 11, 17, 23; 17:1; 18:22; 21:9, 22; 23:23; 24:3; 43:6; 55:25; 61:24; 129:1; 131:18; 133:20; 143:12; 144:3, 20; 147:19; 150:21, 22; 176:7 1,000 145:11; 196:1; 226:5 1,000-patient 212:22 1.1 176:7 10 12:19, 21; 14:25; 17:13, 23; 18:12; 19:4; 20:1, 6; 32:5; 64:3; 104:18; 107:10; 140:13, 14; 196:2; 209:1 10,000 46:25 lo-fold 11:19; 12:1, 9, 12, 23; 14:8, 16; 15:22; 17:5, 6, 7, 21; 18:5, 6, 14, 23, 24; 19:3; 20:6, 8, 14; 21:4; 49:14; 140:17 100 46:17, 22; 105:7; 125:8; 138:17; 156:23; 192:9; 195:25; 211:9; 217:13, 16, 20, 20 loo-fold 125:9 103 19:10, 13, 14; 74:5 105 139:9; 140:18 10:45 90:9 11 18:12; 19:4; 20:17; 21:9 114 17:25 118 40:25; 41:10 11:59 131:20 12 16:14; 17:18; 18:2, 8, 22, 23; 19:12; 82:9; 122:25; 157:9; 192:6 12A-30 6:19 13 11:8, 9; 122:25 13-day 210:16 14 20:8, 8, 21 141 11:5; 16:13, 16; 17:1, 2, 5 149 19:20	2 2 18:17; 12:17; 16:16; 17:1, 5, 10; 20:8; 21:5; 25:17, 19; 80:11; 85:10; 87:19; 139:23; 150:23; 162:15, 17; 167:20; 197:9 2.4 126:3, 3 2.5 12:1; 17:7, 23; 18:14, 24 2IO38:6 ; 42:14; 44:20; 92:5 2IO-fold 33:20 2IO-patient 150:17 200 33:13; 171:24 208 6:14 21 18:21; 210:18 215 9:18; 45:12; 137:4; 167:14; 168:1, 9, 11, 15; 173:14, 16; 175:25; 177:23; 178:9 2'2 17:3; 18:4 23-fold 50:22 2'30 18:25 24 18:20; 50:6, 14; 51:7, 7, 19; 52:2; 82:12; 125:8, 25; 151:15; 157:9, 14; 160:1, 9; 164:6; 166:8; 173:19; 190:24; 210:19 24-week 158:5; 169:13 240 148:15 25 68:2; 145:13, 15 26 17:6 2'7 24:21	4 4 18:6, 23; 19:4; 20:6, 14; 21:22; 23:19, 22, 25; 46:22; 64:3; 90:14, 15, 19; 120:9; 127:8; 131:3; 140:13; 142:12; 178:19; 182:13; 186:20; 201:24; 205:22 4-fold 51:3; 52:3; 140:12; 173:11; 225:17 40 139:13; 166:7; 204:20 40-fold 139:21 400 25:18; 33:13; 87:5; 148:16; 212:11 41 134:11 416 20:23 418 11:8, 8; 17:14; 45:11; 50:6, 15; 51:15, 23; 52:2; 68:14; 82:12; 139:14 48-week 160:14 5 5 12:17; 18:20; 19:1; 20:24; 21:13; 24:8; 46:25; 49:14; 163:15; 205:23; 213:22 5i-fold 17:17, 19, 23 50 22:19; 25:21; 42:18; 64:5, 10; 81:13; 137:4, 4; 151:14; 153:12, 20; 154:1, 12, 25; 155:12; 164:5, 12; 166:4; 195:25; 204:21; 217:13 500 81:11; 99:2; 226:6	6 7 8 9
3	3 7:12, 13, 20; 8:20; 10:1; 11:23; 17:5; 19:1, 3, 14; 21:6, 10; 24:2; 83:19; 85:9; 129:1; 162:15; 163:3, 4;			

<p>accurately 62:23 accused 175:21 achievable 84:5; 97:8; 14; 118: 12; 223:23 achieve 49:10; 208:23 acid 13:4, 7; 30:14 acknowledge 228:3 acknowledged 227:24 acquire 26:13 acquired 71:1; 85:18; 92:23; 117:21 acquisition 204:24 across 11:6; 130:3, 6; 177:18; 183:19 act 192:18 ACTG 37: 1 1 action 107:21; 109:19 active 41:23; 45:10; 75:1; 80:6; 103: 14; 140: 1; 160:10; 169:7; 175:6; 177:22; 181:16 activities 93: 15 activity 50:4; 59:9; 72:15; 79:22; 91:8; 97:22; 98:8; 104:14; 106:2, 11; 107:18; 108:2, 3, 7, 8; 109:5, 21; 110:4, 5, 10; 111:18; 117:25; 118:1; 119:15, 18; 121:22; 126:23; 128:10; 130:18; 138:8; 143:16; 152:25; 162:1, 18; 167:9; 175:18, 23, 24; 175:10; 179:1; 197:13; 199:23; 219:3, 8; 220:10; 223:22 actual 30:6; 42:24 actually 17:22; 20:6; 23:1; 25:19; 29:4, 14; 50:21; 60:1, 14; 74:1; 75:17; 82:22; 87:24; 100:19; 110:24; 126:10; 137:15, 16, 19; 138:15; 145:9; 149:3; 152: 16; 154:5, 13, 14; 155:14; 161:21; 170:14; 175:6; 176:18; 182:1, 2; 203:25; 205:14; 206:4, 7; 210:15, 24; 211:1; 222:1; 227:7 acute 24:9; 70:25 acyclovir 133:9 ad 129:24 adapt 191:14 add 52:11; 82:1; 114:8; 176:1; 190:4; 196:13; 198:23; 199:17, 18; 227:7 added 40:16; 50:12; 52:21; 64:4 adding 212:16 addition 35:18; 36:6; 56:11; 61:21; 82:4 admission 26:9; 30:5; 15; 41:13; 42:1; 48:12; 85:1; 142:8; 151:25; 152:1; 155:20; 212:6 address 7:2; 31:4; 34:9; 38:11; 54:15; 58:4; 60:16; 61:6; 116:3; 130:11;</p>	<p>131:2; 134:22; 136:23; 142:17 addressed 31:12; 151:25; 155:20; 157:5; 158:23 addresses 6:5 addressing 8:23 adds 53:15; 163:15 adefovir 56:2; 124:4; 126:9; 135:25; 161:20 adequate 53:6; 63:20; 74:2; 104:2, 12; 107:8; 117:17 adequately 169: 18; 211:18 adherence 64:21; 85:2; 87:15; 88:11; 148:4, 21; 223:10 adherent 218:4 adjourned 228:21, 23 adjust 48:9 adjusted 17:20 administered 125:2, 3; 150:11 adopted 10:21 Adult 4:25 advance 44:1; 58:8; 77: 15; 132:8; 142:6; 191:8; 214:3 advanced 26:4; 76: 11; 115:10 advantage 77:6; 135:7; 175:4; 184:9 advertising 102:16 advice 177: 18 Advisory 4:4; 67:3; 106:25; 195:5 advocate 22:1 affect 89:7; 94:19 affected 32:3; 94:16; 143:15; 151:1; 167:4 affecting 156:19 afternoon 7:8; 123:3; 131:7, 17; 132:1, 7, 15; 142:25; 219:10 afternoon's 120:3 again 4:7; 9:3; 10:24; 12:8, 18, 23; 13:23; 15:3, 19; 16:12, 16, 17; 17:1, 4, 10, 20; 18:7, 15; 19:13, 14, 17; 20:1, 9, 12, 18, 21; 24:9; 25:1; 28:20; 31:20; 39:9, 12; 42:5, 9; 43:22, 25; 46:24; 48:2; 51:15, 19; 54:16; 57:24; 58:16, 24; 64:22; 67:13; 69:25; 75:18; 79:22; 86:16, 21; 94:2, 22, 24; 95:2, 16, 22; 96:6; 104:4, 23; 105:4, 8, 20; 107:4; 108:8; 109:15; 113:24; 114:1; 117:15, 23, 24; 120:8; 140:7; 148:8, 118; 167:4; 188:1; 198:1; 212:5; 216:16; 217:3; 219:19; 225:16; 226:20; 228:12, 18</p>	<p>against 23: 18; 35: 11; 47:18; 49:11; 53:2; 73:6; 75:1; 80:18; 91:9; 103:14, 23; 106:2; 107:19; 108:8; 109:5, 21; 110:4; 118:1; 119:16; 129:13; 130:18; 136:4; 138:8; 140:1; 149:7, 8; 152:25; 160:10; 167:9; 170:24; 172:20; 177:22; 179:2; 185:14; 197:5, 6, 13; 213:18; 217:10, 15, 21 agencies 121:3 agency 112:22; 152:9; 169:11; 171:16; 197:23; 204:5; 216:7, 18; 220:9, 16; 226:17 agenda 6:21; 67:6; 92:1; 142:19 agent 92:21; 96:16; 97:8; 109:2; 117:6; 146:16; 147:10; 149:7; 162:10; 175:11; 182:23; 199:15; 217:15 agents 93:2; 104:18; 111:2; 118:2; 125:4; 143:20; 149:8, 9, 10; 162:9; 166:7, 8; 181:15; 199:8; 224:16 aggregate 175:15 ago 32:5; 46:11 agree 41:7; 70:14; 74:5; 83:21; 147:2; 159:22; 160:20, 25; 161:6; 163:22; 165:4, 12; 170:4; 172:23; 173:3; 174:15, 16; 178:13; 181:23; 186:7; 188:16; 192:1, 17; 194:11; 208:18; 213:15 Agreed 33:16; 118:19 agreement 196:16; 198:25; 202:3; 215:9 ahead 39:1; 114:10; 113:23 AIDS 5:12, 13 algorithm 128:18 algorithms 39:24; 40:5; 21:6; 122:13 allow 78:18; 97:24; 84:22; 191:23 allows 35:12; 60:19; 19:1; 80:23; 119:18; 213:3 alluded 108:10 almost 25:11; 64:1; 58:23; 69:3; 78:22; 193:7, 12, 18; 197:4 alone 40:23, 25; 41:5, 9, 3, 10; 87:8; 112:14; 144:14 along 29:18; 69:13; 35:21; 164:3; 165:20; 188:17 alterations 135:19 altered 135:14 Alternatively 23:7; 85:1 Although 15:11; 23:22; 25:24; 68:2; 69:8; 75:19; 85:25; 144:18; 148:15;</p>	<p>155:24; 178:1; 183:22; 200:9, 13, 23; 203:5; 207:11; 209:25; 222:5 always 35:6; 41:25; 42:6; 46:4; 58:14; 60:11; 66:8; 103:4; 114:18; 125:3; 128:14; 166:23; 168:19; 175:18, 21; 209:25; 226:10 amendment 189:19, 21; 203:20 America 23:15 American 16:2, 12; 21:3; 27:23; 32:14, 22 amino 13:4, 7; 30:14 among 11:5; 14:8, 19; 16:8; 26:13, 21, 23; 70:3; 176:24; 191:3; 221:3 amongst 137:7 amount 43:23; 63:1; 89:14; 91:3, 6, 10; 117:5; 123:4; 130:15, 17, 21; 146:19; 176:4; 182:8; 195:7, 12; 206:5; 214:18 ampicillin 112:20 amplification 39:13; 226:3 amplified 39:14 amplifies 209:4 amplify 202:16; 208:21 anabolically 147:17 analogies 111:14; 112:12 Analogy 91:24 analyses 23:6; 43:3; 44:14; 46:20; 49:6; 52:6; 59:5; 203:16; 220:3 analysis 14:5; 22:14; 31:1; 43:17; 44:13; 45:5; 49:22, 23; 51:23; 62:20; 63:3, 11, 12; 71:5; 72:1; 73:10; 112:10; 123:18; 126:13; 141:18; 151:21; 155:6; 158:1; 164:8, 10; 167:20; 168:17, 22; 169:9, 14, 24; 170:6; 171:18; 175:12, 13; 177:1, 20; 201:2; 220:2, 8; 226:13 analyze 77:19; 86:17; 100:7; 137:18, 19; 169:11; 175:10; 221:9 analyzed 50:7; 76:25; 137:19; 167:18; 176:22; 220:6 analyzing 175:12; 200:19 anatomic 8: 13; 36: 15; 55:3 and/or 8:16; 14:11; 31:1; 84:24; 97:9; 104:7; 219:7 anecdotal 176:10 anecdote 46: 10; 47:3 anecdotes 160:2 Angeles 11:8 animal 97:22; 108:7, 14; 162:6; 174:21; 217:6</p>	<p>announcement 6:5; 7:6 answered 79: 11; 83: 14; 155:11; 160:22; 166:18; 177:19 anti 111:11 anti-HIV 1 10:25 Anti-Infective 91:18; 101:21, 24; 102:7 Anti-infectives 91:20; 97:16; 122:23 Antibacterial 91:23; 103:3; 111:2; 221:13 antibacterials 92:8, 18; 93:20; 113:18 antibiotic 92:12; 97:21; 98:10; 110:16 antibiotics 99:23; 100:4; 102:2; 111:9 anticipate 192:2 anticipating 212:6 antifungal 111:20; 112:1, 12 antimicrobial 92:21; 93:2; 96:15 Antiretroviral 7:15, 22; 11:4; 13:10; 21:20; 25:13; 91:8, 12; 125:4; 137:1; 143:20; 161:7; 197:13; 201:3; 205:3 Antiretroviral's 198:15 Antiretrovirals 141:8 Antiviral 4:4; 7:19; 139:3; 143:16; 171:7 antivirals 133:6; 228:8 anyplace 163:18 apologize 45:8 apparent 23:17; 70:15 appear 21:14; 51:12; 63:20; 77:8; 112:7; 123:23 appearance 6:8 appearing 30:9 appears 27:9; 85:4; 123:24; 128:15; 167:9; 179:1; 199:25 applicability 86:18 applicable 188:6 application 8:18; 98:9; 100:6; 104:14; 105:5; 113:20 applied 90:6; 91:22; 97:16; 130:3, 5; 208:11 apply 184:4 approach 43:11; 96:18; 101:19; 103:3; 116:21; 156:17 appropriate 66:10; 78:24; 89:9, 18; 91:11; 96:24, 25; 105:24; 113:9; 125:16; 126:3; 155:2; 163:17; 181:25; 182:5, 12; 187:13; 215:20 appropriately 96:15 appropriateness 179:10; 187:10 approvability 124:5;</p>
---	--	--	--	--

<p>127:4, 6 approval 69:3; 77:25; 102:4; 117:4, 7; 122:4, 14; 127:2, 9, 16; 201:19; 220:13 approvals 220: 14 approve 93:16 approved 93:21; 105:14; 124:24; 128:2, 16, 19; 138:19; 147:10 approves 115:6 approximate 207:24 approximately 16: 1 5; 18:2; 19:24 ARAS 5: 18, 18 arbitrarily 48:5 arbitrary 10:20 archived 47:2 area 47:13; 63:17; 84:6, 20; 111:10, 11, 20; 112:18; 118:9, 20; 119:5; 217:2; 223:24 areas 70:3; 116:18; 218:23; 221:16; 222:6, 16 arena 69:4; 91:22 argue 171:12 argument 135:22 arise 226:2 arm 48:22, 22; 158: 19; 160:5; 162:19, 23; 163:1; 172:21; 173:24; 178:17 arms 130:3, 6; 162:25; 177:18; 186:5; 191:3, 3 around 27:15; 70:13; 82:2; 87:4; 99:3; 144:17; 177:15; 199:22; 208:25; 212:12; 226:11, 12 arrange 200: 1 art 43:17 askew 190:10 aspect 67: 18; 111:4; 147:13; 160:12 aspects 110:21, 21; 118:22 assay 7:24; 10:23; 11:5; 17:4, 15; 18:5; 19:3, 21; 20:4, 5; 28:4; 38:8; 39:14, 15; 81:19; 89:8; 93:25; 94:11, 25; 97:5; 98:23; 114:13, 18; 123:15; 133:13; 134:20; 137:18; 146:4, 7, 14; 191:17; 196:21; 197:2, 6; 215:12, 16, 19, 22; 216:2, 4 assays 8:1, 18; 16:6; 23:3; 29:11; 32:5, 10; 63:19; 78:9; 95:14; 98:13; 113:12; 123:15; 129:20, 21; 134:13; 146:18; 148:9, 14; 215:12; 216:5; 221:5, 17; 226:8, 21, 22 assess 58: 5, 7, 69: 16; 76:18; 95:5; 199:6 assessed 20:9 assessing 108:18; 197:22; 198:20; 223:9</p>	<p>assessments 224:7 assigned 156: 18 associated 8:20; 10:16 18; 13:8; 18:17; 22:24; 33:18; 47:21; 52:3, 7; 60:7; 99:25; 133:23; 135:19; 149:13; 173:s; 177:4 association 13:5; 30:3; 164:14 assume 81:18; 148:5; 193:8, 14, 17; 211:6; 223:15 Assuming 148:4, 20; 153:4 assumption 44:15; 194:7 assumptions 58:13; 189:23 assurance 226:22, 24 asymptomatic 11: 13 attack 223:12 attain 87:22 attempt 39:20; 88:4; 99:17; 142:18; 194:17 attempted 92: 14 attempts 111:18 attention 57:8 attractive 134:14 AUC 99:20 audience 214:2; 228:18 aureus 106:13 Australian 16:3; 19:8; 20:20 availability 185:21; 189:4 available 7:24; 66:24; 103: 19; 110:4; 162:24; 179:23; 189:9; 193:7; 199:13, 15 average 209:1, 2, 3; 210:15 avoid 141:13; 193:3 aware 6:23; 28:14; 78:23; 128:25 away 52:15; 171:8 axis 46:18 AZT 9:17, 18, 25; 22:8, 15; 23:23; 24:1; 38:1; 41:18; 54:20, 21, 22; 68:5; 126:4, 13; 133:9, 11, 20, 25; 134:10; 167:13; 172:17, 20, 21 AZTG 133:12 AZTG-333 127:13</p>	<p>183:17; 184:12; 187:6; 190:3, 5, 7, 23; 191:19; 202:20; 204:1; 206:14; 209:7, 23; 210:17, 20; 213:17; 214:19 back-up 209:8 backbone 31:25; 32:3 backdrop 137:2 background 14:13; 15:3; 37:2; 58:12; 136:25; 145:22; 146:22; 158:16, 17, 20; 165:18, 25; 166:1; 181:18; 190:14, 15; 191:14, 20, 24; 227:22 lbacteria 60:15; 94:6; 100:21; 111:23; 113:1; 118:9, 18; 119:2 bacterial 95:11; 96:13; 110:10; 112:18 bacteriology 118:7; 196:20 bad 134:1 trail 186:4; 191:6 balance 74:4; 89:23; 139:13; 163:12; 177:17 balanced 175:20; 191:2 Elalotta 20: 16 bland 71:3 bar 198:3; 199:1 barrier 149:21; 161:18 barriers 150:6; 162:s; 199:3 base 44:6; 75:17; 177:7; 223:23 based 30:17; 34:8; 35:2, 2; 48:23; 56:22; 58: 12; 63:15; 65:16; 72:4; 83:7; 98:25; 102:17; 103:22; 106:7; 113:13; 115:1, 4, 9; 117:24; 120:10; 125:6; 126:12, 18; 128:2; 138:15; 160:18; 167:10; 177:9; 178:25; 179:5; 185:22; 199:3; 200:6; 219:21 baseline 15:9; 31:6; 32:7; 51:1; 52:5, 6; 71:25; 72:6; 73:8; 75:5; 78:7, 14; 79:5; 80:17, 19, 22; 81:22, 24; 88:18; 100:7; 134:7; 145:14, 20; 156:2; 164:9; 167:13; 168:15; 171:13; 179:15; 181:21; 188:10; 191:10; 202:15; 206:8; 212:4; 218: 11 baselines 80:21; 83:2; 159:6 basic 98:11; 130:10, 14; 186:25; 189:23 basically 68:6; 75:21; 79:6; 154:7; 164:15; 177:3; 187:7; 188:15 basics 196: 15 basis 37:22; 38:3; 73:10, 11; 74:23; 79:7; 83:4; 88:25; 89:7, 13; 101:14; 116:23; 121:15; 147:12; 177:12; 186:11; 191:11,</p>	<p>19; 195:23; 210:24; 224:8 basket 84:10 batch 197:3 battery 9s: 1 Baxter 47:20 bears 108:2 beautiful 27:4; 221:8 became 70:14; 208:9; 220:12 become 38:12; 44:1; 54:11; 65:20; 196:19 becomes 27:7; 81:10; 172:12; 179:23; 189:9 begin 4:7, 9; 47:6; 194:9 beginning 15:10; 168:21; 220:21 behaved 108:12 behavior 109:23 behind 90:8; 207:22 believable 170:9; 172:2 belongs 163:20 below 41:12; 46:13; 51:12; 64:25; 65:2; 81:12, 18; 151:15; 156:15; 192:3 benefit 127:12; 223:7 resides 111:23; 160:7 best 28:18; 43:6; 49:1; 59:7; 85:13; 86:4, 17; 118:12; 135:23; 136:3; 163:2; 170:4; 176:24; 178:17, 18; 187:20; 193:2; 213:1; 219:13; 223:6, 11, 25 bet 30:21 beta 97: 12 Eleth 132:23 better 26:15; 39:13; 56:14; 57:13; 58:22; 59:20; 60:19; 81:5; 83:14; 90:7; 112:24; 130: 14; 166:3, 6; 178:2; 184:22; 191:21; 193:12; 196:5; 202:14; 209:24; 222:10; 228:9 beware 166:16 beyond 22:20; 64:19; 120:21; 148:15; 149:14; 194:8; 213:13 bias 130:1; 141:13; 200:10 biased 164:20 big 111:6; 129:23; 172:1; 189:7 bigger 183:17 binding 48:9; 50:3; 125:13 bing 161:18 bioavailability 127:8 biochemical 135:13, 19 biochemically 135:14 biologic 56:12; 109:23 biologically 59:17; 74:20; 125:12 biology 35:21; 42:9</p>	<p>Biostatistics 4:14; 5:18 bit 11:3; 27:10; 31:9; 33:17; 35:24; 50:21; 59:14; 60:15; 85:10; 89:17; 132:16; 136:19, 22; 157:10; 163:25; 175:14; 196:4; 197:25; 205:14; 207:10; 212:12; 224:7 black 13:21; 66:17 blind 193:15, 16, 19; 194:8; 212:21 block 208:13 blood 9:16; 10:11; 24:13, 17; 25:5; 26:4; 36:9; 48:4, 6; 49:11, 14; 55:5, 10, 11, 19; 64:17; 84:6; 96:18; 99:16, 24; 118:12; 210:12, 15 blue 11:18; 22:6 blunted 154:2, 13, 17 Elob 18:7 Eloden 17:8 body 104:8, 15; 105:12; 107:6; 108:21; 110:3 bold 14:11 borne 138:7 Boston 11:9; 135:9 both 15:23; 24:13; 25:20; 26:1; 39:20; 43:16; 52:2; 61:1; 63:24; 99:3; 103:15; 107:19; 117:25; 121:17; 127:20; 154:8; 156: 18; 162:10; 167:16; 176:20; 185:5; 186:5; 213:5, 9; 215:9; 220:13; 222:20; 226:13; 227:21 bothered 32:6 bottom 45:8, 9; 178:15 Bottom-line 63:14 box 123:24; 166:15 boxes 11:18, 18, 25; 12:19; 140:9 BPA 226:25 break 7:10; 33:4; 90:9, 11; 131:18; 175:13 breakdown 30:7; 33:6 breakpoint 103:22; 105:16; 113:16, 16; 122:16; 193:1 tBreakpoints 97:19, 24; 98:1, 6, 14; 113:5, 9; 114:24; 115:2, 7, 8, 11, 18, 19, 20; 116:3; 121:7; 122:13 tBreakthrough 182:9 Erendan 136:14, 15; 142:3, 5; 172:7 trew 20:5 Brian 5:2; 71:4, 10; 164:15 larief 133:1; 227:10 briefly 36:14; 103:7; 120:6, 9; 142:19 bring 111:23; 141:23; 176:15; 185:11; 209:10; 218:20; 221:6</p>
---	--	--	---	---

<p>bringing 156:19 brings 89:21; 228:1 ad 41:3, 19; 66:5 leader 56:21; 75:17; 82:24; 86:18; 117:20; 184:2, 11 broadly 21:12; 75:20; 138:18, 21 broken 100:10 Brooks 5:9; 171:3; 172:3 brought 60:2; 129:9; 220:2; 224:4; 225:11; 227:1 build 114:20 Building 6:19 built 95:4; 96:21, 22 bulk 43:16, 20; 44:5, 12; 62:22, 23; 63:5, 19 bullet 186:22 burden 76:21 burdensome 211:23, 23 business 132:6 buyer 166:16</p>	<p>179:12; 180:3; 181:12; 183:9, 18; 184:18; 185:3, 9, 12, 23; 186:3, 18; 187:7, 9, 21; 191:8; 193:3, 17; 195:3; 196:3, 16, 20; 198:7, 12; 199:3, 9, 20, 21; 200:15; 202:13, 23, 25; 203:3, 13, 16; 204:8, 9; 205:23; 209:7, 13; 211:7, 13, 16; 212:9; 213:11; 214:15, 19; 215:13; 216:3; 217:20; 219:12, 15; 221:2, 15; 222:14; 224:21; 226:23; 228:9 Canadian 19:8 capacity 57:19; 58:5; 60:25 carbon 35:2 care 76:15; 80:19; 208:7; 226:3 careful 60:18; 72:22; 77:13; 79:7; 145:21; 149:6; 178:15 carefully 86:16; 150:16; 158:23; 171:17; 173:17 Carla 5:11; 146:10; 172:5 carries 33:18 carry 106:10 case 10:2; 42:6; 61:19; 66:7; 69:8; 73:8; 81:24; 124:5; 126:11; 135:18, 24; 140:6; 165:4, 16; 167:25; 168:18; 169:25; 173:8; 178:8; 193:22; 194:25 cases 21:24; 24:20; 74:24; 75:2, 4; 127:1; 137:2; 153:5; 162:6, 12; 205:8 catch 194:21 catch-up 122:25 categories 20:7; 98:22; 111:17 categorized 48:20 category 96:22; 97:6; 186:5 cause 61:12; 218:6 caused 191:20 causing 37:24 caution 131:9 caveat 16:17; 19:15, 21; 94:12; 105:4 caveats 95:25; 192:19 CD4 46:2; 47:23; 60:11; 61:12; 122:2; 207:10 CDC 121:8 CDER 5:19; 93:23 CDRH 93:22 cell 203:2 cells 25:16; 47:23; 56:3; 60:12; 78:6 cellular 8:13; 36:15; 48:11; 55:21; 56:6; 147:15; 165:11; 225:7 censored 51:8, 24 Center 4:18; 93:21; 132:23</p>	<p>Centers 5:14 central 109:11 cephalosporin 93:5 Certain 22:23; 70:3; 74:23; 77:14; 90:2; 93:7; 99:22; 102:8; 145:7; 146:11; 153:6; 154:17; 169:7, 10; 173:5; 176:11 181:9; 182:8, 9; 185:14; 186:2, 15; 191:11; 202:1 3; 203:25; 221:16; 226:8 certainly 25: 12; 30:10; 32:21; 52:12; 64:16; 89:6; 90:5; 146:15, 17; 153:5; 160:20; 166:12; 173:10; 174:22; 198:24; 207:5; 216:1; 217:6, 15; 227:13 cervical 25:4 cetera 137:5; 140:19; 148:4; 156:7; 165:12; 177:16; 218:14; 221:17 chair 9:5 Chair's 83:9 Chairing 228: 14 Chaienge 144:14; 162:22 Challenged 162:17 Challenges 100:25 Chance 29:1, 6; 76:12; 85:17; 90:25; 227:7, 8 Chances 181:13 Change 16:25; 50: 12; 52:4; 57:5; 149:15; 156:17; 173:3, 7, 11; 174:13; 185:22; 189:17; 191:6; 192:18; 194:12; 204:12; 216:14; 225:17, 18, 18 Changed 14:22; 50:10, 13; 78:4, 8; 152:17; 179:25; 189:11; 190:11 Changes 56:5; 147:9; 156:18; 157:13; 173:5, 12; 202:14; 225:15 Changing 188:19; 194:11; 218:18 Charache 4:9, 10, 10; 83:20, 21; 114:5, 7, 11; 119:7; 186:21, 22; 196:12, 13; 198:8, 9; 202:11, 12, 19 characteristic 41: 18; 217:9 characteristics 7:25; 93:23; 109:1; 160:14, 18; 165:6; 216:6 Characterization 153:24; 216:22; 218:11; 219:6 characterizations 156:2 characterize 91:8; 121:22; 122:20; 175:5; 197:12; 198:14; 217:4, 24 characterized 14:23; 32:16; 74:25; 81:6; 164:9, 9; 181:8; 195:23 characterizing 39:2;</p>	<p>63:4; 195:21 charge 92:1 check 157:7; 209:17 chemical 94:11, 14 Chicago 4:24 Chikami 91:18, 25; 111:8; 113:18; 117:10; 119:6, 12 children 10:11 Children's 4:23 chimeric 32:3 chip 226:8 chlamydia 100:23 choice 92:23; 96:9; 129:15; 141:11 choices 44:18; 49:2; 223:14 choose 130:2, 6; 137:16 179:16; 188:11; 215:19 choosing 191:10 chose 13:6; 59:13 chosen 48:23; 179:24; 189:10; 190:4 Chris 4:15 Chris's 207:23 chronic 19:1, 9 chronically 31:10 circulate 226:11, 11 circumstance 62:12; 8:15 circumstances 77:25; 3:7; 110:15; 181:21 ited 55:12 ities 11:6; 21:21; 32:15; 70:13 city 11:7; 70:1, 5 Claim 130:18; 143:12; 144:5, 11, 25; 147:5; 148:23; 149:17; 150:23; 151:18; 152:21; 153:4; 156:25; 157:3; 166:25; 167:23; 169:6; 172:17; 178:6; 199:1; 213:18 claims 94:4; 103:7; 106:2, 4, 19, 22; 107:16; 143:5; 145:19; 149:1; 200:6 clarification 31:13; 170:25; 180:3; 187:19; 194:16 clarified 134:19 clarify 29:13 class 6:13; 21:20; 58:14; 99:18; 124:12, 14; 126:25; 130:20; 149:8; 150:24; 151:19, 20; 152:1, 22; 153:2, 7; 155:19; 158:18; 161:25; 162:21; 168:12; 199:8, 13 class-relate 177:6 classes 99:23; 162:13; 200:2 classically 148:8, 15 classification 96:17 classifications 10:20</p>	<p>classify 116:1 5 Clean 173:23 cleanest 169:15 cleanly 200:5 clear 33:10, 14; 66:15; 79:3; 87:15; 113:3; 137:9; 170:15; 181:22; 182:20, 22, 22; 195:17; 196:20; 222:7 clear-cut 165:4 clearest 75:24 clearinghouse 204:4; 223:22 clearly 10:14; 13:8; 36:3; 42:22; 44:17; 49:5; 52:22; 60:3; 61:11; 77:7; 83:2, 24; 100:22; 104:21; 145:16; 172:5, 5; 185:3, 9; 199:21; 208:18 cleavage 225:10 Clevenbergh 48:19 clinic 71:7, 13; 75:4 clinical 8:2, 18, 19; 15:6; 26:17; 27:12, 23; 33:8; 36:20, 23; 39:19; 40:10, 18; 43:14; 59:23; 69:4, 20; 75: 10; 76: 10; 77:7; 80: 12; 82:24; 83:11; 84:12, 25; 85:2; 89:23; 91:5, 7, 8, 11, 15; 95:10; 96:3; 97:10; 98:2, 4, 5, 6, 10; 99:4; 100:2, 5, 8; 101:22, 23; 102:3, 10; 103:9, 15; 104:2, 12, 13, 24; 105:4, 10, 13, 14; 106:9, 19, 22; 107:9; 108:3, 14, 17, 19; 109:7, 12; 110:11, 13, 16, 17, 22; 111:3, 3, 6; 112:3, 9; 114:25; 115:3, 4, 7, 9, 13; 117:5, 15, 20; 120:14; 121:17; 122:2, 20; 123:9, 16, 20; 124:1, 8; 127:20; 128:14, 15, 21; 129:6; 130:16, 17; 133:10; 134:4; 137:11; 138:9; 142:13, 14; 143:23; 144:1, 25; 151:3, 7; 153:10; 164:3; 167:6; 169:2; 177:5; 178:21; 180:4, 6, 18, 19, 24; 183:11; 187:6, 8; 195:8, 22; 197:6, 11, 12; 198:13; 199:4, 5; 206:1; 207:8; 208:7, 14; 211:14; 212:1; 214:22; 217:7, 14, 23; 220:10, 25; 221:5; 222:17; 224:7; 226:14, 16 Clinically 21:15; 103:21; 105:10, 16; 114:14, 22; 119:16; 127:18; 133:8; 185:23; 207:20; 225:17 clinician 204:6 clinicians 46:23; 76:12; 121:13; 129:25; 163:9; 202:3 clinics 121:13 clonal 43:17; 44:14; 45:5; 46:20; 63:3, 11 clones 43:12, 17, 19;</p>
--	---	--	---	---

<p>45:2, 7; 62:20 close 24:14 closed 142:11 closer 217:16 clue 157:6; 161:16 cluster 51:6, 16 Clyde 132:18, 20, 22; 136:10 CNS 118:17 co-sponsored 207: 13 Coast 32:24 Code 6:14 coding 140:11, 11 codon 43:8; 89:12; 148:15, 16; 167:14 codons 43:9; 45:11, 12 coefficient 37: 12 cofactors 8:20 Coffin 135:5 coformulated 50:1 cohort 10:3; 11:3; 12:9, 11, 21; 14:7, 15; 15:12, 20; 17:1, 6; 18:20; 19:15; 20:17; 21:17; 22:5; 27:18; 28:11, 14; 33:19; 81:24; 203:10; 204:25; 205:8; 226:14 cohorts 11:23; 28:15; 31:10; 33:1; 203:5 coin 153:21 Coigrove 23:25 collaborations 221:2 Collaborative 120:19; 122:9; 133:11 Colleagues 9:14; 13:11; 49:17, 21; 52:1; 214:4, 13; 227:9 collect 77:19; 82:21; 110:5; 171:13; 204:9; 205:6, 11; 206:8 collected 31:7; 78:19; 99:1; 106:8; 145:7, 12 collecting 29:9; 117:19; 130:22; 200:19 collection 84:25; 85:6; 145:20, 20 collects 98:4 color 140:10 colors 140:10 Columbia 5:5 combination 8:12; 22:17; 30:9; 36:5; 45:21; 47:24; 53:15; 54:4; 82:3; 87:8; 110:21; 112:19, 20, 24, 25; 119:17; 125:3, 19; 126:4; 133:18; 143:20; 149:12; 151:9; 153:14; 154:3, 7; 155:4; 157:14; 160:16; 165:20, 22; 168:10; 170:17; 192:12; 219:8, 23 combinations 38:20; 39:5; 150:6, 15 combine 49:6 combining 190:17</p>	<p>comfort 112:13; 114:12 comfortable 171:4; 211:9 comforted 127: 17 coming 68:19; 69:13; 81:11; 91:1; 158:15; 180:21; 192:3; 193:8, 14, 15; 194:8, 10; 210:17 comment 7:4; 33:7; 62:4 63:23, 23; 67:10, 15; 70:10; 75:6, 8; 77:2; 80:11, 83:9, 16; 111:16, 25; 120:6, 24; 130:15, 20; 131:6; 146:24; 163:5; 164:18; 171:3; 172:3; 174:20; 179:9; 195:7, 11; 200:13; 201:18, 24; 202:10, 10; 205:24; 208:17; 214:3 comments 57:22; 110:23; 111:5; 118:4; 131:5; 132:14; 133:2; 142:8; 146:1; 150:18, 21; 156:13; 162:14; 168:3, 4; 176:17; 182:13; 186:20; 197:8; 199:17; 205:22; 208:2; 213:22; 227:6 commercial 113:12; 205:15; 216:4 commitment 155:25; 156:5; 227:25 Committee 4:4, 8; 34:19; 59:6, 24; 65:22; 67:3, 5, 7; 71:8, 22; 76:22; 83:6, 16; 90:23; 91:3, 6, 10, 14; 101:3; 106:25; 110:8; 113:25; 121:5; 129:9; 130:15; 131:2; 142:12; 144:15, 15; 145:11; 147:3; 152:6; 166:21; 169:17; 177:2, 21; 178:12; 187:15; 192:10; 194:18, 21; 195:5; 208:12; 214:15; 216:1, 13; 220:4, 16; 227:7, 12, 14; 228:17 committee's 6:9, 16; 79:20; 227:22 Committee-wide 216:17 committees 112:23 common 10:23; 27:9; 35: 13; 47:4, 9; 74:25; 95:11; 118:2 commonly 47:7, 8, 10; 54:8; 96:12 communicate 101:11 community 80:8; 117:21; 208: 10 companies 87:16; 119:5; 135:18; 141:22, 22; 158:25; 159:8; 171:13; 199:25; 210:25; 211:24; 212:13; 216:25; 217:1 company 82:2; 85:11; 116:20; 145:3, 10; 159:1, 2, 9; 171:5; 197:1; 201:9; 202:23; 204:10; 206:12; 210:23; 212:17; 213:17 comparator 154:4, 6, 20;</p>	<p>155:2, 14; 158:19; 178:17 219:12, 14 compare 61:1; 81:24; 113:16; 134:16; 162:19; 164:22 compared 22:10; 24:11; 29:1; 117:4; 122:8; 125:22; 135:8; 174:7; 197: 16 Comparing 134:20 comparison 84:4; 89:18; 155:15; 159:17 comparisons 141:19; 142:1; 159:7 compartment 55:6; 224:24 compartmentalization 8:13; 24:8; 31:14 compartments 36: 15; 55:3; 224:23 compelled 171:21, 23 compelling 171:15 compendium 86:21 compensation 139: 15 competency 84:14; 116:17 competent 25:16, 20 complete 22:18; 25:14, 25, 22; 40: 18 completely 10:20; 19:7; 59:13; 142:16; 160:20; 178:1; 189:14 completeness 203:15 complex 35:22; 107: 1; 149:14; 172:23; 193:2; 217:8 Complexities 178:14 complexity 8:11; 39:23; 42:10; 48:13; 53:16; 55:3; 74: 18; 76:3; 90:3 Complicant 164:24 Complicate 8:7 complicated 36:18; 48:11; 58:11; 74:6, 15; 150:10; 174:3; 196:17; 204:14 complicating 133: 18 component 154:8 components 160:5 composite 139: 17 compound 49:19; 50:1; 102:17; 174:9 compounds 12:4; 102:17; 174:25 comprehensive 101:25 conceivably 170:9 concentrate 139:7; 165:19 concentrated 97:1 concentration 47:14; 48:4; 94:18; 97:8; 99:20; 122:12 concentrations 36:4; 47:13; 48:6, 21, 22; 49:3, 11; 52:9; 103:21; 122:13</p>	<p>concept 92:11; 94:13; 114:17 concern 64:20; 65:17; 127:8; 128:1; 1467; 211:1 concerned 65:22; 66:9; 68:13; 75:13; 204:24; 228:7 concluded 52:1; 144:7; 147:20 conclusion 52:14; 56:9; 109:13; 153:9 conclusions 112:11; 204:25 concomitant 129:15; 150:11; 175:9; 181:15; 190:8, 10 concordance 115:19 concordant 38:13 concur 70:20; 198:10 conditions 85:23; 94:12, 17, 25; 95:3, 11; 96:23; 146:7 Condra 46:10; 62:9, 9 conduct 69:20; 88:22, 25; 98:2 conducted 129:19; 146:8; 151:5; 201:13 conducting 127:13 confer 30:5; 40:14, 25; 41:24; 135:6 Conference 208:1 Conferred 40:23 conferring 9:18; 37:22; 39:9 Confers 41:19 Confidence 23:2; 59: 15 Confident 180:16 Confirmation 135:14 Confirmed 31:24; 32:10; 139:4 Confirms 139:19; 171:19 Conflict 6:2, 4, 6 Conform 17:20 Confound 8:21; 9:1; 34:22; 65:7; 83:10 Confounders 83:17; 165:24; 218:2 Confounding 34:15, 17; 35:17; 88:7; 123:18; 150:12; 219:19 Confounds 90:5 Confused 29:14 Confusing 159:8 Confusion 83:22; 111:20 Conjunction 200:20 Cons 59:2; 215:15 Consensus 13:9; 16:7; 17:22; 56:19; 65:12; 66:12; 79:20; 82:15; 129:20; 147:3; 177:3, 9, 14, 21; 187:12; 217:25 consequences 57:17, 20; 136:6 consequently 72:5</p>	<p>consider 8:4; 35:16; 57:1, 3; 87:4; 101:22; 102:12; 104:23; 105:18; 114:3; 151:19; 152:6, 13, 13; 194:5; 212:3; 222:6 consideration 4:5; 56:11; 66:19 Considerations 7:14, 21; 59:22; 96:22; 97:3; 107:2; 109:15; 117:11; 122:8 considered 41: 14; 55:22; 97:17; 98:20; 99:23; 104:17; 107:10; 128:22 considering 1 16:3; 118:16; 123:9; 162:12; 163:14; 167:16; 176:19; 179:25; 189:11 consistent 52:9; 215:5; 226:5, 5 consistently 143:25 constellation 40:21 construct 44:20, 22 consultant 6:15 consultation 93:22 Contact 10:12 Contain 13:25; 45:9 Contained 104:13 Containing 34:5 Contention 82:10 context 84:24; 89:17; 98:4; 117:10, 12, 24; 135:5; 136:22; 207:21 Contexts 134:24 Continuation 142: 11 continue 8:3; 39:4; 54:14; 60:1; 155:25; 192:13; 201:25 Continued 38:14; 54:12; 157:22; 189:4 Continuously 130:23 Contrast 12:2; 14:19; 24:24 Contrasts 91:24 Contribute 40:15; 83:18; 152:20 contribution 228:13 contributions 223:10 Control 5:14; 48:22; 89:10; 94:23; 98:13; 105:21; 119:6; 121:3; 151:22; 154:11; 155:3, 8; 158:21; 160:4, 6, 7; 162:19, 23, 25; 163:1; 165:17, 18, 23; 173:24, 24, 25; 176:14; 178:18; 204:23; 219:15 Controlled 104:12; 107:9; 117:17; 119:12; 154:7, 8; 165:2, 3; 166:2; 202:25 Controls 29:1; 163:19 Controversial 71:14; 215:1 Controversy 147: 10, 11</p>
--	--	---	--	--

<p>conveniently 99:11 conversation 176:24 verse 103:2 wincing 159:18; 170:6, 12; 171:9, 20 copies 7:8 copy 6:17 Cornell 4:20 corner 191:21 corollary 89:21 corrected 50:3 correlate 60:11; 100:8; 192:24; 203:16; 224:1 correlated 36:22; 74: 12; 213:6 correlates 99: 18 correlation 31:2; 37:9, 11; 61:7; 81:5; 98:5; 100:2, 13 correlations 36:19, 21; 69:10; 95:9, 15 cost 43:22; 212:3, 6, 21; 222:14 cost-benefit 222: 11 costs 206:5 count 46:2; 207:10 counter 212:19 country 32:18; 70:13; 99:3; 176:25; 188:2; 2; 221:21 uple 38:22; 49:25; 57:12, 13; 69:7; 85:15; 88:21; 92:24; 95:25; 101:8; 140:12; 174:18; 181:8; 182:25; 193:22; 223:19; 224:4; 225:14 course 72:9; 95:14; 97:21; 100:4; 101:10; 106:8; 109:17; 110:20; 113:19; 117:17, 20; 119:14, 15; 121:22; 122:19; 124:7; 126:9; 153:1, 15; 159:22; 172:17; 210:2, 3; 222:23 cover 142:19 covered 10:17; 219:10 CPCRA 209:9 create 89:23; 186:18; 214:7 created 57:16 criteria 16:5; 56:14; 82:14; 86:1, 6; 87:2; 93:14; 94:1; 95:21, 21; 96:13; 97:18, 20; 98:15, 18, 21; 100:3, 17, 21; 101:1; 102:22; 103:22; 105:3, 22; 106:16; 113:23; 114:1; 129:8, 15, 22; 168:8, 16; 179:11, 23; 179:5, 11; 2; 184:16, 22; 185:5; 187:11; 189:13; 221:17 critical 84:19; 88:15; 158:6; 202: 17 critically 94:20; 145:18 criticism 163:7</p>	<p>criticized 211:22 Crixivan 125:20 cross 124:12; 152:21; 157:23; 162:1; 165:10; 198:15; 199:7, 14; 200:14 cross-resistance 41:3; 91:13; 128:7, 14; 130:20; 131:9, 12, 14; 137:10; 140:22; 149:6; 150:24; 151:2, 18; 153:8; 165:5; 167:5; 198:22; 199:1; 200:1; 201:9; 202:2 cross-resistant 138:18, 21; 139:8; 162:9 cross-sectional 200:17 crucial 134:12 Crumpacker 132:18, 21, 22 CSF 55:6, 15, 18 current 7:2, 24; 42:14; 43:16; 49:12, 13; 56:9; 58:4; 113:19; 124:4, 17; 125:24; 134:3, 17; 138:22; 166:7, 8; 202:16; 210:20; 222:3, 16; 228:8 currently 23:12; 66:1; 68:14; 120:12; 124:7; 126:15; 138:13; 197:1; 211:25; 222:18 curve 59:2; 84:6; 174:13; 223:24 cut 17:4; 66:15; 209:11 cut-off 14:25; 17:16, 21; 48:5 cut-offs 16:6; 18:5; 20:5 cuts 182:10</p>	<p>65:23, 23; 66:23; 68:8, 20, 23, 25; 69:7, 13; 70:15, 18 21; 72:1, 16; 74:7, 10, 14; 75:15; 76:24, 24; 77:5, 19; 79:24; 84:7; 85:1; 86:23; 88:1; 91:4, 7, 11; 93:14; 97:23; 98:5; 102:18; 103:19; 104:13, 24; 105:4; 107:18; 108:8; 109:7, 20; 110:9; 111:3; 113:14, 22; 115:1, 10; 117:5, 19; 123:4, 7; 124:21; 125:6; 126:1, 21; 127:18; 128:2; 130:15, 18, 21; 133:8; 134:7, 20; 136:22; 137:19; 138:20; 139:6, 7, 8; 140:3; 141:18; 146:22; 148:19; 152:23; 153:21; 157:9, 13; 158:24; 159:1, 7; 160:21; 163:24; 164:1, 16; 168:23; 170:6, 11; 172:6; 176:10; 178:25; 182:24; 185:10, 21; 189:21; 190:10; 193:9; 195:8, 11, 14; 197:11; 198:14; 199:20, 23; 200:6, 7, 20, 21; 203:3, 6, 8, 22; 204:18, 23; 206:14, 21, 22; 209:23; 210:24; 211:8, 12, 14; 212:23; 213:9, 12, 20; 214:17; 216:1, 2, 12; 217:4, 7, 18; 220:5; 221:4, 10; 222:8; 223:17; 225:16, 20; 226:13, 15 database 125:7; 138:6, 12; 139:20; 188:25; 226:19 dataset 117:3, 4; 131:14; 148:18; 150:4, 10, 14; 203:15, 24 date 11:10, 11, 12; 13:5; 16:19; 44:14, 24; 55:8; 63:10; 125:20; 225:1 daunting 92:4; 213:25 day 4:4; 42:25; 50:10, 12; 57:11; 83:7; 126:3, 4; 175:7; 185:3, 9; 197:10; 209:5, 18; 225:24 days 25:21; 28:18; 69:7; 89:4; 140:12; 174:18; 181:8, 25; 195:3; 209:1, 21, 22; 210:15, 19; 223:18; 227:21; 228:11 DI 82:5; 135:10; 149:12 deaconess 132:23 deal 57:23; 67:5; 92:14; 110:20; 130:8; 189:7; 205:23 dealing 44:17; 67:20; 118:8; 170:16, 17; 174:5, 14 dealt 57:23; 66:18; 76:22; 101:25; 102:2 death 133:21 debate 223:4; 225: 13 decay 22: 12 December 185:7 decide 112:24; 157:2; 169:1; 193:9; 207:6</p>	<p>decided 115:9; 166:13; 177:16 deciding 88:17 decision 76:16 decisions 181:9; 211:15 decline 46:2; 47:23; 173:17 declined 46:21; 66:2 decrease 125:9; 128:15; 135:25; 172:15 decreased 60:20; 135:12 deep 191:3 default 126:19 Defense 133:13 defer 113:10 define 119:11; 134:25; 135:19; 136:3; 165:5; 172:25; 206:6 defined 37:4, 6, 25; 57:5; 60:10; 75:21; 81:12; 104:7; 138:18; 141:3; 189:16, 17 defining 81:11; 86:16; 88:16; 93:25; 123:17; 148:8 definite 41:15 definitely 32:17; 67:21; 135:17 definition 135:2; 169:12; 223:3 definitions 96:11; 97:15; 151:6; 197:22; 198:20; 202:17 degree 16:7; 133:17; 140:21; 224:21 delay 210:4 deiberation 227:23 demand 216:7 demographically 70:17 demographics 32:13 demonstrate 26:2; 318:12; 179:6 demonstrated 69:9; 77:15; 108:19; 109:14; 118:1; 182:16 demonstration 181:25; 1182:11 denominator 27:25 Denver 11:9 denying 75:3 Department 4:15, 21; 1133:12 departure 146:23 depend 192:4 depending 59:3; 83:2; 146:14; 186:13; 187:13; 218:8 depends 72:9; 117:10, 12; 146:15; 170:9; 187:24; 188:21; 189:3, 15; 196:4; 198:9 depicted 54:22 depletion 61:12 depth 8:6</p>	<p>derive 84:15; 127:12; 137:17 deriving 147:23 describe 105:21; 125:15; 198:6 described 12:7; 103:16; 106:3, 14; 125:18; 134:11; 205:1; 225:8 describes 125:25 describing 105:20; 124:16 description 102:21; 105:20; 111:1, 4; 151:3; 167:6 descriptions 106:2 descriptive 197:16 design 53:9; 81:24; 89:23; 90:5; 91:16; 98:2; 102:3, 10; 128:21; 129:6; 162:22; 166:22; 178:13; 181:3, 18; 185:17; 189:15, 23; 190:2; 206:11; 213:3; 221:5 designed 85:25; 143:2; 156:9; 166:13; 177:24; 199:5; 218:20 designing 206:17; 210:7 designs 121:17; 123:9; 183:7 desirable 113:6 desperately 22:2 despite 27:25; 220:21; 223:5 destruction 60:11 detail 63:16 details 197:19; 198:17; 214:6 detect 42:14; 66:2; 92:25; 162:7; 181:19 detectable 38:4; 41:1; 54:11; 68:16; 124:19 detected 23:6; 26:2; 39:10; 43:19, 20 detecting 45:5; 181:14 detection 35:23; 38:5; 39:16; 41:12; 42:24; 43:3, 6, 11; 46:13; 55:9; 81:19; 225:25; 226:6 determination 137:10; 223:24 determine 16:7; 30:25; 73:1; 88:13; 91:12; 99:12; 113:8; 115:14; 116:5 determined 153:15, 17; 159:10; 188:25; 223:1 determining 99:24 develop 42:3; 63:17; 71:15; 94:9; 95:7, 17; 109:17; 114:18; 120:22, 22; 131:11; 133:5, 14; 139:25; 141:17; 149:24; 150:2; 196:3; 203:11; 221:4 developed 46: 16; 56: 13; 64:14; 68:6; 70:7; 92:6;</p>
--	---	---	---	---

93:12;97:20;98:7;100:4;
105:3;107:15;108:4;
116:17;127:22;135:16;
137:1,8;196:5;199:25
developing 95:8,14;
98:21;100:25;101:4;
107:23;108:8,22;121:6;
122:18;150:4;199:2
development 4:6; 6:10;
7:16,22;8:4;39:20;43:5;
49:10;53:8;59:6;63:7;
64:18;67:12,13,18;
68:18;71:6,10,19,20;
72:14,20;73:3;79:4,12,
18;83:25;90:17,20;91:5,
20;92:3,8,13,15;93:16;
94:1,8;95:20;96:12;
97:21,25;100:4;101:10,
23;102:1,7;103:9;106:9;
108:5;111:9;112:10;
117:13,13;119:14,23,25;
120:25;122:6,6,19;
123:5;124:8;130:16,17;
143:3,13;144:6;147:6;
152:24;160:13;161:8,9;
195:9;202:1;208:14;
214:7,21,22;215:4,19;
218:21;220:23;222:5;
226:19;227:4;228:7
developmental 175:1
develops 98:18;125:21
Devices 93:22
devised 176:8
devoted 7:20
diagnostic 93:20
diagrams 161:10
Diego 4:16;11:8;27:11,
18;218:14
differ 54:16
difference 39:24;151:22;
155:7,15
differences 25:8; 26: 12;
29:1;37:1;39:12;40:4;
60:4;130:4;154:10
different 17:16;20:4,7;
26:13;35:1;39:5,25;40:5,
5;42:11;43:5;44:11,11,
19,22;45:14;52:18;
57:25;58:25;59:1;60:5;
63:11;66:19;68:7;70:4;
71:5;95:3,3,10,10,15;
99:22;115:13,24;116:6,
8;118:8;119:9;134:19;
135:15;139:15;142:1;
147:22;150:15;154:21;
158:18;164:15;169:11,
12,14;171:24;175:13;
176:3;187:3,4;188:2;
190:7;193:1;197:1,3,14;
226:7
differentially 130:3
differently 108: 12,16;
165:1
difficult 26:6; 34:10;
40:12;42:5;64:3;67:24;
75:15;84:20;85:24;86:8,
12;110:5;133:6;152:11;
153:3,14;155:18,23;

156:6;165:22;166:2,3,
19;172:22;174:19;
176:23;188:8;205:9;
224:8
difficulty 123:17;135:7
diffus 95:13; 105:21
dilemma 76:14;134:17;
181:6
diligent 227: 15
dilution 95:12;105:21
dilutions 95:13
diminished 131:8
direct 60:12;61:3;69:2;
93:3;131:11
directed 40:20,24;
41:20;81:8
direction 38:17
directions 37: 18
directly 40:9;168:24;
169:1;222:4
Director 91:18
disagree 83: 19; 177: 11;
188:18;196:12
disagreement 215:6
disappear 46:9
disc 95:13
discerned 23:2
discernible 13:17
Discordance 38:16; 39:8
discordances 37:17,18
discover 148:17
discovered 148: 16
discrepancies 25:9
discrimination 48:25
discuss 8:3,6;34:15;
46:2;120:9;142:13,15;
144:13
discussed 10:23; 34:23;
35:24;53:9;107:2;
123:16,20;136:19;
215:13;220:12,15
discussing 7:7
discussion 9:4; 42:20;
76:7;85:13;108:10;
120:3;131:7;142:18;
197:19;198:17;219:10
discussions 6:9,16,20;
33:7;137:7;159:5;
183:25;184:13;220:8
Disease 5:14;118:8,21;
183:19;187:8;189:6
Diseases 4:17;
13,17;110:13 19;5:1,4,
8
disseminate 120:20
disseminated 66:
120:24 15;
dissimilar 111:1
distinct 161:9,10
distinguish 144:23
distribution 99:8,12
distributions 98:23
disturb 183:7
diverse 27:19;70:17;
138:8

diversity 99:3
Division 5:11,13,17,18;
7:19;91:18;101:21;
124:11,15
Division's 120:7;121:12
divisions 93:23
doable 206:4
doctor 76:15
doctors 185:13
document 10:3; 75:22;
101:22,25;102:8,11,13;
104:6,23;105:18;120:23
documented 9:24; 10:8;
25:25
domain 19:15,16;20:18
dominant 38: 12;44:6,
15;45:25;62:5;65:21
done 29: 10; 46:4;57:18;
70:6;73:8;78:18,22;82:5;
83:12,16;84:18;85:4;
86:12;95:2;98:8;108:5;
115:15,16;123:10;127:1;
134:14;137:23;138:1;
148:9;150:5;151:10;
156:12;169:21,22;
171:23;177:9;180:19;
185:9;186:11,13,15,24,
25;187:3,3,5,9;188:22;
189:1;191:8;196:16;
197:6;201:1;208:10;
209:14;211:25;216:3;
226:23
donor 23:23;24:14
donors 23:21; 24:10,17
dosage 96: 15;97:8
dose 51:11;87:18,23;
88:5;126:3;176:11
doses 50:11;93:8
dosing 125:19
dots 51:4
double 124:20
doubt 153:13
Doug 5:16;162:20;
173:21;188:16;193:21;
208:17;211:21;215:17;
225:10
down 16:18;33:4;37:23;
43:6;51:6;63:5;78:6,11;
100:10;114:20;170:22;
174:25;182:2;190:12;
192:13;206:22;218:5;
226:6
downward 190:19
dozen 63:15
DR 4:3,9,10,13,15,17,
19,21,23,25;5:2,4,7,9,
11,13,16,18,20,22,23,
24,25;6:1;7:5,18;8:23;
9:5,7,11;13:20;27:1,2,
3,4,17;28:6,6,7,7,14,
19,19,20;29:9,12,12,
13,21;30:24,24,24,25;
31:4,13,17,18,18,19,
23,24;32:1,2,4,11,11,
11,12,17;33:7,7,16;
34:12,14,19;48:18;57:9;
58:2,25;59:11,24,25;

60:1,16,23;61:3,14,14,
15,22,23;62:2,7,9,18;
63:8,22,22,23;64:16,23;
65:4,5,7,9,10,10,11,16;
66:11,25;67:1,4,16,17,
23,23,24;68:11,11,12;
69:5,5,5,6,8,18,24,24,
25;70:3,10,10,14,24;
71:2,2,3,21,21,22;72:7;
73:17,18;74:5;75:6,6,7,
8,19,19;76:5,6,20;77:2,
3,10,10,12;78:2,2,3,20;
80:15,16,25,25;81:1,7,
8,10,21,25;82:1,15,17,
18,22;83:14,20,21,23;
84:21,22,23;85:8,8,9,
24;87:3,4,13,13,14;
88:6,20,21;89:20;90:12,
13,19;91:17,25;110:7;
111:8,15,16,25;112:1,
13,14,16,16,17;113:2,
2,3,18;114:2,5,5,7,9,
11;116:25;117:10;118:3,
5,6,19,25;119:1,6,7,7,
12,19,21;120:2;131:4,5;
132:3,6,18,21;136:10,
13,15;142:3,10,22,25;
144:13;145:2,2,3;146:1,
2,3,10,11,14;150:23;
152:3,5,15,18,19;
156:13,14;157:16;158:3,
4;159:22;160:24,25;
161:6;162:14,15,16;
163:2,4,4,19,21;164:17;
165:3;166:11,12,18,25;
168:2,3,4,5,7;169:4,4,
5;170:3,3,4,13,13,14;
171:2,2,4;172:3,4,23;
174:5,14;175:2,3,16,16,
17,20,24;176:17;178:3,
20;180:3,7,8,10,11,12,
15;181:1,5,23;182:13,
13,15,18;183:24;184:14,
15,25;185:1,2,18;186:1,
7,9,10,20,21,22;187:2;
190:1,13,14,15,16,18,
21;191:1,4,9;192:1,4,
17;193:4,4,5;194:2,11;
195:6,18;196:12,13,18,
18,19;197:8;198:8,9,10;
199:10,11,16,16,19,20;
200:9,11,12,23;201:17,
18,23,24;202:11,12,15,
19,21,22;203:2,2,18,
19;204:2,3,19;205:4,13;
206:2,4,23,23,24;207:5,
14,23;208:3,4,12,16,
17,25;209:2,3,6,7,25;
210:12;211:16,19,20;
212:8,9,11;213:5,8,15,
16,17,21;214:11;227:11,
13;228:16
draft 66:18
dramatically 194:6
draw 109:12;112:11;
153:9;210:15
drawback 206:19
drawn 204:25;210:13,19
drive 72:17;146:18;
221:1;222:4;224:11

drives 218:10
driving 94:12;147:24
drop 47:20;88:25;
114:19;207:10
dropout 89:7
dropouts 51:7,23
dropping 66:9
drug 4:5,6;7:16,19,22;
8:4,5,12,24;9:8,13,21,
22,25;10:6,8,10,15,19,
21;11:16,20;13:3,6,9,
10,13,14,16,17,18,25;
14:2,8,9,10,18,23;15:3;
16:5,9,17,21;17:2,3,12,
14;18:3,8,12,21;19:2,
13,20;21:8,15,19;22:14,
22,24;23:15,16;24:3,7,
25;25:11;26:10,16,22;
29:22,24,25;30:4,8,10,
12;33:21;35:6,7,10,13,
14,17,18,21;36:3,3,3,5,
9,20;37:19;39:25;40:3;
42:9;44:20,21;45:21,22,
23;46:4;47:13,14,15;
48:3,5,14,16;49:3,6,9,
12,14;50:4;51:1,11,13;
52:15;53:8;54:12;56:10;
57:5;58:20,22,23;59:5;
60:14,15,20,21,25;61:1,
2,24;64:13,17,18;65:19;
67:12,13,18;68:4,5,9;
69:11,12,14,16;70:22;
71:6,10,12,18,20;72:9,
11,11,12,13,19,23;
73:3,5,6,14,25;74:12;
75:1,3,7;76:13;77:6,9,15,
22,24;78:1;79:4,7,12,
14,18,21,23;80:6,7,24;
81:20;82:3,4,4,20,21;
83:25;84:2;85:2,2,5,11,
15,22;87:18,20,23;88:3,
11;89:4;90:17,20;91:9,
18,19;92:15;93:16,23;
94:16;96:14,24,25;
97:25;98:9;99:18;100:4,
11;101:10,21,24;103:13,
20,25;104:15;107:22,24;
108:2;109:20,21;113:20;
115:22;117:12;119:5,22,
23,25;120:25;121:23;
122:5,6,12,14,19,22;
123:5;124:24;125:16,21;
126:6,25;128:9,13;
129:13;130:17;134:7;
135:22;136:3,7,17,18;
139:25;143:3,6,19,21,
23;145:17,22,24;148:3,
4,20,21;149:1,3,15,15,
21;150:24;151:22;
152:24;154:2,20;155:8,
22;156:24;157:14,21,22;
158:2,18;159:24,25;
160:4,10,12,18;161:8,9,
11,17;162:18,19;165:1,
8,9;167:11,24,24;
170:17,18,19,22;171:8,
10;172:9,16,18,20;
174:6,8,10,13,15;
175:15;176:2,13;177:4;
178:7,7;179:3;181:17;

182:3; 183:5; 184:2, 2, 8;
185:14, 21; 186:15;
7:19, 25; 188:6; 190:4;
2:25; 195:21; 196:3, 5,
5, 6, 7, 7, 8, 9, 14; 197:7,
12, 13; 198:2, 2, 14;
199:13; 201:12; 202:5;
203:24; 204:11; 206:10,
21; 208:14; 211:2, 4;
213:1, 2, 4, 9; 214:6, 21,
22; 215:3; 216:20, 21;
217:10, 15, 21; 218:1, 9,
12, 14, 21, 24; 219:4, 21,
23; 220:10, 23, 24; 222:4;
223:23; 224:3, 5, 13;
225:12; 226:11; 227:4
drug's 59:8; 91:12;
121:22; 130:19; 206:17
drug-dependent
122:11, 17
drug-related 56:12
Drugs 4:4; 21:21; 22:23;
36:6; 39:5, 6; 47:18, 19,
21; 48:9; 49:10, 12, 13;
52:24; 55:1; 60:22; 62:21;
68:19, 25; 69:3; 70:25;
71:15, 16; 80:10; 84:9, 10;
86:8; 87:20; 92:23; 93:16;
97:3; 98:19; 99:22; 102:7;
110:25; 115:21; 119:10;
122:16, 25; 124:13, 13;
128:25; 129:15; 130:22;
133:7; 134:13; 135:16, 20;
7:7, 24; 139:18; 140:22;
142:1; 145:7; 147:7, 16;
150:11; 151:19; 152:1, 22;
155:19; 156:19; 158:6, 20;
159:7, 13; 162:13; 168:12;
170:23; 174:24; 175:6, 11;
176:1, 11; 179:25; 181:17;
189:11; 190:5; 197:5, 21;
198:19; 199:21; 200:2, 5;
211:10, 17; 219:3; 221:4;
222:12, 13; 223:13, 22
dual 112:24; 165:20
due 94:5; 103:4; 104:1, 8;
106:5; 107:6
Duke 5:1
durability 158:8; 159: 15,
23; 160:17; 161:4
duration 16:14; 18:1, 8;
19:12, 25; 20:17, 24;
128:23; 197:21; 198:19
Durham 5:1
during 24:23; 35:9; 36:4;
54:3, 7; 62:13; 64:2; 71:18;
76:6; 88:24; 98:9; 103:23;
122:19; 123:5; 134:5
dynamic 176:9
dynamics 176:3; 224:12

E

earlier 75:8; 123:16;
135:21, 24; 151:7; 162:9;
169:6; 170:7; 173:22;
181:12
early 13: 15; 38:9; 54:3, 8,

20; 67:9; 68:20, 24; 69:2;
97:20, 23; 112:9; 134:25;
157:10; 160:16; 178:16;
190:23; 206:9; 211:11
easier 33:25; 61:17;
84:10; 110:17; 149:18;
156:11
easily 58:24; 85:1; 216:3
East 32:24
easy 36:21; 41:6; 61:16;
89:3; 99:11; 140:4;
171:10; 187:9; 194:1, 2
echo 77:12; 79:2
editorial 202: 10
effect 13:17; 14:1; 37:4,
25; 38:13; 48:16; 89:16;
127:9; 128:9; 169:25;
171:6, 7; 172:1; 174:7, 10;
176:16; 181:14, 19; 191:7;
221:22
effective 44:23; 70:8;
73:14; 77:24; 108:24;
109:3; 222:14
effectiveness 47:18;
94:5; 102:17; 103:25;
104:12, 25; 105:6, 13;
106:5, 19; 107:8, 16;
108:19, 20; 109:8, 13;
110:11; 111:6
effects 35:22; 36:18, 23,
24; 37:24; 39:23; 40:6;
52:23; 60:8; 61:11, 13;
83:12; 94:18; 170:9;
204:12
eff icacious 69: 16
efficacy 97:11; 98:3, 5,
11; 99:21; 100:1; 117:19;
122:1, 3; 167:1, 23; 178:6,
110; 179:12; 187:21; 200:7;
213:18
efficient 26: 18; 80:17;
122:18, 24; 150:20;
213:12
efficiently 67:6; 135:4;
142:20; 175:14; 213:4
effluxes 56:2
effort 21:2; 87:22;
115:18; 133:5, 12; 221:8;
227:25; 228: 13
eight 209:18
either 25:6; 28:17; 29:8;
39:16; 46: 12; 48:22;
51:20; 54:14; 57:6; 60:12;
72:3; 73:9; 92:23; 106:6;
107:6; 108:14, 15; 144:1;
154:19; 162:11; 175:8
elegantly 135:6
elements 160:6
eligibility 72:4; 86:1; 87:2
eligible 86:11; 184:19
eliminate 102:15
else 88:20; 171:1; 174:7;
199:18; 210:5; 215:18;
227:11
else's 197:7
elsewhere 221:21

emerge 55:5
emergence 144:11;
149:1, 17, 19
emerges 125:1
emerging 35:9
emphasis 124:10;
218:19; 227:17
emphasize 124:12;
125:21; 131:6
emphasized 200:13
emphatic 215:6
enable 141:19
encoded 55:25
encourage 125:18
encouragement 220:22
end 51:16; 87:10; 102:19;
103:6; 142:19; 148:13;
166:16; 168:20; 184:22;
194:15; 221:24
ended 228:14
endocarditis 110:14
endpoint 122:1; 188:22,
24, 24; 189:18; 190:24;
220:12, 13
endpoints 122:3; 189:1
enemy 56: 15
engender 131:9
engenderment 131:14
England 29:2
enhance 73:24
enough 38:6; 44:1;
49:18; 52:25; 66:2; 117:9;
129:21; 144:21; 148:21,
24; 149:3; 155:13; 157:15;
163:7; 165:13; 172:1;
177:14; 191:13; 195:18;
213:7, 11
enrich 121:20; 129:10;
175:8; 178:21
enriched 179:12; 187:21
enrichment 175:4;
180:13
enrolling 117:15
ensure 86:4, 5
enter 72:18; 152:1;
155:19
entering 75:11; 87: 11
enterococcal 110: 14
enterococcus 112:18
entire 6:13; 43:10; 73:2,
12; 148:11
entirely 22: 17
entitled 90:19
entry 51:5
ENVA 42:16
envelope 25:1; 225:1, 4
envision 77:21; 170:5
enzymatic 56:4
enzyme 135:14
enzymes 56:6; 61:9;
136:6
epidemiologic 72: 15;
79:24; 222:7

epidemiology 187:25;
188:3, 4
equal 44:10; 57:16;
103:24; 105:16
equation 99:14
equipment 115:23
equipose 186:4
era 134:3; 157:14;
180:11; 217:3
Erice 9: 14
error 186:13
escape 173:20, 20;
178:16; 217:24; 218:3
especially 64:4; 71:12,
17; 157:11; 182:22; 194:8;
196:22; 209:16
essays 56: 13
essential 134:5; 201:21
essentially 79:13;
216:12
establish 122:4; 196:24;
202:3
established 16:6; 57:3;
65:17; 79:16, 18; 100:18,
22; 104:2; 105:14; 133:11,
25; 159:6; 222:25
establishing 113:5, 7;
212:14
estimate 212:2
estimated 11:10
estimation 30:16
et 137:5; 140:19; 148:4;
156:7; 165:12; 177:16;
218:14; 221:17
etc 197:22; 198:20
ethical 76:14; 173:24;
185:17; 188:18
etiologic 100:14; 104:17;
118:2
Europe 21:22
European 16:2; 19:7
evaluate 34:2, 11; 43:12;
48:11; 52:13; 84:23;
129:13; 167:11; 199:12;
201:21; 205:16
Evaluated 11:3; 13:1;
15:8; 24:25; 25:21; 28:3;
50:14; 60:10; 72:21; 73:2;
79:6
evaluating 33:23
evaluation 137: 11
evaluations 201:12;
206:20
even 6:7; 22:20; 25:14,
22; 26:4; 32:23; 34:10;
47:18; 51:12; 62:23; 69:1;
70:2; 71:8; 77:25; 84:17;
87:6; 118:22; 123:25, 25;
129:5; 152:7, 16; 154:25;
162:17; 168:15; 170:1;
172:12; 173:12; 202:8;
207:3; 210:2; 218:12, 21,
23; 225:6
event 6:20; 24:15; 85:2
eventual 96:3

eventuality 191:5
eventually 54:11; 134:11
everybody 52:20; 80:10;
191:6; 227:20; 228:3, 12
everyone 35:5; 63:19;
71:11, 24; 178:13; 198:24
evidence 8: 1; 99:6;
102:4; 104:11; 106:21, 21,
22; 107:8, 15; 108:15;
109:16, 24; 110:3; 117:21;
143:7; 144:8, 10, 25;
147:21; 149:16; 151:17;
152:21; 154:24; 167:22;
178:5; 225:2
evolution 25:1; 35:13;
81:4; 157:20, 22; 224:23,
25; 225:2, 5
evolutionary 60:6;
157:17
evolve 55:6
evolved 164:1
evolving 177:15; 180:17;
225:4
exact 22:11; 37:13
exactly 64:24; 112: 15;
180:10
examine 8:20; 74:2;
169: 17
examined 43:15
example 16:12; 22:5;
33:12; 45:4; 48:18; 63:25;
64:9; 68:3; 72:11; 73:20;
77:23; 80:5; 82:2, 4, 8, 9,
19; 93:4, 13; 96:23; 97:1,
12, 12, 22; 99:1, 19;
100:23; 106:12; 107:23;
108:22; 112:19; 117:21;
118:12, 19; 124:3; 126:8,
8; 128:12; 130:13; 135:23;
136:3; 137:22, 25; 145:10;
146:4; 148:11; 153:25;
156:22; 165:15; 169:6;
173:15; 176:24; 177:23;
191:16; 195:12; 204:10;
213:7; 221:8; 226:8
examples 38:21; 40:13;
106:10; 130:12; 143:6;
149:20; 186:17
exceed 50:2
except 74:24; 110:13;
227:9
exception 185: 18
exceptional 126:23
excess 138: 13
exclude 6:23; 23:4;
67:25; 74:23; 77:18;
87:11; 129:10, 22
excluded 75:4; 77:14;
80:1; 178:1
excludes 86:7
exclusion 6:24; 72:5;
129:7, 22; 184:1, 10
exercise 133:24
exhibits 103:20
exist 26:13; 32:9
existing 81:13

<p>expanded 76:8, 9, 23; 78:12</p> <p>expect 30:2; 64:9; 65:5; 77:18; 78:6, 10; 119:15; 139:12; 164:23; 174:13</p> <p>expectation 209:22, 23</p> <p>expected 95:1; 123:5; 141:22; 159:13, 13</p> <p>expecting 90:22; 174:12</p> <p>expensive 59:21; 78:6; 162:11; 222:20; 223:7</p> <p>experience 32:14; 42:21; 52:17; 111:10; 165:18; 184:8; 198:2; 203:7; 210:3</p> <p>experienced 44:25; 49:20; 50:10; 64:4, 8; 67:19; 70:23; 80:20; 121:18; 126:11, 18, 23; 127:1; 171:6; 174:2; 184:7; 213:1; 218:22</p> <p>experiential 76:24</p> <p>experiment 174:11</p> <p>expert 177:18</p> <p>expertise 162:4</p> <p>experts 176:25</p> <p>explain 23:10; 65:9, 15; 85:1</p> <p>explained 25:8</p> <p>explaining 183:3</p> <p>explanation 47:22</p> <p>explanations 36:22</p> <p>explanatory 183:2</p> <p>exploited 224:19, 20</p> <p>exploration 107:20</p> <p>explored 108:4; 128:8</p> <p>expose 222:12</p> <p>exposure 11:11; 21:24; 28:13; 85:2; 87:25, 25; 165:9</p> <p>exposures 26:14</p> <p>extended 68:21; 148:15</p> <p>extensive 13:4; 98:5; 137:2</p> <p>extent 37:5; 40:1; 112:2; 137:24; 150:22; 198:1</p> <p>external 226:24</p> <p>externally 216:9</p> <p>extra 179:20</p> <p>extraordinary 204:22</p> <p>extrapolate 1 10:3</p> <p>extrapolated 179:13; 187:22</p> <p>extrapolating 182:23; 188:7</p> <p>extremely 28:23; 74:24, 25; 174:18</p> <p>eye 26:11</p>	<p>facility 149:23</p> <p>fact 14:2; 15:5; 23:7; 35:5; 18; 53:10; 73:13; 78:4, 21; 80:9; 93:8; 94:19; 97:4, 5; 98:9, 12; 99:21; 100:20; 107:25; 108:24; 109:13; 117:14, 21; 128:15; 154:1, 1, 20; 158:23; 171:12; 172:20; 188:23; 191:23; 192:20, 21; 194:20; 207:9; 220:20; 222:13; 223:20; 227:14</p> <p>facto 167:20; 177:19</p> <p>factor 36:2; 47:12; 58:18, 19, 24; 64:3; 70:4; 72:25; 79:22; 85:18; 90:4</p> <p>factorial 181:18</p> <p>factoring 158:20</p> <p>factors 8:7, 9; 9:1; 34:15, 17, 22; 35:1, 17, 20; 56:12; 64:12; 74:8; 83:10; 88:7, 12; 89:22; 96:2, 21; 99:23; 123:15, 16, 18; 148:2, 3; 150:12; 153:19; 210:11; 219:15</p> <p>fail 65:6; 80:18; 147:7; 164:18, 19; 202:5, 13; 206:19; 212:18; 213:2; 219:22</p> <p>failed 51:6, 6; 64:8, 11; 65:9; 68:15; 145:15; 151:7; 204:7</p> <p>failing 36:10; 51:7; 54:12, 17; 55:23; 57:7; 76:1; 86:2, 10, 10; 180:23; 205:18</p> <p>fails 206:10; 212:17</p> <p>failure 10:19; 35:7, 9, 14, 19; 36:9; 51:20; 53:23; 54:1, 3, 20; 57:4, 5; 64:13; 67:19; 72:5; 78:14, 14; 79:16, 17, 19; 80:18, 22; 81:3, 11; 82:20; 83:5; 84:12; 88:3, 13, 14; 96:5; 127:11; 144:3, 21; 145:14, 17, 21; 147:3, 24; 148:6; 151:7, 12; 158:7; 164:9; 165:9; 172:22; 179:6; 180:1, 2; 181:24; 182:1; 185:23; 188:24; 189:12, 13, 17, 18, 18; 190:24; 192:20; 204:17; 205:4; 206:9, 17; 211:11; 212:5; 218:1, 2, 6; 223:4, 11</p> <p>failures 51:16, 20; 54:2, 9; 65:2; 68:19; 75:14, 24; 76:2; 81:23; 129:16; 157:18; 192:6; 199:6; 204:21; 205:2, 10</p> <p>fair 78:20; 89:14; 140:24; 160:8; 194:3, 4; 198:1; 214:18</p> <p>fairly 18:16; 22:10; 31:7; 32:25; 83:6; 142:16; 150:10; 171:10; 172:23; 209:13</p> <p>fairness 7:2</p> <p>fall 17:22; 76:21; 97:9</p> <p>false 39:17</p>	<p>familiar 35:5; 152:16; 154:14</p> <p>far 44:1; 60:23; 63:19; 64:19; 70:2, 16; 79:17; 88:7; 90:2; 110:17, 23; 111:6; 118:21; 120:10; 123:14, 22; 124:10; 125:16; 127:4; 128:21; 135:24; 136:3, 19; 152:12; 163:16; 166:9; 189:3; 195:14; 205:2; 221:15, 16</p> <p>farther 85:21</p> <p>ffashion 73:7; 76:25; 161:12; 205:20; 220:1; 228:20</p> <p>fast 150:1</p> <p>faster 136:8; 176:12; 209:24, 24</p> <p>fDA 5:6, 19, 21, 22, 23, 24, 25; 6:21; 7:19; 93:16; 98:9; 105:23; 113:4, 8, 19; 115:19; 116:15; 117:2; 120:23; 135:21; 141:23; 142:22; 163:10; 179:5; 183:16; 196:14</p> <p>F-DA's 6:18</p> <p>fear 226:1</p> <p>feasibility 123:19; 179:10; 190:2; 205:24; 208:13, 19; 211:20</p> <p>feasible 43:24; 44:1; 162:5, 11; 207:1, 5; 209:15</p> <p>feedback 90:22</p> <p>feel 32:12, 16; 145:8; 180:16</p> <p>fceling 73:19; 155:11</p> <p>few 19:8; 37:5; 78:4; 92:4; 100:24; 115:21; 136:17, 21, 23; 141:14; 143:23; 145:4; 174:18; 213:25; 218:15</p> <p>fewer 55:15; 115:12</p> <p>field 112:12; 188:19; 196:20; 210:13, 18; 214:20; 222:4; 224:11; 228:9</p> <p>fight 158:25</p> <p>figure 89:18; 158:13; 162:22</p> <p>final 35:13; 115:8; 178:20</p> <p>Finally 20:23; 26:9, 20; 36:14; 40:8; 84:13; 97:6; 100:2; 105:18; 108:17; 109:23; 141:16</p> <p>finances 185:24</p> <p>financial 6:22</p> <p>financially 76:21; 211:23</p> <p>find 80:23; 86:12; 118:14; 138:25; 157:1; 158:10; 186:3; 189:24; 205:7</p> <p>finding 28:25; 41:5; 159:16; 211:8</p> <p>findings 33:14; 52:8</p> <p>fiine 174:2; 177:11</p> <p>fiinish 100:16</p> <p>fiirm 6:12</p>	<p>firms 6:21; 7:3</p> <p>first 9:4, 13, 20, 22; 10:1; 11:13; 15:13; 16:12; 27:22; 53:25; 54:3, 9; 57:6, 10, 15; 59:12; 60:17; 67:10, 19; 68:18; 75:24; 79:16; 83:13; 91:17; 103:11; 104:4, 4; 120:17; 124:24; 127:6; 129:6; 132:6, 17; 133:25; 138:17; 139:6; 140:15; 142:15; 144:18; 146:23; 148:23; 149:2; 150:13, 18; 152:22; 157:22; 158:8, 11; 160:1, 9; 161:1; 168:13; 175:17, 19; 176:11, 19; 192:20; 193:11; 194:9; 195:6; 196:6; 207:17; 209:4; 214:11, 11, 18; 220:20; 223:12; 225:24</p> <p>first-time 126:22</p> <p>first-time 21 1:11</p> <p>firstly 137:15</p> <p>fit 58:3, 9, 10, 15, 21; 60:14, 14; 122:15, 16</p> <p>fitness 14:3; 58:5, 17; 60:3, 4, 5, 10, 19, 21; 61:10; 134:23, 25; 135:2; 224:12</p> <p>five 11:6; 31:15; 115:12; 132:14; 142:12, 17; 143:8; 144:13; 150:19, 20; 161:13; 163:14; 194:19; 209:5, 21, 22</p> <p>flawed 194:9</p> <p>flexibility 191:14</p> <p>flip 153:20</p> <p>flurry 86:23</p> <p>focus 63:2; 67:13; 183:8; 184:12</p> <p>focused 67:8; 68:18; 183:25; 184:3</p> <p>focusing 63:6</p> <p>fold 12:20; 19:5; 139:17, 21, 23, 24; 140:5, 7, 19; 147:9</p> <p>follow 63:9; 75:7; 81:22; 83:4; 205:9</p> <p>follow-up 22:20; 24:13, 19; 25:2, 6; 134:7; 156:2; 157:11; 203:7, 15</p> <p>followed 127:14; 158:8; 201:20</p> <p>following 6:5; 10:10, 11; 103:24; 154:18; 204:10</p> <p>follows 96:11</p> <p>tfoot 64:23</p> <p>fforce 94:13; 130:7</p> <p>fFord 5:16; 68:14</p> <p>fore 92:12; 103:8</p> <p>foresee 110:24</p> <p>forget 118:17</p> <p>forgot 31:19</p> <p>form 10:2; 99:10</p> <p>formally 60:13; 142:11</p> <p>format 102:15, 20, 22;</p>	<p>105:19</p> <p>formats 7:9; 215:16</p> <p>former 149:19; 150:13</p> <p>forms 106:6</p> <p>formulation 124:6</p> <p>forthcoming 223:5</p> <p>fortunately 169:5</p> <p>forward 9:3; 66:20; 136:8; 141:23; 142:7; 146:22; 177:12; 220:9; 222:2; 228:9</p> <p>found 17:18; 63:10; 103:12; 139:19; 205:5</p> <p>four 48:20; 130:10, 25; 142:13; 143:1; 161:21; 222:6</p> <p>fourth 176:2; 201:11</p> <p>frame 221:10</p> <p>framework 92:6; 93:10; 102:6; 107:14; 108:18; 110:12; 183:22</p> <p>framing 146:10</p> <p>Francisco 218:14</p> <p>Francois 136:11</p> <p>frank 92:25</p> <p>Freedom 6:18</p> <p>reezer 86:3; 197:4</p> <p>French 19:8</p> <p>requecies 21:22</p> <p>requecy 18:16; 30:9; 46:18; 125:17, 25; 126:2; 149:23; 150:9</p> <p>frequently 22:23; 25:12; 32:19</p> <p>front 71:13, 14; 88:16; 159:3; 177:17; 189:17</p> <p>fulfill 106:16; 127:2</p> <p>fuifills 108:25</p> <p>full 189:23; 224:21; 226:6</p> <p>full-length 191:18, 19</p> <p>fully 49:7; 128:8; 164:8, 9; 165:11; 175:20</p> <p>function 116:8</p> <p>functional 57:17, 20</p> <p>fungi 114:12</p> <p>further 42:3, 22; 52:16; 53:16; 55:17; 71:23; 118:22; 164:3; 174:3, 25; 194:16; 198:7; 200:21; 205:20; 207:11; 220:23; 223:3</p> <p>future 39:18; 49:5; 56:13; 58:7; 72:1; 138:2; 141:10; 196:23; 222:3, 16; 227:3; 228:8</p>
<p>F</p> <p>fabulous 228:19</p> <p>face 187:4</p> <p>facilitate 221:2</p>			<p>G</p> <p>gains 220:19</p> <p>Gaithersburg 120:21</p> <p>gamut 138:14</p> <p>GART 47:19; 130:4</p> <p>Gary 91:17</p>	

<p>gather 75:5 gave 61:25; 154:21 ge 55:25; 160:7; 2:13 genera 109:6 general 6:14; 29:7; 31:8; 11; 52:23; 55:10; 56:25; 57:22; 102:1, 11; 104:17, 22; 105:8; 107:9, 14; 109:5; 111:8; 163:21; 168:4, 25; 187:12; 198:3; 199:11; 215:9 generally 12:7; 13: 15; 33:18; 38:5; 44:16 generate 178:2 generated 135:17; 183:19 generation 196:6, 8 generic 214:5 genes 61:11; 155:4; 167:18; 176:21 genetic 29:23; 37:2; 44:8; 58:12; 84:24; 85:3; 144:4, 21; 145:22; 147:4, 12; 149:21; 150:6; 161:18; 162:7; 165:18; 166:1; 199:3 genetically 42:11 genetics 145:9 genital 24:14, 17; 26:2; 10 gnome 35:25; 44:10, 16; 160:7 gnomes 13:25; 44:11 genotype 26:3; 37:17, 20; 38:18; 40:1, 19; 64:14; 72:4; 87:20; 138:16; 139:4; 141:4; 168:14; 170:21; 193:9; 210:20; 212:8; 213:7 genotypes 41:12; 62:23; 74:13; 167:2 genotypic 7:24; 8:15; 12:8; 29:3; 33:18; 37:10; 39:14, 15; 53:17, 22; 71:25; 122:20; 143:25; 144:8; 147:21; 173:5; 179:22; 189:8; 215:10, 12; 216:21; 222:20 genotypic/phenotypic 201:22 genotypically 39:2; 153:25; 219:6 genotyping 38:5; 39: 11, 21; 48:23; 49:2; 151:10; 179:17; 180:5; 185:6; 186:23; 188:12; 192:9; 193:6; 202:4; 211:2; 212:12; 215:21 geographic 26:12; 22; 99:3 geographically 105:9 Georgetown 4:18 geotype 36: 19 gets 59:4; 74:6; 107:4; 148:22; 173:21; 174:16;</p>	<p>182:10 Girish 5: 18 given 12:4; 37:4, 13; 48:14; 76:9; 82:19; 99:2; 103:8; 114:21; 119:2, 5; 142:12; 198:11; 204:23; 207:9 gives 80:23; 111:1; 205:18; 206:21 giving 43:9; 44:6; 64:5; 131:13 glad 58:2; 197:23 glibly 79:3 glycoprotein 55:25; 56:1 glycoside 112:19 goal 59:17; 63:5; 92:18; 95:22; 102:13 goals 94:9; 101:16; 228:12, 15 goes 62:19; 82:12; 210:13 gold 200:8 Good 7:18; 34:24; 36:19; 37:9; 42:23; 52:2; 56: 15; 65:23; 73:16; 91:21; 116:1; 118:13; 120:20; 126:6; 137:25; 142:25; 145:13, 14, 20; 146:19; 148:19; 155:13, 18; 156:1, 3, 25; 157:16, 25; 158:10; 166:22; 169:6; 170:9; 171:7; 172:20; 174:23; 183:24; 196:6; 204:19; 205:13; 207:22, 23; 223:13, 13; 226:20, 21 government 116:14, 14, 15; 221:3; 228:2 gp120 24:11, 13 grab 203:9 Grail 221:15 grams 126:3, 4 grent 121:5 Girant's 18:7 granted 6:15 grappling 101:4; 137:14 gray 13:21 great 16:1; 28:20; 37:5; 43:22; 57:11; 77:22; 97:5; 116:25; 174:9; 206:12 greater 11:19; 12:9, 11, 19, 23; 14:7, 15; 15:22; 17:5, 6, 17, 19, 21; 18:5, 6, 2, 2; 19:3; 20:6, 6, 8; 21:4, 23; 23:2, 7; 55:17; 59:15; 102:16; 103:23; 125:8; 135:25; 137:24; 140:14, 17; 151:14; 188:14 greatest 110:12; 203:17 green 140:12 gross 164:12 groundwork 91:21 group 13:22; 19:11; 27:21, 21; 34:9, 10; 76:11; 82:10; 89:19; 113:4, 7; 114:15; 116:12; 117:8; 120:19; 122:9, 10; 154:5,</p>	<p>6, 17, 21; 155:3, 16; 157:25; 164:24; 169:10; 176:14, 25; 195:4; 212:22, 215:5; 217:24 grouped 167:18; 176:21 groups 10:9; 23:17; 31:5, 32:15; 48:20; 55:14; 111:22; 116:15; 154:8; 175:14; 202:6, 7, 7; 205:15; 213:4; 221:6, 9; 226:24; 228:2 grow 78:5; 133:15 grows 58:21 growth 135:12 guess 33:5; 62:19, 21; 69:6; 70:19; 75:13; 85:10; 111:8; 113:6; 138:3; 147:22; 164:17; 165:1; 170:25; 182:23; 223:6 guests 4:8; 228:17 guidance 102:10; 120:23; 123:4; 146:9; 198:11 guide 49:2; 96:7 guideline 104:22; 105:8 guidelines 13:10, 12, 22; 16:4; 180:17, 21 GULICK 4:19, 19; 32:11, 112; 54:23; 76:5, 6; 162:15, 116; 181:23; 208:3, 4</p>	<p>191:1, 9; 192:17; 193:4; 194:11; 195:6; 196:18; 197:8; 198:10; 199:16; 200:9, 23; 201:23; 202:15 203:2, 19; 204:19; 205:13 206:23; 207: 5, 23; 208: 12 211:16; 213:15, 21; 214:11; 228:16 hand 73:23; 171:2, 22; 210:23; 212:18; 215:20 hand-pick 141:14 handed 187:6 handle 73:25; 164:25; 185:10; 205:14 handled 66:23; 87:2; 185:23; 187:7 handling 226: 15 hands 72:7 happen 89:5; 211:7 happened 157:9, 11; 220:21 happening 62:24; 75:25; 155:22 happens 114:22; 150:9; 171:10 happy 202:8 hard 47:5; 152:7; 177:1; 228:13 harder 61:4, 16; 174:15 hardly 118: 14 harken 101:2 harmful 131:13 tiarrington 74:16, 17; 77:12; 117:1, 2; 144:19, 20; 147:2; 161:14, 15; 174:20; 182:18, 19; 187:16; 188:9; 193:20; 207:12, 13 tiarvard 132:18, 22 htat 217:1 Haven 5:2 heading 152:10 Health 4:22; 5:12; 93:21, 22 hear 131:1; 163:7; 191:1; 214:16 heard 27:10; 28:16; 35:8, 24; 47:17; 49:13; 53:16; 56:23; 65:24; 120:10, 21; 127:14; 134:5, 23; 135:20, 24; 164:18 hearing 70:20; 132:5, 7, 18; 142:6, 10; 147:14; 217:18 heavily 45:1, 68:13; 69:1; 70:24 Hleidi 5:25; 214:12 help 49:2; 71:20; 72:17; 84:10; 113:1; 114:6; 122:3; 130:13; 131:2; 135:18; 165:2, 3; 174:22, 22; 184:16; 196:14; 224:14, 15 helped 205:16; 220:5 helpful 28:23; 84:1; 116:10; 121:19; 142:4;</p>	<p>203:25; 220:7; 224:2, 5; 226:19 helping 116:10; 206:18 helps 199:23; 221:1, 14 Henry 5:16; 174:4 Henry's 172:12; 175:3 hesitant 163:22 heterogeneity 24:16; 89:14; 181:13, 23 heterogeneous 25:3; 42:11; 183:5 heterosexual 31:16, 17 high 11:11; 12:4; 15:21; 18:16; 51:16; 52:9, 25; 72:12; 83:22; 124:12; 126:13; 129:2; 133:19; 140:17; 149:25; 150:2; 161:18; 167:12; 176:9, 15; 199:1 high-level 14:15 higher 11:19; 16:23; 29:16; 31:9, 11; 49:9, 10; 53:5; 76:4; 93:8; 150:2; 176:6; 198:3 highest 51:12 trighlight 143:2 trighlights 141:7; 194:23 trighly 22:23; 44:25; 139:8; 174:1; 217:20 tiirsch 13:11 tiistograms 99:11 tiistorical 91:23; 92:2 tiistorically 76:23; 103:3; 134:8 tiistory 21:25; 75:22; 110:10, 12; 177:5; 188:6; 200:16, 16, 19; 201:3; 203:7; 223:6 tiit 142:20; 194:23 tiits 209:11 tiIV 4:5; 5:13; 8:13, 24; 9:8, 10, 13, 15, 21, 23; 10:4, 6, 7, 8; 11:5, 10, 13; 16:10, 13; 18:1; 19:9, 11, 25; 21:5, 9, 14; 22:1; 23:15, 16, 20; 26:13, 24; 27:24; 35:11, 21; 67:11; 80:11; 91:22; 101:5; 108:10; 112:6; 119:22, 24; 120:7, 11, 24; 121:23; 122:10; 123:14, 22; 128:7, 25; 129:6; 133:9, 11; 134:1; 143:2, 19, 22; 167:18; 176:21; 183:19; 187:9; 189:6; 205:25; 214:21 tiIV-1 8:5 tiW-RNA 122:2, 8 tiW-RNAs 78: 17 tiivid 126:20 tioc 206:6 tioliday 120:21 tioly 221:15 tiome 20:5 tiomogeneity 24:18</p>
---	--	---	--	---

<p>honestly 156:3;189:7; 194:23;195:2; 225:19 hope 28:5; 111:22;120:2; 131:2; 164:4; 214:19; 220:20, 22; 221:1 hopefully 67:6; 120:18; 126:5; 142:16;152:20; 170:23; 221:2; 223:18; 226:11; 227:17 hoping 141:22 Hopkins 4:12; 5:10 Hospital 4:24; 5:1, 3, 16 host 35:11; 60:8; 96:2 hours 209:18, 21 house 20:5;197:2; 216:5 Houyez 136:11 HSV 133:9 huge 74:19; 76:20; 131:14; 226:15 human 6:10 hundreds 150:15; 203:12 hurt 189:1 Hybridization-based 43:3 hydrolyzed 174:9 hypersensitivity 140:7 hypotheses 177:13 hypothesis 178:2; 207:22 hypothetical 143:5; 152:8; 187:24</p>	<p>identified 12:5, 7; 13:2, 22; 14:7, 20, 21, 22; 15:10, 12, 15, 23; 16:16, 20; 17:12, 23; 18:3; 20:11; 21:18; 23:17, 19; 24:9, 10, 16; 25:3; 30:13, 14; 31:6; 33:22; 38:23, 24; 52:7; 53:11, 13; 82:11; 110:15, 16; 126:24; 143:25; 145:16; 167:25; 178:8 Identify 13:7, 12; 14:17; 15:14; 39:2; 55:4; 62:8; 82:6; 132:9; 134:9; 144:4, 21; 147:3; 204:6, 17 Identifying 26:11, 19 ii 78:23; 97:25; 213:14 II's 200:2 I/III 91:15; 213:3 III 5:19; 78:23; 80:5; 98:2, 4; 100:5, 9; 206:11, 18; 212:20, 21 illustrate 8:17 illustrates 45:23 illustration 217:19 imagine 220:8 imbalance 90:2 immediate 47:23 immediately 68:21; 69:4; 72:8; 140:23 immune 35: 11 immunization 204:5 immunocompromise 112:22 immunodeficiency 6: 11 Impact 6:11; 68:25; 123:9; 218:24 impaired 57:25 imperfect 56:10 impetus 127:13 implications 6:13; 23:11; 179:17; 186:23; 188:12 Implied 102: 16 imply 29:25 implying 172:7 import 97:5 importance 75:9; 92:12; 224:17 important 27:7; 35:17; 36:10; 39:18; 42:21; 44:4, 17; 45:13, 16; 47:10, 15; 53:8; 54:8; 63:14, 17; 66:11; 71:11; 84:3, 13; 89:20; 92:21; 93:15; 94:20, 24; 95:7, 16; 96:2; 98:24; 99:17, 21; 100:22; 101:15, 16, 18; 102:12; 104:10; 110:11; 115:16; 134:15; 137:11; 138:17; 141:13; 144:22; 145:5, 19; 146:15; 150:6; 154:16; 156:16; 157:2, 4, 8; 159:4; 160:13; 161:8; 168:7; 172:11; 173:4; 181:6; 184:12; 192:14, 25; 193:5; 199:12; 200:14, 22; 201:7, 15; 202:12; 210:6; 214:11;</p>	<p>215:10; 216:9; 217:3, 7; 218:5; 219:7; 220:21; 221:21; 222:1; 223:16; 224:22; 225:9, 19; 227:22 Importantly 101:14; 221:19 Imposed 216:9 impossible 34:1; 175:8; 189:24; 197:5 impressed 69:6 impressive 78:1; 139:24; 205:16 Improve 14:3; 43:2, 11, 21; 48:15; 121:17; 181:13; 221:20 Improved 56:13; 225:25 Improvements 226:4 improves 223:2 improving 209:17 inaccuracies 97:4 Inactive 47:19, 21; 174:9 Inaudible 138:5 include 8:10; 70:23; 86: 1; 94:10; 95:12; 98:23; 116:14; 124:11, 16; 129:12; 130:6; 138:20; 143:15; 153:1; 163:7; 196:15; 197:19; 198:17; 216:11 included 40:2; 64:13; 92:10, 16; 101:10; 102:20; 103:10; 104:20; 106:13; 107:11; 126:5; 128:3, 18; 143:21; 171:18; 201:2 includes 35:21; 98:12; 99: 15; 108:20; 143:4 including 42:13; 45:10; 56:5; 78:12; 94:11; 128:17; 151:9; 164:10 inclusion 82:14; 86:6; 94:3; 102:25; 103:20; 105:3; 106:17; 129:7, 21; 168:8, 16; 179:5, 11; 184:15, 16, 22; 187:11 inclusion/exclusion 169:23 incomplete 40:9; 127:21 incorporate 179: 15; 181:20; 188:10, 16 incorporated 91:15; 100:s incorporates 185:2 incorporating 205:25 incorporation 179:10; 187:11 increase 15:14; 20:12; 38:7; 68:9; 140:5, 7, 13; 176:10; 194:6; 221:19 increased 40:14; 139:21; 157:6 increasing 216:8; 218:19; 222:8 increasingly 83:1; 115:20; 217:8; 226:5 incredibly 227: 1 S increment 63: 1</p>	<p>Incremental 212:3 incrementally 43:21 incurred 212:7 indeed 36:19; 38:21; 42:16 Independent 113:7; 161:12; 171:25; 205:20 Independently 55:7; 66:18; 113:22; 114:1; 123:10; 171:19; 179:17; 186:23; 188:12 Index 97:4 indicate 11:18; 12:1; 37:19; 38:18; 41:10; 44:7; 51:4; 53:4 Indicated 51:10; 163:23 indicates 37:20; 46: 11; 179:23; 189:9 indicating 12:19; 47:1; 203:4 indication 73:13; 79:23; 104:7, 11, 19; 107:5; 122:5; 126:10, 15, 17; 131:8, 13; 167:23; 177:22; 178:6; 184:5, 5, 6; 185:14; 187:14, 18; 197:15; 198:1; 203:21; 205:18; 218:13, 22; 219:4 indications 92:14; 102:4, 5; 103:12, 16; 104:5; 105:15; 109:18; 123:8; 124:3; 126:8; 143:5; 151:2; 167:5; 187:17 indinavir 12:17; 22:9; 46:16, 21, 24; 50:22; 54:20; 125:24; 126:2; 127:15, 23; 128:17; 139:1, 20; 140:8, 19; 174:3 indirect 60:12; 131:11 individual 48: 14; 62:20; 63:4; 74:12; 75:18; 132:17; 144:14; 173:5; 188:4; 224:5, 8; 226:14 individually 151:20; 204:14; 215:13 individuals 8:25; 22:3; 50:6; 65:1; 75:14; 126:18; 132:8, 9; 224:25; 225:16 induce 91:12; 198:15, 25 induced 56:2 inducing 130:19 industry 116:13; 206:8; 221:3; 228:1 ineffective 77:16 inexpensive 78:16 inexperienced 213:2 infant 24:3, 4 infected 8:25; 21:14, 18; 23:22; 24:1, 3, 4, 25; 26:21; 31:10; 57:2; 65:13, 14, 24; 85:12; 129:6; 225:6, 16 infection 9:16; 11:6, 10; 16:10, 14; 18:1, 8, 20; 19:1, 11, 11, 25; 20:1, 21; 21:6, 7, 10, 11, 14; 23:11,</p>	<p>20; 26:18, 24; 27:21, 24; 31:6; 57:3; 65:18; 68:1; 70:25; 71:1; 79:16, 16, 18; 92:20; 96:16; 97:2; 100:11, 12, 14; 107:5; 117:25; 160:23; 222:25 infections 85:19; 94:5; 99:4; 103:4, 15; 104:1, 8, 18; 105:13; 106:5, 23; 107:11; 108:21; 110:10 Infectious 4:17, 19, 25; 5:4, 7, 17 infer 66:17 inference 227:10 Inferential 172:25 Inferior 162:25 inferring 114:9 inflection 173:6 inflections 173:9 influence 122:5; 129:5 inform 204:13 Information 6:19; 32:9; 49:19; 63:13; 64:17; 71:16; 72:1; 73:22; 75:3, 5; 84:4, 8, 15; 88:11, 11; 92:10; 94:4; 97:17, 22, 23; 98:11, 13, 14, 17, 18, 20, 25; 99:15; 101:9, 12, 13, 16, 17; 103:1, 10; 106:7, 8, 11; 108:11, 17; 109:12; 114:8; 115:5, 9; 121:13; 124:19; 143:4; 160:15; 163:8, 9; 168:25; 169:3; 172:24; 179:23; 180:9, 24; 183:18; 189:9; 191:12, 22; 192:14, 17, 22; 193:25; 200:15, 21; 202:25; 203:6, 7, 10, 23; 205:16; 207:25; 220:10, ii; 226:21; 227:22; 228:10 infrastructure 161:3 Infrequent 144:11; 145:1; 149:17 inhibit 137:9 inhibited 58:23; 97:7 inhibitor 19:23; 20:22; 49:3; 61:18, 19; 127:7; 128:4; 138:4; 139:12; 148:12; 151:8, 10, 11, 12; 165:19, 25; 167:8; 178:24; 179:2 inhibitors 11:17, 25; 12:13, 16, 22; 15:13, 16, 18, 23; 18:10; 22:15; 33:25; 41:24; 48:7, 8; 50:20; 62:13, 13; 124:22; 127:10, 22; 128:8, 10, 17, 19; 137:10; 141:20; 150:3; 173:10 inhibitory 35:10; 59:2; 94:13 initial 9:24; 68:7; 85:14, 22; 166:1; 179:22; 189:8; 191:14; 228:11 initially 151:11 initiate 35:9; 91:4; I 130:17; 156:8; 191:13</p>
<p>I</p>				
<p>i.e 153:20; 171:5; 219:22 I/II 125:7; 212:25; 213:7, 8, 12 IACONO-CONNORS 5:22, 22 IAS 65:11; 193:16 IAS-USA 56: 18 IC50 33:13; 37:13; 38:7; 48:5; 49:11, 15; 50:3; 51:2, 3, 9, 16; 59:3, 8, 14, 19, 22; 63:24, 25; 64:3, 5; 65:3; 83:24; 116:7; 139:21; 140:5, 13; 146:18; 223:21 IC50s 51:4, 12; 59:13; 116:s IC90 59:3, 8, 19; 64:2; 223:21 IC95 59: 19 ICAAC 9: 14 ICAC 200:25 idea 63:3; 107:4; 116:1; 160:8; 162:3; 176:13; 204:19; 207:2 ideal 193:21 idealized 173:1, 14 identical 36:24; 154:7, 23; 173:18 identification 22:3; 38:22</p>				

<p>initiates 36:8 initiating 22:11; 34:8 initatives 121:1, 8 initiator 35:6, 19 injection 10:10 Inn 120:21 inner 70:1, 5, 12 innocent 152:18 inoculum 94:18; 146:5, 15, 17 input 227:20 insertion 38:22; 41:17 insofar 182:15 instance 33:19; 202:2 instead 184:23 instituted 61:24 Institutes 5:12 instructive 46:10; 47:4 insurance 193:24 integrated 101:18 intelligent 223:13 intended 214:2 intensify 54:14 intent 127:2 interaction 94:15 interactions 59:10; 224:18 interactive 35:22; 37:23; crest 6:2, 4, 6, 22; 7:2; 37:3; 86:22; 121:9; 160:8; 166:2; 220:17 interested 7:7; 19:10; 85:21; 121:21; 159:23; 187:16, 18; 228:2 interesting 9:3; 49:18; 55:16; 67:22; 85:12; 148:14; 168:22; 192:23; 224:16 intermediate 53:1, 3; 93:7; 96:17, 22, 23, 24; 98:22 intermediates 140:25 internally 213:21 international 80:9 interpatient 153:16 interpret 11:2; 39:25; 41:5; 49:7; 62:11, 15; 84:11; 112:15; 146:25; 195:14; 202:14 interpretable 95:7, 17; 189:22 interpretation 8:7, 21; 9:2; 11:1; 15:25; 29:21; 34:15, 17, 22; 35:17; 42:5, 23; 56:14; 83:10; 89:8, 22; 90:6; 126:12; 146:12; 183:19; 177:12; 181:22; 226:8; 226:13 interpretations 40:4, 12; 84:1; 177:10 interpretative 83:24; 93:14 interpreted 114:13;</p>	<p>137:20 interpreting 28:9; 36: 11; 89:10; 90:3; 123:18 interpretive 89:24; 94:1; 95:20, 21; 96:13; 97:18, 20; 98:15, 18, 21; 100:3, 17, 21; 101:1; 102:21; 103:22; 105:22; 113:23, 25; 215:16 interprets 90:7 interrogates 19:22 interruption 161:23 interruptions 86:23; 207:16; 224:13 intervention 89:25 interventions 224:20 into 4:3; 30:22; 36:7; 39:6; 47:13; 48:20; 52:22; 56:11; 58:3, 19; 68:21, 22; 73:9; 76:24; 78:11; 82:8; 91:15; 95:4; 96:22; 100:5; 101:18; 111:9; 112:18; 114:16; 116:12; 136:22; 158:8; 159:5; 168:24; 169:1; 176:6; 185:2; 191:5, 21; 193:8, 10; 194:8, 10; 200:2; 201:23; 210:10; 211:5; 212:20, 20; 217:2; 218:2; 219:20; 224:3 intracellularly 147:16 introduce 4:8; 7: 12, 20; 9:4; 63:3; 82:8; 90:13; 120:14 introduced 8:11; 13:20 introducing 206:20 Introduction 7:17; 11:1; 90:18; 131:17 invest 213:14 investigate 42:22; 205:10; 225:21 Investigation 143:20 investigations 8:19 investigator 205:5 investigators 10:22; 16:3; 123:11; 129:24; 130:1; 210:7 investing 212:25 Invirase 124:6; 127:6, 9, 11, 14; 128:2 involve 6:20; 143:5 involved 56:6; 82:9; 86:13; 93:24; 153:20; 216:25; 221:13 involvement 6:24; 7:3 involves 143:12; 150:23; 211:25 involving 143:22 ion 94:17 Iowa 4: 14 irrespective 58:1; 81:3 isolate 25:20; 31:6; 40:18; 41:14; 42:2; 54:19; 140:6; 147:23; 170:24; 207:24</p>	<p>isolated 10:2; 14:15; 25:16; 100:7; 143:24 isolates 14:6; 15:8; 19:18; 36:20, 24; 51:4, 10; 91:9; 96:20; 99:4; 105:7, 10; 115:13, 13; 117:20; 119:4, 17; 127:20; 130:18; 134:4; 138:7, 9; 139:18; 140:16; 141:3; 144:1; 149:7; 152:25; 153:1; 156:2; 159:2, 14; 177:5; 195:22, 23, 25; 197:3, 6, 7, 21; 198:19; 199:4; 203:9; 217:10, 13, 20, 21; 221:16 Israel 132:23 issue 6:6; 24:6, 7; 35:22; 36:8; 38:2; 41:17; 42:23; 44:3, 5; 53:25; 54:15; 57:19; 59:4; 64:21; 66:1; 67:13; 85:12; 86:16; 88:15, 16; 89:9, 12; 103:7; 106:24; 107:1; 109:23; 118:11; 124:5; 127:5; 141:12; 147:15; 148:18, 22; 149:5; 157:4; 158:22; 159:16; 161:1, 9; 165:8; 166:14; 173:21; 185:11; 189:5; 191:2; 192:18; 199:2, 7; 201:15; 206:24; 210:23; 211:2; 216:15; 217:25; 218:6, 7, 8; 220:3; 224:22, 24; 226:15; 228:7 issues 6:9; 8:11; 36:1, 14; 57:23; 59:6; 74:19; 78:13; 87:14; 92:9; 94:3; 101:2, 3, 8; 102:1; 104:21; 110:16, 22, 24; 111:24; 119:22, 25; 121:21; 127:4, 6; 129:8; 130:14; 136:21; 137:13, 14; 141:11, 13; 143:2; 146:21; 149:19; 152:9; 155:17, 21; 157:23; 165:5, 10; 166:22; 174:23; 180:13; 182:4; 186:14; 189:4; 201:8, 16; 207:6, 7; 219:19; 220:12; 221:12; 225:14, 23; 226:3, 7, 9, 18, 23; 227:4 Italian 20:16 IV 156:8; 203:3, 20</p>	<p>John 4:25; 46:10; 47:19; 62:4, 7, 9; 135:5 John's 62:3 Johns 4:11; 5:9 join 71:3 JOLSON 5:25, 25; 28:6, 7; 71:21, 22; 152:5, 18; 211:19, 20; 212:9; 214:13; 227:11, 13 Jon 5:13 Journal 29:2; 43:14 judgment 117:8, 23; 163:2</p>	<p>24; 166:17; 179:24; 183:16; 189:10; 203:21; 204:1 label-worthy 203:18, 19, 23 labeled 197:15 labeling 92:10, 16; 94:4; 101:11, 13, 23; 102:7; 103:3; 106:15; 110:24; 111:25; 121:14, 15; 123:7, 23; 124:10; 125:15; 143:6, 15; 151:1; 152:14; 163:11; 167:4; 210:5; 228:10 labeling's 106:2 labels 106:10; 123:24; 126:16, 17, 20; 128:4; 164:1 labor 43:23 laboratories 39:25; 40:5; 42:18; 84:18; 95:4; 115:12; 116:6; 119:9; 149:11 laboratory 37:1; 43:13; 59:15; 84:15; 95:2; 113:6; 115:15; 143:23; 186:25; 187:3, 4; 195:22; 210:2; 217:14 ILabs 62:9; 95:3; 115:17; 133:12; 209:13 lack 47:23; 124:16; 128:14; 131:14; 140:21; 143:12; 144:6; 147:5; 148:22, 23; 149:1; 150:24; 151:18; 152:21; 198:25 lacked 217:25 lactamase 97: 13 ladder 196: 10 LAESSIG 5:20, 20; 142:22, 24, 25; 150:23; 166:25; 178:20; 180:7, 10 laid 106:17; 107:17; 117:11 landscape 60:6 language 116:24 Larder 134:8; 136:14, 15, 15 large 34:11; 38:6; 43:24; 99:1; 100:20; 110:3; 118:2; 138:6; 140:21; 150:10, 14; 200:2; 212:24 largely 56:7; 58: 17 larger 10:2; 15:20; 21:17; 27:25; 187:18; 188:8, 8; 196:11; 201:15; 218:5 largest 32:20 last 27:6; 55:13; 78:4; 83:7; 87:18, 23; 88:5; 110:6; 117:12; 142:5; 146:21; 179:19; 181:8, 25; 185:19; 195:3; 197:10; 202:10; 223:18 last-minute 136:16 Lastly 225:23 late 34:7 latency 36: 1 latent 46:12; 224:23, 25</p>
		<p>J</p>		
		<p>JACKSON 5:9, 9; 32:11; 33:7; 83:23; 118:25; 119:1, 7; 171:3; 172:4; 208:16, 17; 209:2, 6, 25; 213:16, 17 JAMA 13:9; 17:8; 56:19 Jeff 5:24; 91:25; 119:21; 175:4; 214:13 Jefferson 5:8 Jeffrey 90:13; 120:1 jeopardizes 124:13 Joanne 5:23; 7:11, 18 job 227:21; 228:4, 19 Joe 55:15</p>		
		<p>L</p>		
			<p>L90 128:15 L90M 128:18 lab 42:23, 24; 84:5; 135:9; 144:1; 210:16 label 103:4, 13; 110:25; 124:1, 11, 25; 125:17, 20, 24; 126:5, 16; 128:3; 131:8, 13; 163:8, 12, 18,</p>	

<p>later 15:12; 46:23; 53:9; 54:2, 17; 57:7, 24; 68:7; 94:2; 149:5; 173:21; 178:16</p> <p>latest 68:22</p> <p>latter 149: 18</p> <p>Laughter 175:23; 197:23</p> <p>Lauren 5:22</p> <p>lay 107:1</p> <p>layer 48:13</p> <p>laying 103:1</p> <p>lays 105:19; 106:1</p> <p>lead 35:11; 37:3; 46:5; 58:9, 9; 60:20; 130:1</p> <p>leads 39:23; 40:3, 12; 42:10; 121:7; 124:12</p> <p>leap 111:6, 6; 144:19</p> <p>learn 26:17, 18; 192:15</p> <p>learned 128:12; 134:2; 157:19; 208:7</p> <p>least 16:18; 21:3; 25:23; 38:6; 50:4; 60:4; 69:15, 15; 70:12; 81:2; 83:13; 86:3, 8; 88:4, 14; 104:18; 105:7; 107:10; 111:19; 124:1, 5; 139:21; 147:9; 154:24; 165:17, 25; 175:12; 181:21; 196:1; 202:16; 204:12; 205:18; 208:6; 211:14; 212:3; 215:1; 216:12; 218:15; 222:2; 224:6</p> <p>leave 63:19; 67:9; 172:21</p> <p>left 4:9; 60:2; 175:21; 194:21</p> <p>legible 45:9</p> <p>legitimate 115:4</p> <p>length 203:15</p> <p>less 16:14; 17:9; 18:1, 8, 20; 19:7, 11, 25; 20:16, 23; 22:18; 25:6, 18, 21; 28:17; 40:18; 58:9, 10, 21, 21; 60:13; 61:12, 23; 78:1; 85:18; 87:5; 103:23; 105:16; 108:13; 109:24; 25; 126:2, 3; 135:4, 7, 11; 140:12; 164:20; 176:14; 193:15, 15; 211:9; 212:12</p> <p>lesser 137:24</p> <p>level 10:17; 11:15, 19; 12:6, 15, 22; 13:3; 15:15, 22; 16:21; 18:14, 17; 20:14; 33:16; 36:3; 38:5; 41:1; 43:2; 46:13; 48:3; 49:13; 52:6; 54:11; 64:1, 25; 65:1; 66:23; 74:9; 76:3; 87:25; 102:4; 124:12; 126:13; 129:3; 133:19, 22; 140:17; 148:5; 149:25; 150:2, 2; 153:15; 156:15; 167:13; 182:2; 208:6; 216:15, 16, 19; 219:2, 2, 3; 220:16; 224:3; 225:6, 15; 226:1, 1, 14, 14, 15</p> <p>levels 33:12; 35:10; 48:12, 15; 49:7, 9; 50:2; 51:2, 11, 12; 52:25; 53:5;</p>	<p>64:17; 66:19; 84:6, 6; 87:18, 20; 88:3; 96:18, 19; 99:16, 16, 25; 223:23; 226:6</p> <p>lib 129:24</p> <p>liberties 16:1</p> <p>light 77:20; 194:20</p> <p>lighter 11:25</p> <p>liked 193:10</p> <p>likelihood 73:1; 175:10; 179:6</p> <p>likely 30:4, 15; 37:20; 38:18; 41:7; 48:6; 92:19; 95:23; 97:10; 99:24; 110:1; 121:20; 122:s; 129:11; 164:20, 24; 181:16, 19; 189:19</p> <p>limit 41:12; 42:24; 132:13; 151:15; 184:18; 211:7, 12</p> <p>limitation 211:5</p> <p>limitations 7:25; 8:17; 120:9; 123:13; 124:18, 21</p> <p>129:19; 158:5; 205:25; 215:17</p> <p>limited 10:7; 14:1; 43:9</p> <p>limits 43:6; 56:17; 81:18</p> <p>line 19:21; 63:5; 69:2; 140:4; 164:3; 178:15; 191:16, 19; 192:3; 207:17</p> <p>lining 140:20</p> <p>linkage 35:24; 44:4, 8; 45:6</p> <p>linked 45:2, 15</p> <p>links 105:14</p> <p>list 13:4; 35:16; 83:22; 100:17, 23; 103:11, 11, 18; 104:4, 20; 105:2, 2, 2, 4; 106:14, 14, 17; 107:12; 146:9; 222:16</p> <p>listed 51:2, 3; 54:2; 104:5, 16; 153:11</p> <p>listing 102:22</p> <p>lists 104:4</p> <p>literature 45:1</p> <p>Little 8:23; 9:7, 11; 11:3; 27:2, 17; 28:7, 14; 29:9, 21; 31:4, 17, 23; 32:1, 17; 33:16; 50:21; 60:15; 61:16; 69:25; 70:3; 75:20; 85:10; 157:10; 163:25; 171:9; 175:14; 187:17; 196:4; 197:25; 199:2; 200:7; 205:14; 211:1, 9, 14; 212:12; 224:7; 225:1</p> <p>Liile's 218:10; 225:16</p> <p>load 22:18; 31:2; 36:12, 13; 47:20, 23; 49:1; 57:6; 58:1, 20; 62:11, 16; 66:9; 81:11; 135:25; 145:15; 151:15; 172:15; 176:6, 15; 180:11; 187:8; 190:11; 208:7, 8, 20; 209:11, 11; 210:3, 19</p> <p>loads 10:16; 25:18, 20; 31:9, 10, 11</p>	<p>local 60:6</p> <p>log 176:7</p> <p>logical 213:21</p> <p>long 65:18; 67:6; 133:13; 161:1; 162:8; 166:17; 177:10, 16, 17; 210:22; 222:16; 223:17</p> <p>long-term 57:3; 160:21</p> <p>longer 38:14; 65:14; 153:21; 157:11; 172:18; 173:21, 201:3, 20; 210:1</p> <p>look 9:3; 27:12, 17, 22, 25; 28:2, 3; 29:7; 32:21; 47:6; 50:17; 53:21; 59:3, 8; 63:10, 11; 70:11; 76:7; 78:13; 99:17; 108:7; 111:13; 112:18, 21; 119:18; 138:6, 23; 139:17; 140:10; 145:12, 21; 148:13; 149:14; 152:16; 153:7; 155:14; 156:9; 157:9; 158:7; 160:11; 161:4, 4, 21; 166:14; 170:21, 25; 171:6, 17; 173:17, 20; 174:1; 176:9; 177:10; 179:3; 190:9; 191:17; 196:25; 199:14; 206:8; 214:19; 218:19</p> <p>looked 19:8; 20:13; 29:3; 127:20; 138:12; 145:11, 13; 148:10; 153:6; 170:1; 182:7; 190:24; 226:10</p> <p>looking 30:22; 33:5; 43:17; 49:19; 51:18; 52:17, 18, 22; 53:15; 58:19; 59:1, 2, 9; 61:8; 62:22; 71:17; 72:14; 84:11; 117:19; 119:9; 140:4; 154:4; 156:20; 157:12, 17; 168:25; 173:1, 19; 175:7, 15, 19, 21; 177:21; 181:14, 17; 198:4; 199:7, 16; 207:2, 16; 213:1; 217:15, 16; 218:3; 219:22; 220:5; 224:6</p> <p>looks 123:13; 174:8; 178:15; 200:17; 205:19; 207:25; 220:16</p> <p>Los 11:8</p> <p>lnot 47:5; 49:4; 65:23; 75:15, 25; 90:25; 111:18, 18; 112:23; 113:13; 116:11; 127:25; 132:15; 137:24; 148:16; 164:6; 174:12; 176:24; 181:6; 183:7; 198:3; 200:6; 217:11, 25; 218:24; 221:25; 227:3</p> <p>lots 30:7</p> <p>low 11:22; 42:13, 24; 80:8; 87:24; 159:3; 164:23; 225:6, 15; 226:1, 1</p> <p>lower 10:16; 12:7; 18:13, 17; 20:14; 33:17; 43:6; 54:11; 64:9; 96:19</p> <p>lowest 64:1</p> <p>lunch 130:11; 131:1</p> <p>lunchtime 213:25; 219:9</p>	<p>lush 90:22</p> <p style="text-align: center;">M</p> <p>M.D 120:1; 142:24</p> <p>M184V 38:1</p> <p>M97 49:22</p> <p>macro 95:13</p> <p>magnitude 76:3; 93:4; 196:2</p> <p>main 70:4; 181:14</p> <p>major 14:7; 15:1; 21:3; 37:23; 45:10, 10; 63:20; 64:21; 88:12; 115:22; 148:19</p> <p>majority 33:3; 159:25; 169:17; 193:23</p> <p>makes 81:15; 153:14; 174:15, 18; 213:21</p> <p>making 182:23; 186:1, 2</p> <p>male 33:2</p> <p>manage 185:22; 206:18</p> <p>managed 185:20</p> <p>management 129: 14</p> <p>mandate 77:13</p> <p>manner 26:19</p> <p>manufacturer 158:15</p> <p>manufacturers 43:5; 114:24; 115:23, 23; 196:14</p> <p>many 8:9; 16:8; 21:17, 24; 30:8; 31:10; 34:22; 35:20; 41:22; 46:23; 48:2; 56:12; 59:11, 21; 71:24; 75:2, 24; 99:20; 117:3; 137:17; 138:3; 148:14; 152:24; 153:19; 157:2, 3; 165:24; 175:6; 182:6; 184:16, 17, 18; 185:20; 189:6; 193:24; 201:8; 219:15</p> <p>map 87:24</p> <p>Mark 174:20; 187:16; 188:9; 219:11</p> <p>Marker 122:10; 203:8</p> <p>markers 29:3</p> <p>market 127:7; 130:23; 152:2; 155:19</p> <p>marketed 143:19</p> <p>marketing 93:17</p> <p>Masur 113:2, 3; 114:2; 170:13, 14; 174:s</p> <p>match 180:18</p> <p>MATHEWS 4:15, 15; 29:12, 13; 73:17, 18; 80:25; 81:1; 88:20, 21; 169:4, 5; 175:2, 3; 180:12, 15; 181:5; 186:9, 10; 200:11, 12; 206:23, 24</p> <p>matter 15:17; 35:3; 189:18; 225:5</p> <p>matters 6: 14</p> <p>maximally 59: 17</p> <p>may 6:12, 17; 7:3; 8:7;</p>	<p>9:1; 14:1, 2; 15:4; 17:21; 19:17; 23:1, 10; 25:7, 8, 23; 26:3, 5, 12; 34:9; 35:6; 36:6, 21, 24; 37:19; 38:4, 6, 9, 9, 17, 18; 39:10; 40:4, 6, 7, 8, 13, 15; 41:22, 23; 42:12; 45:24; 46:8, 9; 47:2; 52:24; 54:1, 10, 16; 55:17, 22, 23; 56:13; 57:25; 58:6, 22; 60:3; 62:23; 65:19; 69:2; 70:10; 71:18, 19; 74:8; 76:11; 78:21; 79:13; 81:21; 83:10, 12, 16; 84:17; 85:18; 88:11; 89:11, 16, 24; 93:2, 8; 94:16, 19; 95:10, 12; 96:6, 8, 14, 19, 24, 25; 97:5; 99:21; 100:6; 104:19; 106:6, 8; 107:11; 108:1, 1; 110:3, 24; 113:21; 117:22; 121:9; 122:3; 134:2; 135:6; 148:16, 19, 24; 149:9, 10; 152:11; 153:17; 164:20; 174:21; 178:25; 183:3, 3; 184:8, 22; 186:4; 187:3, 3; 192:24; 194:1, 12; 203:23, 25; 207:10; 210:21, 21; 216:9; 217:2; 218:6, 7, 10, 15; 223:5, 7; 224:5</p> <p>maybe 43:6; 64:3; 82:23; 85:14; 111:16, 25; 112:21; 121:1, 3; 128:12; 129:1, 3; 137:25; 141:9; 152:19; 157:5; 161:3; 162:1; 163:6; 165:1; 171:7; 186:6; 190:22; 193:22; 202:21; 204:15; 208:17; 211:21; 212:9; 214:7</p> <p>MAYERS 5:16, 16; 68:11, 12; 70:24; 78:2, 3; 80:15, 16; 81:7, 10; 87:13, 14; 145:2, 3; 158:3, 4; 160:24, 25; 162:20; 166:11, 12; 171:2, 4; 173:21; 185:1, 2; 186:1; 188:16; 193:4, 5; 194:2; 196:18, 19; 199:19, 20; 206:2, 4; 208:25; 209:3, 7; 210:12; 212:8, 11; 213:8; 225:11</p> <p>MDR 56:1</p> <p>mean 16:14; 17:10; 18:1; 30:7; 31:9; 33:16; 50:21; 51:11; 63:5, 18; 66:6; 69:8; 73:25; 105:15; 112:1; 114:2, 18; 116:7, 8, 20; 119:4, 6; 121:14; 139:17, 21, 23; 148:24; 163:11; 165:25; 168:23; 172:16; 177:9; 180:4, 20; 182:16; 183:1; 184:1; 185:19; 190:9, 13; 193:21; 202:15; 223:4</p> <p>meaningful 188:23; 192:7</p> <p>means 59:20; 114: 14; 116:21, 23; 135:1; 149:14; 182:20; 183:21; 186:16; 188:14, 15; 192:16; 223:13; 225:17</p>
---	--	---	---	--

meant 29:14; 65:7; 98:3;
184:1; 186:8, 8
measurable 173:7
measure 48:7; 59:18, 20,
23; 60:24; 74:10; 89:4;
133:14; 135:1, 2; 147:9
measured 94:21; 133:20;
134:18
measurement 59:14, 16;
93:1; 94:13, 14, 15; 223:25
measures 105:22; 133:5
measuring 133:3
mechanism 68:24;
75:16; 107:21, 21; 109:19
19; 121:6; 199:25
mechanisms 26: 15;
36:15; 55:21, 24; 56:5;
60:12; 97:10; 99:7;
105:11; 131:12; 135:21;
147:8, 15, 18; 165:12;
185:10; 225:7
media 118:14
Medical 4:18; 5:20;
93:21; 132:19, 23, 23
medications 129: 15
Medicine 4:11, 16
meeting 4:4; 6:7, 8;
46:11; 48:2; 56:24;
120:11, 17; 121:2; 132:24;
134:6; 194:25; 211:25;
213:24; 214:8, 9, 14, 25;
215:18; 220:20; 221:1;
227:16; 228:14, 21, 22
meetings 106:25
megahertz 34:25
member 6:15
members 4:7; 63:4; 67:7,
8; 144:16; 153:2; 194:21;
228:17
Memorial 4:23
men 29:8; 32:19, 19; 33:3,
3; 70:4, 16, 16
mention 116:12; 152:5;
200:23
mentioned 28:16; 64:12;
65:11; 70:11; 149:4;
175:24; 180:13; 194:19;
226:25
mentioning 228:5
mercifully 227:10
Merck 54:24; 62:9; 174:1
merged 187:1, 2
merging 64:22
merit 14:21
merits 55: 17
message 63:14, 14, 18;
215:5
met 151:6; 180:1; 188:24;
19:12; 228:15
metabolism 164:25
methicillin 106:13
method 39:17; 94:10;
116:9; 139:3
methodologies 26:5;
95:16

methodology 95:23;
101:1, 5; 102:21; 105:20,
24; 113:21; 169:21, 23
methods 43:4, 8; 60:12;
93:11, 25, 25; 94:8; 95:9,
10, 12, 12, 13; 96:4;
169:14; 197:20; 198:18
MIC 96:23, 24; 99:19, 20,
21; 100:13; 103:20;
118:11
MIC90 105:15; 119:8, 11
MIC90s 119:4
Michael 136:2
micro 95:13; 105:19
microbial 97:10
microbiologic 102:18;
110:18; 111:17
Microbiology 43:14;
98:12; 102:15, 20; 115:2;
123:25; 143:16; 151:2;
167:5; 197:17
micromolar 133:20
microorganism 103:24;
104:9, 16; 105:7; 107:6;
109:6
microorganisms 95:1;
99:8; 102:23; 103:5, 15;
104:1
microphone 62:7; 70:19
MICs 93:5; 96:18; 98:24;
99:8, 13; 100:7; 119:13, 16
middle 137:14; 185:16
midst 219:25
night 19:17; 20:12; 30:5;
32:3; 34:24, 24; 39:7, 8,
3; 40:17; 41:11; 42:3, 18;
3:12, 21; 44:19; 54:11;
9:6; 61:16; 67:12; 72:7;
4:20; 77:6, 22; 79: 12;
3:17; 84:10; 87:4; 111:3;
14:2, 5; 126:16; 129:5;
30:1; 134:18; 135:4, 17,
2; 136:4; 141:9; 146:24;
52:10; 157:10, 12;
61:21, 25; 162:3, 10, 12;
63:9, 14; 164:14, 19, 23,
3; 168:24; 169:2; 170:6;
71:15, 21; 176:12;
81:17; 192:10, 22;
94:25, 25; 205:8; 207:19;
21:14
like 200:24
ilestone 228:5
tiller 136:2; 207:14
tiller's 20:23
rind 36:8; 64:21; 97:15
rinds 127:25
vinal 94:13; 112:4;
16:16
vinalistic 219:2
vinally 217:23
vimize 39:17
vimum 151:24; 155:9;
16:20; 217:9; 218:8
vior 24:20; 26:3; 63:21;
5:3

minorities 35:23; 43:3;
54:10
minority 38:4, 12; 39:10,
13; 42:15; 43:11, 18; 45:6
7; 157:12
minus 191:11
minute 38:2; 103:17
minutes 90:8; 92:4, 5;
132:14; 136:23; 143:1, 9;
144:13; 150:19
Mirex 19:21
misclassification
186:12
misinterpretation
186:18
misleading 46:6, 8
miss 42:18
missed 29:3, 5; 81:21
missing 63:20
mixture 42:18; 226:1
mixtures 24:1; 37:21;
38:2; 39:8; 44:18; 225:25
mL 87:19
model 97:23; 108:7;
118:7; 138:1; 141:9; 162:6
modeled 122:10
models 84:16; 108:14;
174:21
moderate 14:20; 22:22,
25; 26:21; 27:8, 13; 28:24;
29:7; 30:1; 31:22; 33:24;
34:3; 133:22
moderately 23:12; 29:6;
31:20; 33:9; 71:17
modest 174:6
modestly 148:25
modifications 191:23
modifies 115:6
modify 203:25
molecular 43:12
molecule 148:13
moment 185:19
Monday 124:3; 137:7;
161:20; 170:16; 174:6
mone 183:13, 15;
212:18; 213:14
monitor 26:10; 202:1
monitoring 48:14;
121:23; 122:12, 12; 224:3
monkey 162:6
monophosphates 56:3
monotherapy 46:16;
125:2, 7; 128:24; 129:1, 4;
162:7; 174:17; 217:4
month 17:8
months 16:14, 15; 17:9,
11; 18:2, 8, 20; 19:12, 25;
20:17, 24; 22:20; 24:13,
19; 25:2, 6; 31:8; 46:23;
87:5; 182:9; 184:18
more 8:6; 9:22, 25; 10: 1,
2; 11:24; 13:25; 14:1;
17:22; 19:18; 22:1, 10, 12;
23:3, 5; 25:3, 8, 12; 26:17;
29:4, 24; 30:4, 15; 32:23;

38:10, 23; 39:6; 42:3;
44:23; 47:6, 7; 48:10;
52:13; 58:16; 59:14, 20,
21, 22; 61:3, 12; 63:9, 13;
64:10; 65:20; 67:20;
70:17; 74:14; 75:20; 76:3;
86:24; 96:2; 98:5; 102:9;
103:17; 106:3; 108:13, 15
109:24, 25; 110:5, 22;
118:2; 122:11, 23; 124:18
125:10, 21; 126:21;
131:11; 133:20, 20;
134:10; 136:5; 144:18;
147:15; 148:13, 13, 17;
150:16; 163:22, 22; 164:2,
16, 24; 168:20; 169:2;
170:1; 171:4, 9; 174:17;
175:14; 179:25; 181:19;
183:9; 189:11, 19; 192:25;
193:6, 7, 22; 196:6; 199:2,
3; 202:8; 203: 12; 204:6, 6,
205:20; 211:1, 25; 216:3,
13; 217:17; 218:7; 219:25;
220:6, 15; 221:2; 224:8;
227:14, 19
moreover 92:25
morning 7:18; 14:22;
20:15; 72:16; 74:6; 82:19;
90:25; 93:6; 123:16;
34:21, 24; 147:14;
93: 17; 222:8
most 10:21, 22; 19:10;
16:18; 27:23; 28:15;
9:21; 30:12; 31:5; 32:19;
3:1, 5; 34:10; 35:16;
7:20, 24; 38:18; 41:8;
9:14; 54:8; 68:17; 70:15;
6:10; 78:21; 79:14, 17;
0:16, 20, 23; 81:17;
0:22; 99:10; 100:18;
03:14, 23; 111:9, 10, 13;
18:9, 18, 20; 126:8;
28:16; 140:5, 6, 16, 17;
56:16; 162:24; 181:11;
82:12, 21; 183:18;
02:17; 212:4; 215:19;
220:14, 21; 221:19;
222:20; 225:8
mostly 30: 19; 70: 16
mother 90:21
mothers 23:25
move 19:18; 34:13;
47:12; 49:5; 67:1; 73:7;
77:10; 85:5; 101:7;
119:19; 142:11; 162:15;
163:3; 177:12; 195:3;
198:12; 221:12; 228:9
moved 46:25
moving 47:13; 83:1;
180:21; 188:1
MPIs 138:22
MRP4 56:1; 225:8
MSM 31:15
much 22:11; 27:1, 5, 24;
29:16; 30:20; 33: 11; 34:6,
12; 35:3, 23; 41:21, 24;
48:10; 56:21; 57:8; 58:16;
59:20; 61:4; 64:9; 67:2;
85:19; 97:21; 106:21;

109:12; 110:7, 13; 116:25;
117:22; 118:2, 24; 119:20;
122:11, 23; 131:4; 136:10;
168:20; 171:4; 173:6, 10;
176:6; 183:13; 193:3;
200:13; 205:8; 210:9;
212:5, 18; 214:21; 220:11;
223:14; 224:11
multi 149:13
multi-drug 9:23; 10:3;
21:18, 25; 53:15; 55:25
multi-variant 201:1
multinucleoside 40:19;
41:19
multiple 21:21; 22:15;
33:20; 35:25; 36:5; 43:12,
19; 44:4, 15; 45:1, 6, 9;
76:2; 79:16; 95:2; 115:16;
134:13; 150:1; 157:14;
164:19; 170:18, 23
multiply 45:24
multitasking 34:25
MURRAY 5:24, 24; 90:13,
19; 119:21; 120:1, 2;
131:5; 163:4; 164:17;
190:1, 14, 16, 21; 202:21;
203:18; 214:13
mutagenesis 177:6;
216:24
mutant 37:22; 38:2; 39:9;
40:9, 24; 42:12, 19; 46:16,
18, 21, 25; 55:4; 135:3
mutants 36:25; 40:21;
41:20; 46:9, 12; 47:2;
58:14; 62: 17; 66:2;
173:20; 216:22; 217:16,
24; 218:3
mutated 45:25
mutation 14:11, 12, 23,
24; 15:3; 18:9; 33:21;
36:18, 23; 37:3, 4, 14, 25;
38:23; 39:23; 40:14, 23;
43:19; 45:12; 51:20; 58:8,
9, 12; 60:19; 64:9, 10;
67:21; 89:15; 125:12;
128:15, 18; 129:3; 135:10;
136:1; 137:5, 5; 143:25;
147:22; 151:13; 167:13;
168:1, 9, 11; 169:19;
172:5, 10; 173:2, 9, 15;
175:25; 177:23; 178:9;
183:2; 191:17; 224:18;
225:13
mutational 40:10; 44:19;
45:14; 53:12; 54:1; 73:24;
89:11, 13; 121:6; 122:13;
153:6; 158:1; 169:8;
174:23; 175:10; 195:23;
207:4
mutations 13:13, 15, 16,
21, 22, 24; 14:1, 9, 18;
16:5, 17; 17:2, 3, 12, 14;
18:3, 13, 21; 19:14, 17, 20,
23; 20:2, 3, 11, 14, 18, 19,
22, 24, 25; 21:8; 22:15, 24;
28:10; 29:17, 17, 18, 19,
19, 22, 25; 30:4, 8, 13;
31:3; 35:22, 25; 37:24;
38:20, 20, 24; 39:1, 3;

<p>40:2, 16, 21, 24; 41:13, 19, 23; 42:1, 2; 44:4, 9, 11, 15; 45:1, 6, 10, 11, 13; 51:18, 21; 52:5; 54:22, 23, 25; 57:15, 17, 19; 74:18, 24; 80:24; 81:4; 89:16; 125:11; 127:19, 21, 24; 128:13; 129:10, 12; 134:10; 135:6, 10, 13, 20; 136:7; 139:11, 16; 144:4, 9, 21; 145:16; 147:4; 148:14; 149:13, 22; 150:1; 154:10; 155:3; 157:17, 21; 167:17, 18; 168:12; 173:12; 176:20, 21; 177:4, 6; 182:1; 199:4; 216:23; 217:5; 225:10 mute 154:21 mycobacteria 114:14 mycobacterium 100:24 mycologist 111:20</p>	<p>132:15; 136:7; 141:24; 149:14; 150:1, 7, 14; 153:23, 25; 155:2, 3, 14; 157:2, 10; 160:16, 20; 164:16; 171:13; 177:12; 183:11, 17; 188:17; 204:15; 208:19; 213:5; 214:6; 215:19, 23; 216:5; 218:10, 15; 219:14, 15, 19; 221:4, 5, 5, 11; 222:1, 8, 10, 19; 223:23; 225:21, 25; 226:23 needed 22:3; 48:3; 130:15, 18; 137:8; 144:10; 149:16; 151:18, 23; 153:11, 22; 155:8 needs 56: 10; 73:2; 79:6; 84:25; 108:4; 146:23; 152:24; 157:4; 163:24; 191:4; 207:11; 208:11; 216:2; 217:23; 219:20; 220:15; 223:1; 227:1, 12 negatives 39: 17 neither 144:7; 147:20 nefinavir 12:18; 30:19; 50:22; 128:17; 138:25; 139:20 nevirapine 32:4; 33:12; 50:4, 13; 52:21; 124:23; 125:7 new 22:17; 29:2; 39:3, 6; 49:19; 50:13, 14; 61:24; 65:11; 69:12, 14; 83:25; 87:19; 98:9, 18; 113:20; 119:18; 122:14; 130:22; 134:7, 13; 136:3; 137:1, 1, 10; 141:8; 152:24; 154:2; 160:12; 161:11; 162:10; 165:15; 176:2; 180:21; 182:23; 194:5; 195:21; 209:16; 213:9; 217:21; 218:14; 219:23, 23; 224:16; 226:2 newly 8:25; 70:6 next 34:14; 45:18; 72:2; 77:11; 86:24; 95:18; 107:17; 136:11; 142:25; 159:9; 161:13; 162:18; 166:24; 175:18; 182:5; 199:22; 200:1, 4, 5; 201:6; 209:20; 218:15; 219:2, 3; 222:23; 223:19 next-door 159:11 rice 48:25; 139:25; 156:22 nicely 53:22; 213:6 niche 122:4; 136:4 niches 183:14 NIH 27:20; 121:4 NNRTI 34:3, 4, 8; 134:17; 225:18 NNRTIs 23:9; 27:9, 14; 16; 33:10, 21, 22, 25 nobody 205:8 non 14:16; 30:19; 111:19; 214:25; 217:3 non-adherent 182:3</p>	<p>non-anecdotal 63:25 non-nucleoside 11:16; 15:17; 48:8; 124:22 non-nucleoside-based 122:17 non-nucleosides 12:3, 10; 18:15, 18 non-nuke 68:15; 158:17; 162:21 non-overlap 128:13 non-success 69:20 nonchimeric 31:25 nonclinical 161:16 nondetectable 89:3 None 28: 14; 58:4 nor 15:16; 144:8; 147:21 normal 97:8 North 16:2, 11; 21:3; 23:15; 27:23; 32:13, 21 note 126: 16; 227:6 noted 6:24; 34:4; 36:24; 14: 16 noticed 114:11 notion 175:4; 195:17 notions 218:18 novel 138:4 NIR-48 127:19 NRTI 73:21 nucleoside 11:24; 12:12; 18:9; 40:23; 41:7; 50:14; 56:2; 149:14; 165:18; 167:8 nucleoside-experienced 165:16 nucleosides 11:16, 22; 14:17; 30:20; 41:4, 8, 11; 48:10; 50:5, 13; 56:5; 225:9 nruke 165:20 nuke-experienced 126:11 nukes 158:16, 16, 17; 190:16 number 11:7; 17:20, 21; 18:16; 20:12; 27:18; 31:2; 34:11; 44:24; 51:18; 52:4; 61:20; 62:1; 74:18, 21; 94:10, 16; 99:1; 100:21; 102:1, 2; 108:6; 114:21; 116:17, 22; 137:13; 138:6; 141:2; 149:9, 11, 20; 151:24; 155:9; 159:3, 10; 176:9; 194:3, 4, 20; 197:20, 20, 21; 198:18, 18, 19; 202:6; 203:3, 5; 208:18; 217:13; 220:19; 224:18; 226:23 numbers 15:19; 74:2; 115:24; 116:7; 117:5; 140:9, 18; 149:22; 163:16; 165:24; 195:20; 201:15; 204:22; 205:1; 225:2 numerous 9:20; 14:13; 15:4; 16:2; 93:12; 186:17</p>	<p>0 o'clock 131:18 objective 187:13 objectives 8:14; 91:2; 120:8; 123:3 observation 166:4; 171:16; 182:6 observations 32:6 observed 14:13; 21:5, 9; 23:10; 94:19; 100:8; 108:3 observing 181:9 obtain 91:2, 6, 10, 14; 123:4 obtainable 96:18 obtained 6:17; 9:16; 36:13; 45:20; 86:3; 101:9; 177:24; 179:17; 186:23; 188:12 obtaining 88: 10 obtains 180:5 obvious 82:18; 83:7; 96:8; 137:6, 6; 170:8 obviously 27:7; 35:10; 56:4; 64:19; 113:12; 137:13; 139:2; 140:15; 169:15; 191:6; 205:17; 207:11; 208:19; 209:25; 212:18; 216:3; 218:18; 221:18 occupational 28:12 occur 25:12; 29:22; 38:16; 39:4; 41:22; 47:8, 10; 125:19; 220:20 occurred 24:23; 25:7; 76:6 occurring 8:10; 157:18 occurs 41:17; 135:12 off 17:5; 45:21; 57:12; 62:12; 86:8, 9, 19; 111:18; 118:21, 22; 142:21; 158:11; 172:18; 183:13; 200:2; 204:1; 213:14; 217: 16 off-treatment 188:14 office 6:19; 226:16 officers 5:20 officially 90: 12 often 13:17; 96:2; 98:17; 9:10; 103:11; 110:17; 104:6; 211:22; 223:15 old 182:7, 24; 217:1, 2 old-fashioned 32:5 older 115:21 in-line 185:8 in-the-fly 185:10 once 9:3; 17:20; 101:9; 71:23; 180:21; 213:11; 28:18 oncology 4:11 One 7:6; 11:24; 13:25; 14:14, 21, 22; 15:2; 21:20; 22:5; 29:24; 30:1; 31:17; 19; 32:18; 33:19; 36:6;</p>	<p>37:8; 39:18; 40:17, 21, 25; 41:13, 25; 42:2; 43:4; 44:3, 20; 45:4; 47:2, 22; 48:18; 50:10, 11, 13; 52:15; 53:2; 54:19; 56:10; 57:16, 22; 60:9; 61:15, 16, 17, 19; 64:9, 18; 66:8, 8, 22; 67:18; 68:12; 69:9, 21; 71:23; 72:25; 76:3, 7, 12; 78:3; 82:24; 84:25; 86:4, 8; 87:9; 88:9, 14, 23; 91:17; 92:24; 93:6; 102:17, 19; 108:7; 109:11, 18; 110:9, 19; 112:21; 113:3; 115:25; 116:19, 22; 118:6, 10; 119:1, 3; 122:15, 16; 124:1, 5, 24; 125:10, 21; 133:6; 134:10; 135:4; 137:25; 138:24; 141:9; 144:17; 145:10; 146:18; 147:9; 152:5; 153:9, 23, 23, 25; 154:4; 155:24; 156:8, 21, 22; 157:1; 158:4; 159:1, 9, 10; 161:17; 162:16; 163:5; 164:18; 165:14; 169:13, 16; 170:22; 172:4; 173:13, 16, 16; 175:24; 176:2, 12; 177:10; 179:24; 180:16; 186:10, 16; 187:15; 189:10; 192:19; 193:15; 196:19; 200:12, 23, 24; 201:18; 203:10; 204:23; 207:6; 208:4; 212:10; 217:23; 218:6, 7; 219:11, 20; 220:4, 6; 222:6, 21; 223:22; 225:14; 227:19 one-arm 183:16 One-third 116:13, 13, 14 Ones 29:5; 212:17; 216:12 Ongoing 39:20; 63:16; 155:23; 222:8 Only 11:23; 12:8, 11, 23; 13:7; 15:2; 16:20; 18:9, 10, 13, 15; 19:16, 22; 20:2, 10, 18; 23:23; 24:2, 3; 29:3; 37:5; 42:14; 47:13; 50:11; 52:6; 54:8; 55:10, 10; 58:17; 60:20; 61:10, 25; 64:14; 68:2; 70:7, 23; 71:15; 75:14; 84:4; 98:10; 99:5, 15, 24; 100:11; 102:1; 103:19; 104:14; 114:12; 126:9; 131:6; 133:7; 134:9; 138:24; 139:1; 140:25; 149:7; 154:9, 19; 158:10; 164:6; 183:13; 184:5; 200:24; 201:5; 208:9; 213:7; 215:7; 221:3; 225:4; 226:16, 20, 21 onset 11:12; 133:17 Open 132:5, 7, 18; 142:6, 10; 166:15; 179:24; 183:16; 189:10; 217:18 open-label 129:25; 153:10 operated 192:21</p>
--	---	--	---	---

<p>operation 226:17 operator 42:21, 25 union 67:17; 69:12 unions 52:12; 59:7 opportunity 27:12; 34:20; 76:17; 85:20; 192:5 opposed 61:25; 63:5; 182:3 opposite 38: 16 optimal 34:25; 48:21; 49:3; 93:25; 96:8; 163:1; 179:16, 24; 188:11; 189: 10 optimally 42:14; 91:15 optimize 191:24 optimized 94:20 option 222:20 Order 4:2; 31:8; 33:2; 49:7; 76:3; 86:11; 117:6; 132:4, 6; 150:13; 185:24; 196:2; 210:18 organ 118:9 organism 94:16; 97:12; 99:18; 100:10, 14; 107:20; 108:20; 109:4, 9; 110:15; 117:6 organisms 92:22; 95:6, 6; 98:19, 24; 99:1, 2, 6; 100:7, 17, 23; 103:12, 18, 18; 104:5, 17, 24; 106:3, 6, 11; 107:10; 111:23; 114; 118:1; 119:13 organization 98:16; 113:10; 132:10 organizations 93: 12 organize 222:2 oriented 118:9 original 32:4; 92:1; 115:11 others 17:22; 40:25; 70:21; 85:21; 136:2; 152:19; 157:25; 194:21; 202:8; 227: 1 otherwise 46:5; 219:16 otitis 118:13 ourself 204:7 ourselves 141:17 out 7:9; 16:16; 17:1, 2, 5, 13, 14, 18, 23; 18:22, 23; 19:1, 13, 14, 20; 20:1, 8, 19; 24:12, 19; 25:2, 5; 31:8; 53:5; 56:3; 60:2; 66:7; 68:19; 71:16, 18; 74:20; 75:16; 76:14; 78:9; 80:23; 83:23; 84:19; 87:24; 88:25; 89:18; 90:24; 99:22; 103:1; 105:19; 106:1, 17; 107:1, 17; 109:16; 116:11; 117:11; 118:14; 122:23; 131; 130:13; 133:15; 134:8; 135:5; 138:7, 17; 139:19; 140:16; 145:22; 147:13, 14; 148:15; 153:8; 154:16; 156:19, 23; 157:13, 23; 158:2, 4, 10, 13, 15; 162:22; 163:13;</p>	<p>170:11; 171:22; 175:13; 176:16; 180:21; 186:4; 191:6, 18; 194:5; 197:4; 201:9, 16; 205:6, 7, 15; 207:19; 209:14; 210:13, 18; 211:8, 13; 214:6; 217:12 outcome 8:21; 57:24, 25; 84:25; 92:19; 95:24; 96:3; 98:6; 110:16, 17, 18, 22; 223:2 outcomes 100:3, 8; 112:3, 9 outline 155:5 outlined 56:22; 153:18; 215:17 outside 72:20; 166:1; 180:5; 204:25 outstanding 84:16 over 9:5; 15:15; 25:1; 28:4; 66:3; 69:7; 83:7; 86:23; 92:6; 93:10; 116:12; 118:14; 140:11; 150:19; 156:1, 10; 159:1; 161:7, 13; 166:10, 21; 174:17; 188:5; 189:6; 193:16; 204:18; 205:9; 220:5; 223:19 Overall 11:21; 12:21; 16:9; 77:22; 78:1; 95:22; 99:12; 102:13; 115:25; 117:12, 24; 225:3 overcome 48:3; 49:9; 74:8; 77:9 overinterpreted 79:9 Overlap 127:21 overlapping 161:10 overrepresented 32:17 Overvaugh 26: 1 overview 7:23 overwhelming 204:20; 205:2 own 11:3; 22:5; 52:11; 131:1; 132:24; 155:11; 163:23; 188:3</p>	<p>196:10, 16, 21, 25; 217:10, 12, 16, 20 panels 42:16; 134:16; 177:3; 221:16 paper 56:20; 66: 18 parallel 184:2 parameter 146:5; 171:5; 196:23 parameters 69:22; 85:7; 94:24; 99:19, 25; 113:6; 118:16; 160:17 pare 78: 14 parenthetically 97:19 Parklawn 6:19 part 6:7; 58: 11; 60: 16; 76:9; 78:21; 79:14, 17; 82:13; 83:13; 85:9; 99:14; 115:9; 130:2; 139:10; 150:13; 157:5; 167:12; 170:18; 172:16; 181:2; 185:4; 204:15; 227:18 partial 35:16 partially 85:16 participant 6:22 participants 6:22; 7:1; 212:4 participate 202:8; 214:16 participated 27:22 participating 6: 16 participation 129:23; 228:18 particular 6:12; 58:14; 62:17; 66:22; 71:20; 73:5, 24; 74:8; 75:9; 89:10, 11; 92:20; 99:18; 100:7, 13; 104:19; 108:21; 128:13; 141:7; 149:21; 153:18; 154:2, 5; 158:14; 184:7, 8 particularly 26:11; 27:9; 33:10; 34:7; 39:5; 57:18; 59:5, 9; 61:8; 75:13; 80:6; 88:10; 92:22; 147:16; 156:6; 160:13; 194:20; 211:23; 214:16; 215:17; 218:12; 224:2; 225:8; 226:9, 10; 228:19 partly 72:9 partner 23:24 partners 23:20, 22; 24:10 parts 82:23; 102:8, 11; 103:11; 155:4; 188:2 passage 216:20, 21 passaging 143:22 passive 204:24 past 38:21; 42:17; 69:7; 118:10; 120:12; 140:12; 154:15 pathogenesis 60:8; 118:21; 160:23 pathogenetic 224:10 pathogenic 98:24; 100:22; 109:25 pathogens 105:12; 117:16</p>	<p>Pathology 4:11; 5:9 pathway 35:13 patient 9:15; 14:6, 17, 24; 19:19; 22:6, 7, 11; 29:25; 30:15; 33:19; 36:9; 45:21; 46:15; 54:19, 21; 57:2, 2; 62:12, 16; 64:4, 8; 65:14, 17; 67:11, 19, 21; 68:12; 69:22; 70:1, 9; 71:12; 72:2, 23; 75:11; 76:11; 77:16; 78:7, 11; 79:4, 11; 80:3; 84:9; 86:9, 10; 87:16, 21, 24; 96:6; 133:15; 154:3, 21, 24; 156:6; 161:7; 165:6; 168:8; 176:5; 178:21; 179:25; 180:1; 182:2; 186:5; 189:11, 12, 20; 190:6; 193:8; 197:20; 198:18; 199:22; 204:7; 206:13; 212:17, 22; 213:4; 219:6, 17; 221:6; 224:8; 226:15 patient's 92:20; 175:6 patients 11:7, 11, 15, 19, 21; 12:2, 5, 8, 15, 19; 13:2; 14:6, 9, 14, 19; 15:14, 21; 16:9, 13, 13, 16; 17:9, 13, 25; 18:7, 19, 25, 25; 19:9, 10, 24; 20:13, 16, 20, 23; 21:13, 18; 23:19; 24:8; 25:12; 26:19, 21, 23; 27:14, 19, 23; 28:3, 11, 16; 29:5, 23; 31:5, 21; 32:13; 33:15, 18; 33:23; 34:2, 7, 7, 11; 39:6; 44:25; 45:2; 48:20; 49:20; 50:10; 51:5, 5, 6; 52:17; 54:25; 55:10, 11, 23; 64:25; 65:13, 24; 68:3, 4, 10, 15, 22; 69:1, 15; 70:23; 71:7, 13; 72:17, 18; 74:2; 76:1, 11; 77:8, 14; 78:14, 17; 79:19; 81:14, 17; 87:11; 96:8; 117:3, 5, 9, 16; 121:13, 18, 20; 125:8, 10; 126:12, 13, 23, 24; 127: 11; 129:6, 10, 10, 12, 22; 134:12; 145:8, 13; 147:7; 150:8, 15; 151:6, 8, 14, 24; 155:10; 163:16; 164:8; 167:12, 21; 168:10, 13, 15; 171:7, 8, 14, 18, 22, 24; 179:4; 184:17, 18, 23, 23; 185:3, 13, 20, 22; 187:6; 194:7; 197:18, 20; 198:18; 200:5, 25; 201:19, 21; 202:1, 4; 203:12; 204:22; 205:18; 206:9, 18; 211:12; 212:23; 213:2, 2, 14; 219:5, 22, 24; 220:24; 222:12; 225:3 Patricia 4:10 pattern 40:10; 45:17; 53:10, 12; 54:1; 67:20; 73:24; 76:18; 77:9; 89:11, 13; 157:17, 22; 158:1; 181:9; 186:2; 191:11 patterns 26:12; 44:19; 45:15; 77:5; 81:4; 153:6; 175:11; 181:7; 182:9, 21; 186:18; 207:4</p>	<p>pause 191:20 payers 222:12 pays 213:14 PBMC 31:25 PBMC-based 133:13; 134:19 PBMCs 78:5 PCR 43:4, 12, 16, 20; 44:5, 12 peak 60:6; 99:20; 223:24 pediatric 68:3 peer-reviewed 66: 14 penetrated 118:14 penetration 218:24 penicillin 53:2, 4, 6; 93:4, 8; 106:12; 107:24; 108:1, 23 people 30:7; 59:11; 62:20; 70:24, 25; 74:21, 23; 75:1, 4; 77:18; 81:12; 82:8; 85:20; 88:24; 138:3; 156:23; 158:15; 161:22, 24, 24; 164:18; 171:11; 175:21; 180:22; 191:2; 193:14, 15, 22, 23; 194:3, 4; 206:25; 210:21; 211:5 people's 127:25 per 126:3, 4; 146:4; 189:2; 205:5 percent 11:15, 23; 12:9, 11, 17, 17, 18, 18, 21, 23; 15:11, 11; 17:1, 3, 5, 6, 14, 15, 18, 24; 18:4, 4, 6, 6, 12, 20, 21, 22, 24; 19:1, 2, 3, 4, 13; 20:1, 2, 8, 14, 17, 21, 24, 25; 21:5, 6, 9, 10, 13, 23; 24:21; 33:2; 38:6; 42:15, 18; 43:7, 15, 18; 44:21, 22; 46:17; 47:1; 61:24, 24; 64:6, 10; 68:2, 14; 103:24; 104:18; 107:10; 125:8, 11; 127:8; 134:9, 11; 137:4, 4; 139:13, 14; 151:14; 153:12, 20; 154:1, 12, 12, 25; 155:13; 164:5, 12; 166:4, 7; 192:9; 204:21; 211:9 percentage 12:15; 68:10; 140:25; 151:23; 155:9 perfect 36:21; 37:13; 177:8 perfection 56: 15 perfectly 36:22; 69:9 perform 202:4 performance 7:25; 95:5; 116:4; 216:5 performed 22:14; 216:22; 226:9 performing 100:12 perhaps 25:7; 30:5; 33:8; 43:25; 48:8; 53:8, 9; 57:21; 75:12; 76:8; 85:16; 114:8; 129:2; 134:20; 162:21; 178:2; 182:4; 198:4; 203: 12; 220:6</p>
<p style="text-align: center;">P</p>				
	<p>P 55:24, 25 p.m 131:21; 132:2; 228:22 package 92:16; 98:12, 17 packages 141:23, 24; 220: 11 paid 132:24 painted 191:21 pair 88:4 paired 80:18 pairing 80:22 pairs 31:15; 134:9, 12 Pandora's 166:15 Panel 56:19; 65:12; 66:12, 20, 23; 119:4, 10; 134:4; 137:7; 139:10; 141:3; 152:25; 195:13, 21;</p>			

perinatal 10:9
period 65:14; 184:24;
186:15, 17
periodically 207:2
periods 129: 1
permit 22:3
permitted 21:12; 132:12
permutations 149:10
persistence 36: 1
persistent 35:12; 46:13
person 57: 13; 85: 15;
142:5; 164:22; 188:4
personal 52:12; 214:5;
216:17
personally 83:14, 15;
86:12; 163:19; 206:19
persons 26:13; 85:12
perspective 90:21;
91:20, 23; 92:2; 120:8;
121:12
pertaining 192: 11
pertains 84:4
PETTINELLI 5:11, 11;
65:10, 11; 67:16, 17;
146:2, 3, 11; 168:3, 4, 7;
178:3; 199:10, 11; 201:17,
18
Pettineili's 75:20
pharmaceutical 68:18;
141:22
pharmacodynamic
99:15, 17, 25
pharmacokinetic 97:23;
99:14; 148:3; 153:16;
196:23
pharmacokinetic/phar-
macodynamic 109: 1
pharmacokinetics
223:11
pharmacologic 74:8;
88: 10; 116:3; 192:25;
223:25
pharmacologic/phar-
macodynamic 59: 10
pharmacological 8:12;
115:10; 118:11
pharmacology 64:22;
84:2; 98:11; 115:1
Phase 78:23; 80:5; 91:15;
97:25, 25; 98:2, 4; 100:5,
9; 125:6; 156:8; 200:2;
203:3, 20; 206:11, 18;
212:20, 21, 25; 213:3, 7, 8,
12, 13
phases 122:6
phenolgeno 138: 12
phenomenon 47:5, 6,
16; 52:13
phenotype 37:17, 19;
38:17, 25; 51:1; 64:14;
72:4; 87:20; 138:16;
145:8; 168:15; 170:21;
173:11; 193:9; 195:24;
212:8; 222:22
phenotypes 62:23;
138:14; 167:2

phenotypic 7:24; 16:6;
20:4; 23:3; 27:8; 28:4;
31:22; 37:10; 38:8, 13;
41:1; 52:4; 53:17; 72:1;
81:5; 84:24; 85:4; 122:21;
125:9; 143:24; 144:5, 8;
147:4, 21; 172:6, 13;
173:3; 179:23; 189:9;
201:2; 213:19; 215:10, 12;
216:22; 222:19
phenotypically 29:7;
74:13; 219:7
phenotyping 39:11, 21;
179:18; 180:5; 185:6;
186:24; 188:13; 193:6;
202:4; 205:15; 212:14;
215:22
phenotyping/genotyp-
ing 192:7, 13, 15
philosophy 157:13
phone 203:2
phosphorylated 147:17
phosphorylation 56:6
physical 94:10, 14
physician 76:15; 180:9
physician's 223:6;
226:16
physicians 150:7
PI 48:21, 21; 49:19; 50:9,
10; 51:19; 52:4, 17; 54:4,
10, 23; 55:11, 11; 138:8,
18; 154:15, 20; 157:20;
165:15, 20; 190:17
PI-associated 154:10
PI-experienced 50:5
pick 7:9; 87:9; 124:23
picked 138:17; 140:16;
190:7
pickle 114:16
picture 75:24; 183:17
piles 114:19
pin 218:5
PIs 23:9; 54:14; 55:24;
68:15; 127:12; 138:24;
140:17; 154:17, 18;
163:15
PK 87:14, 16; 182:4;
196:6; 218:4
place 115:3; 189:21;
193:11; 204:7, 15, 16;
205:6; 223:13
placebo 161:21
placed 68:21; 144:18
plan 49:23; 201:25;
206:20
plasma 25:18; 46:22;
52:9; 62:5; 78:9, 10, 11,
22; 86:3; 87:19, 19; 88:5;
145:14; 209:14
platform 114:20; 215:22
plausible 125:12
play 122:25; 227:2
lease 27:3; 45:18; 62:7;
57:10; 80:11; 81:9; 83:9;
14:10; 132:9; 143:8;
51:19; 179:9; 195:7;

197:19; 198:17; 205:24
plenty 207:15
plus 50:4; 86:24; 191:11
PMEA 225:8
pneumo 106:12; 107:24;
108:23
pneumococci 53:5
pneumococcus 53:1, 3;
119:3
pneumonia 100:24;
108:25; 117:21
pneumoniae 93:5, 7
Point 14:21; 27:6; 30:16;
31:13; 32:25; 33:8; 37:23;
43:25; 45:23; 46:3; 50:25;
52:23; 57:4; 62:6; 63:2;
65:8; 66:6, 10, 12; 67: 18,
20; 68:1; 80:4; 83:25;
86:15; 87:9, 11; 89:20, 21;
95:8; 104:10; 105:18;
114:25; 115:16; 134:8;
145:7; 146:20, 23; 157:16,
25; 161:3; 172:12; 173:6;
175:3; 182:8, 25; 183:2,
24; 184:11; 186:1, 2, 10;
188:19; 190:10; 201:5;
205: 13; 207:23; 209: 12;
214:20, 22
pointed 83:23; 135:5
points 59:1; 101:22;
104:23; 146:21; 158:4;
169:16; 172:4; 177:11;
183:1; 210:8
polymorphism 8:11;
29:15; 225:12
polymorphisms 14:14;
15:4; 29:20, 23; 30:22;
128:1; 139:15; 167:17;
176:20; 225:12
POMERANTY 5:7, 7;
28:19, 20; 31:18, 19, 24;
32:2; 59:25; 60:1, 23; 71:2,
3; 134:21
pool 43:4; 137:16
pooled 125:6
poor 127:7
pop 85: 17
population 16:13; 17:9;
24:18, 21; 30:2; 38:7;
42:14; 43:7; 44:7, 21; 45:6,
7, 24, 25; 46:17, 19, 23;
47: 1; 59:4; 63:12; 64:6;
65:20; 66:4, 18; 67:21, 25;
68:3, 6, 12, 14; 70:1;
72:15; 73:2, 12, 15; 76:7,
19; 77:23; 79:7, 13, 23, 25;
80:2, 8; 81:3; 82:6; 83:3;
86:16; 88:17; 98:23;
99:12; 112:25; 139:7;
154:3, 9, 24; 155:22;
156:16; 164:20; 165:17;
173:25; 176:15; 178:10,
22; 179:12; 183:6; 184:7;
187:15, 21; 188:1, 8;
194:10; 198:2, 4; 203:25;
207:18; 218:9, 11, 13, 16,
22; 223: 1; 225: 19
population-based 14:5;

23:6
populations 8:6, 16, 25;
25:4; 26:23; 30:15; 63:4, 5
66:22; 67:11; 68:20;
69:14, 23; 70:9, 12, 21;
71:12, 24; 72:3, 10, 21;
75:21; 79:11, 21; 85:6;
86:7, 19; 121:20; 156:7,
11; 165:14; 173:16;
179:13; 180:13; 183:12;
184:3, 11; 187:19, 22;
204:21; 205:1; 218:23;
219:18; 221:6, 21
posed 143:9
position 9:18; 37:22;
39:9; 44:6; 153:3
positions 44:11
positive 11:13
Poss 24:24
possibilities 174:21
possibility 23:4; 89:6;
175:24, 25; 186:12
possible 8:17; 24:15;
25:24; 26:11; 30:25;
47:22; 54:10; 56:5; 60:13;
65:20; 86:18; 120:17, 22;
121:1; 127:5; 129:19;
132:14; 146:13; 165:24
possibly 29:20; 121:19;
128:23; 183:9
post 167:20; 177:19;
188:22; 206:5
poster 159:8
postmarketing 121:22;
122:15; 123:6; 130:22;
152:1; 155:17, 20; 156:4;
161:3; 201:12; 202:24;
204:16
potency 146: 16
potent 15:13; 148:21, 25;
158:18; 176:13, 14
potential 37:16; 43:2;
55:18; 90:16, 19; 91:12;
128:7; 130:19; 131:9;
141:7; 188:5; 214:2; 219:3
potentially 41:14; 44:18;
52:7, 18; 71:24; 78:12;
83:17; 87:15; 110:20;
121:17; 131:12; 143:5;
150:4; 164:10; 165:15;
172:24; 203: 19; 206: 15;
217:5; 226:6
power 14:21; 188:15
powered 117:18; 169:18
powerful 135:22
practical 7:14, 20; 8:18;
9:22; 160: 11
practically 119:2
practice 180:18; 202:7;
20:25
practitioner 101:13
pragmatic 210:25
We-existing 35:8
re-exposed 68:13
re-randomization
7:20

pre-therapy 65: 12
precaution 128:3
Precautions 128:6
precise 23:3; 69:9
precision 32:8
preclinical 37:1; 40:8;
77:5; 129:2; 136:18;
167:10; 169:2; 178:25;
195:8, 10; 216:19
preclinically 128:22
preclude 6:7
predetermined 37:14;
151:23; 155:9
predict 30:5, 10; 32:18;
37:13; 92:19; 95:23; 96:1,
5; 128:14; 133:20
predictable 58:8
predictably 92:22
predicted 51:1; 100:1;
125:10
predicting 26:6; 99:21
prediction 48:16
predictor 201:4
predictors 56:10
predicts 53:22
predisposed 42:3
pregnancy 79:17
pregnant 204:10
prejudge 211:13
premise 83:20, 21
prepared 195:1
prerogative 83:9
presage 165:9
prescreening 72:3
presence 8:10; 9:18;
14:23; 22:25; 29:24; 36:2,
5; 60:14, 20, 25; 124:18;
143:22; 144:4; 147:4, 24;
172:22; 216:21; 220:24
present 8:23; 9:7; 11:2;
23:5; 24:21; 25:4; 29:15;
30:3; 35:7; 36:4; 41:20;
42:12; 46:5; 47:14; 48:4;
51:13; 54:10; 55:5, 9, 18;
58:13; 64:10; 112:12;
114:25; 143:4, 8; 167:17;
176:21
presentation 27:4; 28:8;
34:13; 62:3; 64:15; 65:25;
141:18; 142:21, 23;
218:10; 222:7
presentations 28: 15;
90:24; 91:17
presented 16: 1, 4, 8;
18:13; 27:8; 28:17; 42:16;
46:11; 48:18; 49:20, 24;
54:24; 55:13; 99:10;
137:20; 139:6; 157:5;
163:13; 164:1; 214:17
presenting 54:25; 143:1
presents 115:22
pressing 145:25
pressure 46:5; 65:19;
86:5; 87:1; 148:22, 25;
149:3; 172:18; 218:19;

<p>221:20 Presumed 10:11 suming 211:4 treated 45:2; 54:25; 69:1; 70:24 pretreatment 10:16; 57:1 pretty 36:19; 41:6; 61:16; 150:14; 183:5 prevalence 8:5, 15, 24; 9:8, 10; 16:9; 23:15; 26:10; 28:10; 29:16; 80:8; 139:10; 218:9; 220:25; 222:9 prevalent 22:23; 26:23 prevent 223:12 Prevention 5:14, 15; 104:7 previous 7:3; 109:16; 126:16, 20; 154:18; 200:16 previously 38:19; 74:9 pricings 212:14 primarily 115:1; 220:6 primary 9:15; 11:5; 13:13, 14, 25; 14:9, 10, 18; 16:5, 10, 13, 17; 17:2, 12, 13; 18:3, 7, 8, 12, 21; 19:2, 11, 13, 20, 22, 25; 20:1, 10, 13, 17, 21, 24; 21:5, 8, 9, 13, 19; 22:14; 26:17, 24; 21, 24; 29:17, 18; 30:3; 33:4, 21; 34:4; 45:11, 11; 76:15; 79:15; 122:1; 137:25; 203:21; 219:4; 220:13; 222:24 prime 207:21 primers 209:8 principle 208:10 Princy 4:17 prior 54:21; 137:11 151:10; 182:3 priori 155:12 private 193:24 privilege 214:16 probably 33:2; 35:2; 41:6; 47:4; 49:14; 58:18, 18; 59:22; 77:1; 80:3, 16; 81:19; 116:1; 126:9; 129:23; 147:2; 149:18; 150:14; 168:11; 172:7, 21; 177:20; 185:16; 193:18; 194:9; 196:3; 202:12; 207:20; 208:11; 210:18; 212:16; 223:15 probe 19:21; 191:17, 19 problem 41:16, 22; 68:17; 76:13; 81:10; 88:22; 111:10; 148:21; 158:19; 169:21; 170:16; 185:17; 186:6; 209:3 problematic 1 10:22; 165:6; 170:2; 174:24; 207:10 problems 115:22; 118:10; 129:18; 168:19;</p>	<p>180:23; 200:17; 210:1 procedure 209:5 PROCEEDINGS 4:1; 120:18; 131:20; 132:1 process 13:15; 24:23; 25:7; 36:13; 64:18; 68:25; 73:4; 95:18; 97:25; 98:8; 115:25; 136:8; 175:1; 187:8, 9; 209:13 processive 135:11 processor 34:25; 35:2 produce 92:10; 101:13 produced 99:9; 115:10; 226:21, 22 produces 50:2 producing 135:25 product 6: 12; 43: 16, 20; 44:5, 12; 94:4; 101:10, 15, 17; 102:7; 105:15; 106:1, 9, 15; 107:23; 108:3, 4, 5, 18, 20, 22, 24; 109:5; 117:24; 119:15, 18; 123:7; 152:14; 166:17; 169:7; 228.10 productive 9:4 products 6:13, 21; 7:3, 19; 43:4, 13; 91:19; 92:13; 101:22, 24; 103:4; 120:17 Professor 4:11, 13 profile 70:1; 72:12; 73:6; 130:19; 138:5, 6; 178:25; 191:15; 192:25; 196:3, 6; 201:22 profiled 137:23 profiles 137:10 profiling 136:17, 18, 19; 137:23; 141:8; 192:23 prognosis 181:10 prognostic 175:13 program 76:9; 91:5; 129:2; 130:16, 17; 195:9; 212:20, 21, 25; 213:3; 226:25 programs 76:8; 117:13; 226:25 progress 111:21 progression 122:2; 133:23 project 114:3 prominently 123:24 promote 22:1 promotes 126:6; 157:21 promotion 101:15, 17; 102:16; 121:15, 16 proof 159:15; 161:16 proper 125:19 properties 8: 12 prophylaxis 28:12 proportion 11:18, 21; 12:2; 15:14; 32:20; 38:7; 42:13; 61:17; 66:3; 81:23 proportional 61:25 proportions 42:13; 44:10; 61:21; 62:17 proposal 113:8; 124:4</p>	<p>proposals 124:2; 142:23; 166:22 propose 85: 11 proposed 27:20; 70:22; 85:23; 98:12, 14; 99:2; 100:3; 113:20; 115:6; 120:13; 167:11; 179:3 proposes 115:2 proposing 183:15 pros 59:2; 215:15 prospective 8:1; 56:23; 73:7; 82:25; 83:2; 167:19; 169:16; 176:22; 222:18 prospectively 78:25; 82:6, 13; 170:5; 177:13, 23, 24; 178:4; 218:20 protease 12:16, 22; 13:2, 14, 23; 14:10; 15:13, 16, 23; 19:15; 20:3, 10; 22:15; 33:24; 41:23, 24; 43:10; 45:11; 46:17; 48:7; 49:3; 50:20; 57:19; 61:9, 18, 19; 62:13; 127:7, 10, 22; 128:4, 8, 10, 16, 19; 138:4; 139:11, 12; 150:3; 151:8, 9, 11, 12; 158:17; 173:10; 178:24; 179:2; 212:13; 225:2, 5, 10 protease-sparing 34:8 protect 152:18; 174:7 protected 158:9 protein 48:9; 50:3 protocol 129:14; 151:6; 184:19, 24; 189:19, 21; 190:2; 191:4; 192:2; 207:8 protocols 93:13; 184:17; 206:1; 207:15; 208:15, 24 prove 30:16; 153:19; 155:5; 170:19, 22; 183:9, 9, 11; 222:11 proven 83:24; 177:4 provide 9: 1; 38:9; 49: 18; 84:3; 92:6; 105:23; 121:12; 135:15; 228:9 provided 7:23; 84:7; 102:6; 104:22; 197:12; 198:14; 216:3 provides 93:13; 105:22; 108:17 providing 101:16; 227:21 proving 166:9 proviso 187: 15 PRSP 107:7 prudent 181:20 public 120:24; 132:5, 7, 18; 142:6, 10; 217:18; 228:6 publication 100:19; 120:18 publicly 66:15 published 13:10; 16:2, 4, 8; 17:8; 43:14; 56:19; 70:2; 101:22; 160:2 pudding 159:15 pull 197:4</p>	<p>pulled 64:23; 126:1; 139:19; 171:22 pump 147:18 purely 106:7 purported 170:18 purposes 59:23; 69: 15; 72:1; 104:6 pursued 176:13 put 16:23; 41:2; 66:20; 73:21; 78:11; 87:1; 100:16; 116:11; 117:9; 136:16, 22; 141:3; 146:19; 155:5; 162:10; 163:11; 173:23; 176:25; 180:13; 185:3; 195:19; 205:15; 209:17; 211:5; 213:25; 220:9; 222:2 puts 118:21 putting 146:17; 148:24; 149:2; 150:6; 214:13; 228:4</p> <p style="text-align: center;">Q</p> <p>quality 94:23; 95:3; 98:13; 105:21; 106:20; 119:6, 12; 121:3; 226:22, 24 quantifiable 141:2 quantitate 140:23 quantitation 151:15; 156:16 quantitative 93:1; 95:21 quantity 106:20 quasi 42:11 quasi-clinical 76:25 quasi-species 164:10 quick 7:6; 28:9 quickly 46:25; 160:22; 195:4; 205:24; 209:17; 214:1; 226:2 quinilone 107:25 quinilones 97:1 quite 15:19; 27:10; 29:14; 31:9; 33:17; 46:5; 57:10; 58:3, 11; 60:14; 85:24; 89:17; 101:25; 106:25; 114:3; 131:13; 137:23; 138:16; 139:24, 24; 141:12; 142:19; 166:17; 176:18; 187:12; 193:2; 203:13 quoted 29:2</p> <p style="text-align: center;">R</p> <p>R 143:19, 21, 23 Radiologic 93:21, 22 raise 73:16; 146:21; 166:22 raised 44:3; 17322; 226:7 raises 76:20, 22 raising 72:8</p>	<p>Ram 4:23 random 194:10 randomization 74:l; 158:9; 181:3; 185:4; 186:12; 193:10; 200:4; 210:8 randomizations 158:6; 219:21 randomize 73:21; 83:4; 158:21; 169:18; 173:14; 199:21; 200:1 randomized 89:12; 159:17, 21; 161:5; 171:17; 191:18 randomizing 73:lo; 191:11 range 12:1; 21:23; 30:17, 21; 51:9; 89:6; 97:9; 139:15; 159:13; 195:25; 208:22; 212:15 rapid 22:3, 12; 133:21; 193:7; 209: 13 rapidly 22:7; 42:3; 46: 13; 55:5; 125:1; 134:14; 194:11; 209:16 rarely 55:8 rate 153:13, 21; 154:1, 2, 12, 12, 25; 164:6, 12, 23; 166:5, 8; 176:11; 188:14 rates 26: 16; 96:19; 151:22, 24; 155:7, 9; 156:1, 10; 165:21; 173:20 rather 6:12; 22:9; 43:9; 74:2; 131:3; 144:16; 203:21; 206:22 ratio 99:20, 21; 118:15; 156:25 rational 111:24 rationale 65:15, 16 rationales 39:19 RCG 176:25; 220:2, 7; 221:8; 227:24 re-analysis 31:1 m-analyzed 16:3 w-analyzing 28:22 re-review 102:9 re-seeding 207:9 reaches 148:5 reaching 60:6 read 6:2; 58:7; 124:25; 201:23 readily 110:2 ready 188:17; 207:20 real 129:20; 158:5; 183:10; 187:6; 206:7, 16; 208:13; 210:3 real-time 123:19; 180:16; 185:10; 205:25; 206:5, 21, 21; 208:8, 13, 23; 210:7, 10, 24 realistic 210:9 reality 183:4 realize 193:6; 194:2 really 15:6, 13, 19; 27:7; 28:25; 37:4, 5, 9; 41:15;</p>
---	--	---	--	--

<p>43:24; 44:24; 45:8; 47:7; 51:6, 12; 59:15; 60:5; 61:10; 62:10, 11, 15; 63:2, 6; 68:9; 74:22; 75:3, 8; 76:18; 77:3; 78:3; 80:1; 82:10; 92:11; 100:11; 101:2, 11; 111:11; 112:4; 120:2; 121:12; 123:3; 124:21; 125:6, 16; 126:18; 127:17; 134:7; 136:4, 17; 137:23; 139:11, 24; 140:3; 141:12; 144:22, 24; 145:5; 146:6; 149:20, 22; 155:18; 159:4; 162:3, 25; 166:9, 18; 168:14; 172:8, 9, 14, 15; 173:1; 174:10; 176:19; 178:12, 12; 181:1; 182:16; 183:8, 8; 184:16; 187:25; 188:2; 189:15; 191:6; 192:7, 15, 18; 195:12, 17, 21; 196:8, 24; 198:7, 24; 199:6, 7, 14; 200:3, 12; 201:6, 8, 14; 203:4, 8, 12, 14; 204:24; 208:9; 210:9; 213:5, 13; 214:2, 5; 216:5; 217:11; 218:15; 219:11; 220:4; 221:24; 222:19, 25; 224:20; 225:16; 226:15; 227:19, 22; 228:5, 6, 15 reappear 46: 14 reappeared 61: 18 reason 37:8; 38:19; 39:7; 59:13; 64:13; 103:1; 146:6; 149:7; 204:17; 206:13; 218:1 reasonable 86:25; 150:5, 22; 175:10; 177:8; 189:20; 190:9; 203:5; 209:10; 221:14 reasonably 161:18; 180:16; 181:22 reasons 37:16, 21; 69:19; 131:10; 164:19; 208:18 rebound 36:12, 13; 54:7; 57:6; 89:4; 207:3 rebounds 47:24 recall 59: 12 recap 194:24; 213:24; 214:9, 12, 25; 227:6 receive 167:23; 178:6; 205:17 received 25: 13; 28: 12 receiving 25:13, 17; 62:21, 21; 204:11 recent 10:1; 16:10; 17:25; 18:19; 20:20; 21:7, 11, 13; 23:20; 26:24; 49:18; 99:4; 100:18; 103:8; 105:10; 106:24; 126:8; 138:12; 216:13 recently 9:22, 25; 10:2; 24:25; 27:20; 31:7; 38:23; 57:2; 65:13, 24; 71:1; 85:12, 18; 92:12; 102:9; 106:3; 135:9; 156:23; 158:25; 225:8, 15, 20 recessed 131:21</p>	<p>recipient 23:24 recipients 24:19 recognize 72:19; 166:20 recognized 22:24 recognizing 124:17; 221:12 recollection 62:3 recombinant 134:13; 139:2 recommend 66:5; 72:3; 85:3 recommendation 66:20; 168:13; 199:14 recommendations 56:19, 20, 22, 25; 66:12; 89:24; 91:3, 6, 10, 14; 193:16; 194:5; 223:5 recommended 57:6; 66:17, 17, 21, 22; 83:6; 96:16; 102:19; 215:14 recommending 65:12; 72:23 recommends 179:5 reconfirmed 171:25 reconvene 90:9, 12 record 4:9; 6:7, 25; 132:10; 195:7; 201:24 record-setting 221:10 recycling 224:14 red 11:18; 140:14 reduce 83:12, 17; 88:7, 9; 181:12 reduced 8:16; 9:16; 10:15, 17, 21; 11:15, 21, 23; 12:1, 3, 6, 16, 22; 13:3; 15:5, 15; 16:21; 18:17; 23:12; 28:10; 30:10, 17; 33:9, 11, 17, 20; 143:24; 144:4, 8; 147:4, 20; 172:9 reducing 83:22; 176:3 reduction 12: 10, 12, 24; 14:7, 8, 16, 20, 24; 15:1; 16:21; 17:17, 19; 20:15; 21:3, 4; 30:6; 35:10; 87:7, 8; 176:12; 190:6 reductions 11:20; 12:20; 15:22; 17:6, 7; 18:14, 23; 19:4; 20:9; 22:22, 25; 26:22; 30:1; 33:24; 34:3 refer 190:22 reference 105:23; 116:4; 159:14; 196:24, 25 referred 93:6; 121:5 referring 188:9 reflection 61:4 refraining 131:8 refuse 114:7 regard 6:6; 74:14; 92:9; 93:19; 94:8; 102:25; 104:4; 113:18; 124:25; 152:14 regarding 124:23; 125:17; 128:1; 201:12; 202:21 regimen 22:8, 11, 16, 17;</p>	<p>34:5; 36:10; 44:20, 22; 45:21; 49:2; 52:21; 53:25; 54:4, 9, 12, 17; 57:4, 5, 7; 74:11; 86:2, 10, 11; 130:2; 151:9; 155:4; 160:6, 19; 164:19, 21, 25; 165:20; 167:12; 170:18; 172:16; 173:15, 17; 175:6; 179:22, 24; 180:23; 181:16; 184:19, 20; 189:8, 10; 190:8; 207:24; 219:22; 224:6; 226:2 regimens 27:19; 28:1; 36:5; 47:24; 52:19; 53:15; 57:5; 58:20; 89:24; 151:23; 155:8; 156:6, 10; 165:7, 10, 23; 179:7, 16; 188:11; 190:11, 15; 191:13, 14; 199:7; 219:8, 12, 14; 223:13 regimenwise 219:16 region 166:1 regional 188:3 registration 69: 15 regulation 112:22 regulations 141:21 regulatory 7:7; 91:1; 92:9; 93:19; 94:3; 101:8; 102:6; 119:22, 25; 120:3, 11, 14; 130:12, 25; 142:13, 14, 15, 18, 21, 23; 143:1; 183:22; 194:15 reinstated 61:19; 62:14 reiterate 71:5; 77:3; 88:8; 120:8; 172:4; 227:25 relate 84:1; 88:2; 95:21; 104:21; 109:15; 149:20; 196:22; 197:5 related 6:10; 36:3, 15; 9:12; 66:12; 88:14, 23; 92:11; 102:14; 109:18; 112:3; 118:11; 119:22 relates 59:1; 61:10; 95:10; 89:9; 94:24; 148:23; 149:21; 195:12; 227:4 relating 121:3 elation 57:24; 59:8, 9; 88:19; 215:25; 224:13 elational 226: 19 relationship 51:19; 92:16; 107:25; 112:8; 113:4; 114:21; 223:21 relationships 213:10 relative 24:18; 36:12; 39:12; 47:16; 49:11; 109:21; 223:9; 224:12 relatively 11:22; 43:5; 58:14, 15; 67:6; 74:21; 156:10; 174:6, 12, 14; 200:24; 225:3 release 15:13 released 130:22 relevance 33:9, 14; 83:3; 93:3; 107:20; 122:20 relevant 21:15; 24:6; 40:9; 48:7; 58:18; 59:23;</p>	<p>64:17, 20; 79:21; 99:4, 6; 103:21; 105:11; 108:1; 119:16; 227:5 reliability 94:9; 123:15 reliable 94:22; 95:9; 97:11; 129:21 reluctant 124:15 rely 211:16 remain 46:12; 47:2; 131:10; 184:23 remainder 79: 1 remained 86:2 remains 54: 13 remember 45:17; 75:9; 215:11 remind 52:20; 67:7 remote 37:2 removed 152:12 repeat 133:16; 134:6 repeatedly 195:15 replicate 57: 19; 65: 18; 136:7 replicates 42:10; 59:21; 135:4 replication 25:15, 20; 35:12; 60:7; 61:11; 135:7 replicative 58:5, 5; 50:24; 61:9; 136:6 report 9:15, 20; 13:7 reported 9:14; 13:5; 14:25; 149:11; 155:23 reporting 102:14 reports 9:21, 24; 10:1, 2 represent 23:1; 26:3; 92:24; 99:2, 5; 105:10 representative 33:1; 05:9; 197:24 representatives 113:24 epresented 99:7 epresents 32:15 eproducibility 94:9; 15:14 eproducible 59:19; 94:22; 95:9; 112:7 eproducibly 10:18 equest 6:18; 187:14; 113:25 equested 126:10 equire 89:17; 106:21; 117:3 equired 43:23; 63:1; 149:22; 197:14 equirement 78:16 equirements 80:20; 211:22 equires 150:10; 161:2 equiring 76:8; 182:8 equisite 109:2 equisitions 188:5 escue 219:23 research 39:18; 54:13; 62:9; 111:18; 121:1;</p>	<p>202:6, 7, 7; 222:3, 3, 17, 17; 227:5 reselect 86:11 reservoir 145:13 reservoirs 224:23, 25; 225:6 resistance 4:5; 7:15, 21; 8:4, 8, 18, 21; 9:2, 10, 19, 25; 10:1; 12:8; 13:6, 9, 10, 13, 14, 16; 14:1, 9, 11, 18, 23; 15:3; 16:5, 9, 17; 17:2, 3, 12, 14; 18:3, 9, 13, 21; 19:2, 14, 20; 20:18; 21:8, 19, 20; 22:2, 6, 14, 24; 26:10; 27:8, 13; 29:7, 19, 22, 24; 30:1, 4, 8, 13; 31:2, 22, 25; 33:19, 21; 34:3, 15, 18, 23; 35:6, 13, 18, 19, 25; 36:11, 16; 37:20, 22, 24; 38:1, 10; 39:9, 16; 40:1, 2, 6, 14, 15, 19, 23; 41:1, 19, 21, 23, 24; 42:4, 17; 45:10, 12; 46:4; 47:7, 16; 48:3, 15; 49:6, 7, 9, 21; 50:20, 22; 52:15; 53:1, 3, 5, 10, 12; 54:4, 5, 8, 15, 22, 23; 55:4, 9, 21, 23, 25; 56:9, 11, 18, 18; 57:1, 3, 15, 24; 58:4; 60:18; 63:3; 64:22; 65:12; 66:10; 67:11; 68:10; 69:10; 70:1; 71:7; 72:13; 73:1, 3, 12; 76:9, 18; 77:5, 8; 79:5, 12, 15, 21; 80:2, 11; 81:4, 5; 83:11; 88:3, 13, 18, 24, 25; 9:8, 22; 90:1, 6, 16, 20; 91:4, 7, 11, 13; 92:3, 13, 23, 25; 96:5; 97:10; 103:2, 7; 107:21, 25; 109:19; 110:25; 115:5; 117:3; 119:22, 24; 120:7, 10, 11, 13, 19, 24; 121:11, 19, 25; 122:9, 11; 123:4, 8, 10, 13, 17, 19, 22, 23; 124:12, 13, 16, 18, 19, 23, 25; 125:15, 18, 21, 25; 126:2, 14, 19, 25; 127:5, 18; 128:7, 23; 129:3, 5, 14, 18, 25; 130:1, 4, 18, 19; 133:3, 6, 8, 10, 9, 22, 25; 134:17; 135:17, 9, 21; 136:19; 137:2; 38:4, 23; 139:18, 21, 23; 40:8; 141:1; 143:3, 13, 7, 21; 144:6, 11, 12; 145:1; 147:6, 8, 16; 148:7, 23; 149:1, 3, 9, 13, 17, 18, 19, 24; 150:1, 2; 152:22; 153:15; 155:22; 157:12, 17, 20, 24; 158:24; 159:9, 19, 24; 160:4; 161:19; 162:2, 8; 163:8, 24; 165:11; 167:9, 13, 25; 172:6, 8, 13; 178:8, 21; 179:6, 11, 13, 16; 180:15, 18, 20, 22; 181:2, 7, 15, 21, 25; 182:11, 16, 20, 21; 183:2, 20; 184:15, 21; 185:4, 12, 13, 15, 21, 24; 186:3, 11, 13; 187:11, 22, 25; 188:11, 21, 25; 189:4; 191:10, 15, 22; 192:11, 23;</p>
--	---	--	---	---

<p>193:13;195:8, lo. 14; 196:7, 22, 25; 198:15, 16, 25; 199:2, 8, 15; 14, 15, 18, 20, 21, 25; 201:8, 13; 202:2; 205:11, 19, 25; 206:5, 6, 9, 25; 208:5; 211:10; 212:4; 213:18, 19, 19; 214:20; 215:3; 216:11; 218:1, 9, 20; 219:21, 24; 220:10, 24; 221:20; 222:4, 11, 14; 223:8, 10, 12, 17; 224:18; 225:13; 228:8 resistance-associated 167:17; 176:20 Resistance/Cross 128:6; 201:12 resistant 6:10; 8:5, 24; 9:8, 13, 21, 23; 10:4, 6, 8, 21:15, 18, 25; 23:5, 15, 16, 18, 23, 23; 24:1, 3, 7; 25:11; 26:16, 18; 28:24; 29:6; 31:20; 35:7, 21, 23; 36:1, 7; 38:4, 11, 17, 25; 39:10; 41:7, 8, 15; 42:9, 12; 46:9, 12; 47:2, 18; 53:11; 54:10; 55:4, 8, 11, 12, 18, 60:25; 61:16; 68:2, 4; 71:17; 73:6, 15; 74:9; 80:7; 82:3, 11; 87:9; 91:9; 92:14; 94:6; 97:6; 98:22; 99:6; 105:11; 106:6, 11, 13, 22; 107:7, 19, 24; 109:9, 11, 11, 13, 20, 23; 109:9, 22, 24; 110:5; 112:19; 117:6, 14, 16, 19; 121:23; 125:1; 126:13; 129:13; 135:3, 6; 136:4; 137:9; 138:9, 21, 21, 24; 139:1, 12; 140:5, 16; 153:1; 159:2; 160:10; 161:25; 167:24; 172:20; 178:7; 179:2; 182:3; 188:5; 196:9; 197:13, 15, 17; 198:2; 204:17; 205:6; 217:16, 21; 218:13, 17; 219:4, 5; 222:9, 24; 225:7 resolve 17:17 resources 43:23 respect 6:13; 7:1; 92:18 respected 113:7 respective 24:10 respector 33:4 respects 112:5 respond 96:7; 108:15; 110:1; 121:20; 129:11; 143:9; 144:16, 17; 150:21; 156:17; 157:7; 164:20 responder 151:22; 155:7; 165:1 response 22:9, 13; 33:8, 4; 52:3; 73:24; 74:11; 10; 96:19; 136:12; 142:9; 151:24; 153:13, 21; 154:1, 2, 12, 12, 22, 25; 155:9; 156:1, 9; 159:16, 17, 23, 24, 25; 160:18; 163:21; 164:5, 23; 165:21; 166:5, 7; 169:12; 170:20;</p>	<p>173:6; 176:4; 178:16; 181:13; 192:24; 197:22; 198:20; 218:25; 224:1; 225:21 responses 26:20; 27:23; 28:3; 33:23; 34:2; 35:11; 49:1; 50:6, 25; 52:3, 8; 56:10; 58:20; 80:13; 154:17; 211:3; 219:17 responsibility 93:19 responsiveness 128:16 rest 83:16; 160:7; 204:13; 224:11 restart 46:24 restarted 208:5 result 10:20; 22:16; 44:12; 56:12; 89:25; 126:22; 135:3, 11; 210:13 resulted 22:18 results 27:15; 36:11; 46:6, 8; 49:6, 7; 59:10; 69:10, 11; 77:19, 20, 22; 84:11, 24; 86:21; 90:1; 94:19, 22; 95:1, 7, 17, 22; 100:2; 112:3, 7, 8, 15; 151:13; 181:22; 186:8; 190:3, 3, 5, 6, 22; 192:5, 20, 23; 193:13; 204:8 resumed 131:21 retain 167:9; 179:1 retrospective 8:1; 28:2; 56:23; 82:25; 168:17; 169:20; 170:6, 11; 175:13; 177:25; 178:3; 218:17 retrospectively 34:11; 50:7; 74:3; 79:1; 198:4; 201:1 retrovirai 70:25 Retrovirus 208:1 return 131:18 revealed 151:12, 13 reversal 37:24; 40:6 reverse 11:17, 24; 12:13; 13:1, 13, 23; 14:9; 15:17; 18:9; 19:16, 22; 20:21; 124:22; 135:12; 148:11; 167:8 revert 85:20 reverted 85:16 review 8:15; 9:1; 10:24; 93:16, 23; 98:8, 10, 10; 103:23; 104:21; 105:23; 106:4; 113:20, 20, 21, 22; 189:24 reviewed 19:7; 93:20; 163:10 reviewing 106:4 reviews 93:13; 98:16 revise 188:17 revised 122:14 RHOADS 5:23, 23; 7:11, 18, 18 Rhonda 5:6; 6:2 Rich 57:9; 60:1; 65:7; 67:2; 74:7; 224:17 Richard 8:25; 34:14</p>	<p>Richard's 88:9 Richman 13:20; 32:4 Richman's 215:18 ridiculously 183:15 right 46:3; 58:24; 71:10; 77:1; 82:22; 88:23; 112:14; 116:1, 7; 122:24; 145:6, 12, 12; 147:11; 148:13; 155:15; 159:11; 162:25; 175:18, 19, 22; 177:25; 180:20; 181:4; 182:1, 10, 17; 193:25; 200:3; 202:19; 209:1, 4; 210:13, 22; 212:23; 213:4; 219:12 rigor 133:17; 189:15 rise 92:12 rising 145:15 risk 11:11; 26:13; 46:1, 1; 80:8 ritonavir 12:18; 50:1, 11, 23; 51:2; 127:23; 128:17; 138:25; 139:20, 22; 140:8, 19 RNA 46:22; 52:6; 62:5; 160:3; 173:6; 185:22; 214:21; 220:12; 223:7 road 170:22; 192:13; 206:22 Robert 4:13 robust 59:14; 170:8 Roger 5:7; 134:21 role 8:3; 81:2; 120:6; 121:11; 170:19; 215:3, 7; 222:24; 223:3; 225:10 Roles 90:16, 19 rollover 151:5, 8, 13, 16; 153:13; 157:20 Room 6:19; 59:12 roughly 18:21 round 21:12; 158:7, 8, 9; 159:21; 161:1, 2; 194:9; 200:2, 4, 5 routinely 58:7; 148:16 Roy 4:19 RT 20:13, 18; 38:23; 40:18; 41:17; 43:10; 45:12; 48:8; 57:18; 61:9; 62:12; 125:10, 12; 148:12; 154:8; 165:19, 19, 25; 212:13; 225:2, 5 RTI 54:4 rug 64:23 rule 40:2; 170:11 rule-based 39:24 run 111:9; 115:7; 158:18; 194:22 running 90:8; 212:11; 213:23 RVA 78:9</p>	<p>safety 98:3; 103:25; 104:25; 105:5; 171:5; 178:25; 207:6, 8 salvage 44:17; 86:22; 121:18; 137:8; 161:2; 162:23, 24; 179:1; 182:6, 7; 183:12; 184:17, 18, 19, 20, 23; 199:6; 207:17; 224:15, 16 salvageability 158:8; 161:4 salvageable 158:11 same 17:8, 13, 15; 18:16; 20:5; 22:11; 28:4; 33:5; 35:25; 38:13; 41:17, 22; 42:7; 44:10, 12, 16; 45:2; 51:23; 54:1; 63:14; 89:16; 98:17; 114:16, 18; 115:12, 22; 116:5, 7, 21, 24; 124:14; 126:25; 133:17; 149:8; 151:19; 152:1, 22; 153:2; 154:7, 20; 155:19, 19; 159:11; 164:16; 171:24; 173:17, 18; 176:15; 186:25; 206:5; 208:10, 20; 209:13, 14; 220:12 sample 15:9; 36:13; 74:19; 78:14, 15, 25; 80:18, 19, 22; 81:13; 82:21; 88:5; 99:7; 138:11; 139:8, 9, 12; 140:8, 9, 18, 24; 141:11, 12; 168:18, 25; 171:17, 19, 25; 207:3; 209:10, 12; 210:17, 19; 212:12; 218:15 sampled 32:19 samples 9:16; 16:18, 19, 20, 23; 29:4, 11; 30:17; 38:24; 137:4, 16, 17, 17; 138:12, 13, 18, 23, 25; 140:20, 24; 141:15; 145:6, 11, 14, 15, 20, 21; 156:23; 169:12, 23; 171:13; 206:8 sampling 8:11; 25:8; 36:9; 54:7; 75:9, 17 San 11:8; 27:11, 18; 218:14, 14 saquinavir 12:17; 50:22; 124:6; 127:5, 19; 138:24; 139:20; 140:8 save 183:15 saw 30:18; 48:18; 49:23; 72:16; 112:21; 145:23; 161:20, 25; 171:15; 222:17; 228:11 saying 29:17; 31:11; 113:15; 164:15; 180:22; 190:19; 194:3 scale 43:24 scenario 142:21; 143:8, 12; 144:3; 146:3, 13; 149:5; 150:18, 21, 22, 23; 152:3; 153:10, 10; 156:14; 158:14; 162:15, 15, 17; 163:3, 4, 17; 166:24, 25; 168:2; 176:17; 178:19, 20; 179:19; 182:13; 184:1; 186:20</p>	<p>scenarios 7:7, 8; 88:23; 91:1; 120:4, 15; 130:12, 25; 142:13, 14, 15, 18; 143:2; 146:25; 152:7, 16; 194:16; 198:21 schedule 132:16 schedules 97:9 schema 50:9 scheme 116:16 School 132:19, 23 science 215:18 scientific 103:9 scientifically 121:14, 15 score 37:10, 11; 51:20; 53:22; 224:6 scores 53:17 Scott 5:4; 9:5; 60:2; 66:25; 81:7; 132:21; 152:5; 186:1 scrap 84:10 screen 66:8; 175:22 screened 165:14; 167:12; 168:14 screening 38:24; 50:9; 57:1; 65:13; 66:5 se 146:4; 189:2; 205:5 second 37:23; 54:17; 57:11; 60:16; 62:19; 64:7; 103:18; 105:2; 106:14, 19; 144:7; 155:6; 157:21; 158:7, 9; 159:21; 161:2; 164:21; 184:20; 196:8; 217:9 secondary 13:22; 14:12; 16:5; 17:3, 14; 18:4, 22; 19:2, 14; 20:2, 3, lo. 13, 19, 25; 29:16, 18, 22, 24; 30:8, 12; 45:13; 139:15; 220:19 Secondly 60:13; 94:23; 96:4; 109:3 secretions 24:14, 17; 25:4; 26:3; 29:8, 10 section 100:16; 102:15; 103:13, 16; 104:6; 110:25; 123:25; 124:1; 151:1; 164:2, 3; 166:16; 167:4; 189:24; 197:17 sections 102:2, 19; 123:24; 143:6, 15 seeing 18:16; 68:4; 70:5; 116:18; 137:3 seeking 109:18 seem 26:23; 32:23; 63:20; 152:11; 182:11; 183:8 seems 84:23; 124:20; 156:14; 165:9; 168:20; 182:5; 204:19 select 32:15, 15; 149:3, 9, 10, 12; 212:23 selected 8:5, 16, 24; 13:15; 14:2; 41:18; 53:12; 80:7, 24; 115:18; 127:19, 21, 23; 128:13; 135:10, 10; 137:18; 145:16, 22;</p>
<p>resistance-associated - selected (20)</p>		<p>S</p>	<p>Saag 200:25 safe 73:14</p>	

<p>164:24; 169:10, 13; 171:17; 205:17 selecting 36:2; 169:11; 181:15 selection 23:18; 24:23; 25:7; 46:4; 65:19; 138:8, 11, 15; 141:13; 143:21; 200:10 selective 22: 1; 86:5; 87:1; 89:7; 148:22 self-evident 22:10 semen 24:22; 55:6, 9, 12 seminal 25:16; 29:4 send 93:14; 204:8, 16, 17; 209:12 sense 33:1; 81:15; 83:1; 84:19; 100:11; 101:15; 146:12; 213:21; 214:5 sensitive 24:1; 66:2; 140:6, 24; 159:3, 11 sensitivity 37:10, 10; 53:17, 22; 64:6 sent 191:18 separated 76:2 separately 40:22 separating 71:8 September 43: 15 sequence 9:17; 13:2; 14:5; 16:18; 19:18; 22:13; 23:6; 24:16; 25:1; 43:8, 10, 20; 75:14; 191:19; 209:8 sequenced 16:19, 20, 24; 19:16; 20:19; 139:3; 148:12 sequences 24:11, 13; 37:2 sequencing 43:16; 44:5; 78:9; 191:18; 209:12 sequential 154: 15; 157:19; 162:7; 165:7; 200:9 series 156:8; 187: 17 seriously 228:7 seroconversion 16:15; 17:10, 10; 18:2; 22:8; 24:12, 19; 25:2, 5; 31:7 seroconverters 11:12, 13; 24:9, 12 serve 137:25 serves 178:18 serving 122:1 session 4:3; 7: 12, 13, 20; 8:14; 9:5; 67:5; 90:13, 15, 19, 23; 91:2; 120:9; 130:10; 131:3; 132:3; 142:12; 159:11 sessions 90:21; 166:20 set 13:12; 57:10; 103:23; 113:25; 115:11; 116:2, 9; 119:13; 120:2; 131:1; 170:5; 185:9; 188:25; 203:4; 206:20; 209:15 sets 114:23 setting 4:5; 9:22, 23; 10:9; 13:3; 15:2; 25:15, 25;</p>	<p>54:16; 65:23; 80:12; 82:23; 83:11; 89:15; 97:17, 24; 98:15, 21; 113:23; 121:6; 169:8, 18, 19; 180:25; 208:14 settings 117:18 seven 28:18; 209:21, 22 several 10:9; 23:17; 37:16; 41:2; 43:4; 45:12, 20; 46:11; 54:2, 25; 55:13, 24; 67:18; 88:19; 89:4, 15; 96:21; 134:5, 24; 160:2; 203:12; 206:24 sex 32:19; 33:3; 70:16 sexual 9:21; 10:7; 23:20, 24; 24: 10 SGL 161:24 share 121:2 Sharilyn 4:21 sheer 204:22 shift 45:24 ship 210:14 shipment 210:17 shiv 162:6 shopping 227:18 short 129:1; 159:24; 161:16 shortened 209:19 shortly 25:5 show 14:12; 18:15; 49:24; 133:19; 136:22; 140:3; 148:14; 154:13; 172:8, 9, 13; 173:4 showed 9:16, 17; 18:22, 24; 19:16; 22:9, 14; 24:24; 29:16, 16; 54:21; 61:17, 23; 62:20; 63:24; 64:24; 65:1; 66:7; 74:7; 129:2; 141:1 showing 11:23; 2621; 27:8; 54:3; 126:1; 154:17; 172:7 shown 10:14, 22; 11:7, 17; 13:13, 23; 14:10, 11; 16:18; 21:21; 22:6, 20; 23:8; 31:21; 47:3; 62:6; 98:15; 103:14; 135:9; 156:22; 157:24; 162:18; 173:8; 193:17 shows 22:11; 45:4, 5; 50:9, 19; 53:21; 54:19, 24; 139:10, 11, 13 sickest 68:22 side 111:6; 175:18; 204:12; 217:23; 221:22; 222:17; 224:10; 228:3 signed 132:8, 11, 17; 136:13; 142:5 significance 15:6; 26:17; 27: 13; 74:20; 117:7; 133:10; 216:23 significant 74:11, 21; 133:8, 21; 151:21; 155:7; 201:3 significantly 209:19 silicon 35:2</p>	<p>similar 51:15; 52:25; 55:14; 82:1, 5; 84:8; 98:17; 112:6; 154:21; 155:25; 173:15 Similarly 12:11; 23:25 simple 62: 15 simply 23:2; 34:1; 78:19; 88:1; 99:16; 153:19 simultaneous 84:25; 85:6; 88: 10 single 9:22, 25; 33:21; 41:22; 75:11; 110:15, 16; 115:15; 129:3; 144:14; 160:5; 167:13, 25; 172:5, 10; 173:2, 12; 175:15; 178:8; 201:4; 215:12 single-step 149:25 Sit 175:18 site 40:20, 24; 41:19, 23; 45:10; 89:11; 96:25; 100:10, 12, 13; 104:8, 15; 107:6; 108:1, 21; 117:25; 125:13; 225:10 site-directed 36:25; 40:8; 177:5; 216:24 sites 105:12; 210:4 situation 40:17; 48:10; 60:21; 61:4; 62:17; 73:11; 76:10; 77:21; 82:2; 112:5; 176:7 situations 41:25; 107:17 six 20:17, 24; 22:19; 31:8; 51:6; 133:12; 134:9; 163:14; 210:15 Sixty 43:18 size 74:19; 122:15; 140:24; 141:12; 146:15; 171:19, 25; 195:13; 217:12 sizes 203:5 skill 89:24 slide 7:8, 9; 12; 10:5, 13, 25; 11:14; 12:14, 25; 13:19; 14:4; 15:7, 24; 19:6; 21:1, 16; 22:4, 20, 21; 23:13; 24:5; 25:10; 26:8; 31:14; 34:21; 35:4, 15; 36:17; 37:7, 15; 38:15; 39:22; 40:11; 42:8; 43:1; 44:2; 45:3, 7, 16, 18, 19; 46:7; 47:11; 48:1, 17, 24; 49:8, 16; 50:8, 16, 24; 51:14, 17, 22, 25; 53:14, 20, 24; 54:6, 18, 23; 55:2, 20; 56:8, 16; 62:6; 92:17; 93:9, 18; 94:7; 95:19; 96:10; 97:14; 100:15; 101:6, 20; 102:24; 104:3; 105:1, 17, 25; 106:18; 107:3, 13; 109:10, 16; 110:6; 117:12; 120:5, 16; 121:10, 24; 122:7; 123:2, 12, 21; 124:9; 125:5, 14, 23; 126:7; 127:3; 128:5, 11, 20; 129:17; 130:9, 24; 136:24; 137:12, 21; 138:10; 139:5; 140:2; 141:5; 143:11, 14, 18;</p>	<p>144:2; 150:25; 151:4; 167:3, 7, 15; 178:23; 179:8, 21; 214:10, 24; 215:8; 216:10; 217:22; 219:1, 9; 220:18; 221:23; 222:15; 224:9; 225:22 slides 14:22; 49:25; 60:3; 107:17; 136:17; 139:8; 213:25 slight 147:22 slightly 16:25; 164:14; 213:24 slope 173:17; 174:13 slow 22:9, 13; 144:11; 149:17, 19; 150:3 slowly 125:21; 199:2 small 15:19; 27:18; 44:24; 74:21; 165:13, 24; 169:25; 183:16; 187:17; 188:7; 200:24; 225:3 smaller 34:6, 9; 117:22; 203:24; 211:23 smarter 221:19 so-called 13:12; 68:10; 112:19 sock 78:6 sole 218:1 solely 102:18 solid 113:14 somebody 73:20, 22; 171:22 somebody's 209:18 somehow 158:21 someone 171:1; 180:4; 185:2 sometimes 31:8; 79:8; 116:15; 128:22, 25; 130:13; 157:20; 204:21; 210:1 Somewhat 24:24; 38:14; 71:14; 124:15; 127:17; 141:17; 152:8; 163:25; 164:2; 178:24; 214:5 somewhere 139:22; 217:13 soon 194:22; 209: 11 sophisticated 46:20; 164:8, 13 sorry 61:22; 118:25 sort 28:12; 29:21; 33:9; 59:5; 72:13; 73:18; 75:15; 76:14, 24, 25; 92:1, 2, 3, 6; 93:24; 94:10, 12, 12, 17; 95:11; 100:25; 101:14, 18; 103:1, 8; 106:1; 107:1; 109:11; 117:8; 119:10; 126:19; 133:3; 138:1; 141:1, 9, 24; 157:23; 161:15; 164:10; 182:1; 184:12; 192:21; 198:6; 208:22; 216:16; 217:19, 19; 220:5, 9; 227:3 sorts 32:6; 69:13; 93:15; 97:16; 98:17; 152:8, 12; 203:11 sought 99:5; 219:5</p>	<p>sound 121:14, 15; 152:6 sounds 71:23 source 23:20, 22; 24:10; 101:11 Spanish 19:19 speak 34:20; 103:6, 17; 114:7; 132:9; 214:15 speaker 9:4; 34: 14; 136:11, 13 speakers 7:23; 227:21; 228:19 speaking 119:2 speaks 109:8; 110:2; 132:13 special 110:14 species 42:12; 63:21; 93:2; 109:6 specific 13:18; 40:3, 10; 43:9; 54:16; 82:10; 94:4; 97:9; 100:12; 102:3, 5, 9; 103:7, 13, 19; 104:8, 15, 18; 106:4; 107:11; 119:14; 130:13; 150:17; 167:1; 177:4, 22; 184:5, 6; 187:14; 191:17; 192:12; 199:9, 13; 215:11; 218:22 specifically 72:12; 86:1; 92:13; 102:3, 13; 103:12; 117:14; 143:16; 156:9; 222:s specification 94:23 specifications 94: 11 specifics 190:18 specified 94:21; 104:8; 107:6, 6; 191:7 specimen 36:12; 40:10; 45:4, 17, 20; 85:14, 22; 86:2, 3 specimens 43:15, 18; 44:25; 83:5; 167:21; 169:10; 177:20, 24; 210:4 spectrum 183:19 speculation 42:20 spelled 109:16 spend 49:4; 113:13; 201:6 spent 63:9 splay 37: 12 spoke 156:23 sponsor 53:9; 69:18; 78:6; 84:14; 100:6; 107:23; 109:17; 126:10; 151:5; 167:11; 168:23; 169:10; 183:4, 13; 184:4; 202:2; 220:16 sponsor's 84:2; 126:12 sponsored 132:24 sponsors 77: 19; 78: 11; 123:5; 128:22; 130:21; 152:9, 12; 197:12; 198:14; 210:6; 211:16; 214:2; 220:9 spot 180:14 stage 68:22; 115:7; 120:2; 134:25</p>
---	---	--	---	---

<p>stages 122:21 standard 57:10; 72:13; 3; 93:13; 94:11, 25; 5:11; 116:21; 117:4; 119:10; 124:20; 134:16; 165:19; 200:8 standardization 93:11, 24; 94:25; 111:19; 115:14; 116:19; 134:4; 141:18, 25; 146:4, 20; 156:5; 158:24; 159:12; 216:8 standardizations 221:11 standardize 146:8; 163:25; 221:16 standardized 56:14; 94:21; 95:6; 98:13; 101:1, 4; 112:2, 3; 114:13; 118:20; 119:4; 134:19; 156:10; 196:21, 21 standardizing 95: 15 standards 111:24; 116:4; 197:14 Stanford 145:13; 154:17; 157:24 STANLEY 4:21, 21; 30:24; 31:13; 77:2, 3; 82:17, 18; 202:22 Stanley's 199:16; 201:24; 203:2 Graph 106:13 Graph 57: 12; 68:4; 72:7; 88:24; 114:25; 120:22; 123:8; 129:21; 144:18; 152:4, 19, 23; 168:5; 174:25; 176:9; 180:12; 191:24; 199:7; 215:2; 226:2 started 22:7; 35:8; 46: 15; 59:12; 90:24; 102:9; 143:10; 214:25; 227:16 starting 66:8; 115:3; 152:13; 153:3; 179:22; 185:6; 189:8 stat 189:24 state 78:20; 79:3; 82: 18; 83: 15; 86:9; 220:4 state-of-the 43:16 state-of-the-art 228:20 stated 84:21; 86:1; 88:8; 100:3; 131:10; 169:22 statement 6:3, 4; 75:20; 132:11; 182:19; 185:19; 199:11; 228:6 statements 6: 17; 79:8; 124:16; 197:17 States 6:14; 11:6; 21:14, 22; 72:20; 128:6 statistical 74:19; 81:15; 7:7 Statistically 74:11; 117:18; 133:21; 151:21; 155:7 statisticians 171:20 status 113:19 stay 67:8; 80:14; 112:17;</p>	<p>171:8; 206:13 steady-state 50:2 step 71:23; 95:18; 116:19; 129:23; 131:13; 142:7; 162:18; 182:6; 184:12; 228:11 steps 93:24 still 34:9; 41:10; 47:17, 24; 53:2; 56:7; 63:17; 71:14, 16; 81:20; 82:21; 102:11; 111:19, 20; 123:14; 127:11; 130:7; 134:3, 15, 25; 160:25; 166:3; 172:19; 189:22; 190:12; 207:7; 218:17; 223:4 stipulating 196:15 stop 56:17; 90:9; 110:6; 114:9; 222:12 stopped 45:21; 46:21 storage 78:22; 168: 18, 25 stored 167:20; 177:20 STOVER 5:6, 6; 6:2, 5 straightforward 152:3; 168:2, 21 strain 26:2; 68:2; 82:3; 84:5; 96:14; 109:4; 188:5 strains 28:24; 71:17; 96:17; 97:7; 103:14, 24; 107:19; 108:9, 11, 12, 12, 13; 109:22, 24, 25; 110:4, 5; 137:9; 143:22, 23; 196:21, 25; 217:14 strategic 89:25; 161:12, 23; 219:21, 25; 224:13 strategically 161:11; 219:24 strategies 22:2; 122:6; 161:7 strategy 46:3; 86:25; 158:11, 12; 213:12 stratification 181:3 stratify 74:3; 169:19 stratifying 73:10; 74:1 Strep 93:5, 7; 106:12; 107:24; 108:23 strict 99:16 striking 140:15, 20 strong 155:25; 156:5; 220:22 strongly 85:3; 221:14 struck 169:9 structured 161:23; 207:16 struggled 133:13 studied 25:17; 36:25; 40:20, 22; 45:5; 50:5; 52:18; 54:20; 58:17; 69:14; 79:13; 128:25; 150:16; 160:19; 161:12; 178:10; 207:11; 225:3 studies 8:2; 10:3, 14; 15:21; 16:8, 12; 21:17; 26:10; 27:11; 29:15; 32:5, 22, 23; 33:5; 52:16; 53:10;</p>	<p>54:2; 55:15, 16; 56:23; 70:11; 71:12; 77:7, 15; 78:12, 18; 82:13; 97:11; 104:13; 107:9; 117:18; 121:3; 125:7; 126:1; 127:1; 130:5; 137:15; 141:20; 143:22; 145:6; 151:3, 25; 154:15, 16, 16; 155:20; 156:1, 4; 157:20; 158:5; 160:14; 162:24; 165:13; 167:6, 10, 19; 169:20; 171:14; 173:4; 174:17; 175:7; 176:22; 177:6, 9; 178:1; 179:15; 182:6, 7; 183:16; 185:4, 8; 186:25; 188:10; 194:10, 11; 200:10; 201:10; 202:9; 206:9, 11, 18; 211:11; 212:24; 216:21; 217:6; 218:17, 20; 222:9, 10, 18; 225:21 study 11:3, 11, 23; 12:9, 11, 21; 15:8, 12, 21; 16:12; 17:8, 25; 18:7, 19; 19:8, 19, 24; 20:16, 20; 22:5; 23:19, 25; 24:8, 24; 26:1; 27:22, 22; 29:2; 31:14, 23; 33:1; 40:21; 43:13; 47:10, 19; 48:19; 49:22; 50:10, 12, 14; 51:5, 11; 53:12; 54:24; 55: 17; 58: 16; 63:15, 24; 64:2, 8, 10; 66:4; 67:22; 79:4, 7; 82:8, 9, 12; 87:10, 12, 17; 88:14; 121:20; 126:22; 127:13; 129:3; 137:16; 141:6; 150:17; 151:6, 9, 13, 16; 153:12, 13, 18; 154:5; 157:5; 158:6, 15; 159:21; 160:5, 12; 161:22; 162:23; 163:1, 6; 164:5, 13; 165:2, 3; 166:22; 167:11; 168:8, 17, 24; 169:1, 16; 171:25; 172:14; 173:1, 14; 174:1; 176:8; 177:17; 178:3, 13; 179:2, 12; 181:3; 185:5, 16, 17; 186:4, 5; 187:13, 21; 188:7, 9, 16, 17; 189:15, 23; 192:14, 21; 193:8, 10; 194:8; 200:24, 24; 201:4; 203:9; 206:13, 19; 207:21; 208:6; 211:7; 226:14 studying 39:19; 71:18; 72:11; 88:17; 218:12 stuff 87:1; 169:24 subgroup 126:13 subgroups 198:5 subject 147:17; 215:6 subjective 117:8 subjects 11:5; 21:5, 6, 9, 10; 23:19; 25:17; 52:8; 201:5 submitted 56:21; 66:13; 105:5; 220: 11 submitting 6:18 suboptimal 48:21 subpopulation 167:1; 226:1</p>	<p>subpopulations 23:5; 197:16; 224:12 subsection 102:20; 105: 19 subsequent 35:12; 127:10, 12; 128:10 subsequently 208:1 subset 19:10; 34:6; 55:10, 11; 73:2; 81:2; 82:6; 169:9; 175:12; 202:13 subsets 75:12; 197:20; 198:18; 202:1 substantial 104:11; 107:8 substantially 16:22 substitute 200:15 substitution 38:1 substitutions 13:5, 8; 30:14 substrates 55:24 substudies 218:4, 4 subtitle 34:24 subtle 25:8; 157:23; 165:10; 173:12 subtype 226:7, 9 subtypes 226:10 succeed 202:17; 222:13 succeeding 206:25 success 51:20; 69:19; 84:12; 202:18; 206:17; 224:7 successes 81:23 successful 81:12; 96:2 successfully 104:19; 107:11 suddenly 205:7; 208:8 suffering 82:11 suffers 127:7 sufficient 91:4, 7; 144:5; 156:21; 167:22; 168:9, 18; 178:5; 195:8 suggest 21:25; 25:23; 52:13; 144:15; 186:24 suggested 42:17; 53:18; 126:23; 127:19; 134:21; 162:20 suggesting 24:22; 25:6; 26:4; 205:21 suggestion 83:22; 192:10 suggestive 154:25 suggests 15:4; 53:7; 88:9 suitable 151:24; 155:10 summarize 21:2; 26:9; 79:10; 88:6; 141:6; 176:18; 187:10 summarized 56:24 summation 214:7, 9 summer 207:14 summer's 42:17 superb 34:12 superimposed 181:18 superiority 166:10</p>	<p>support 44:14; 91:4; 98:3, 15; 102:4; 104:14, 14; 105:3, 5; 106:21; 107:16; 113:22; 122:4; 124:8; 126:21; 128:23; 130:16, 16; 131:15; 144:5, 10, 25; 147:5; 149:16; 151:18; 152:21; 167:23; 178:6; 195:8; 197:14, 16; 211:12 supported 104:11; 107:7 supporting 8:2 supportive 143:6; 203:22, 24 supposedly 156:24; 183:1 suppress 47:25; 59:18 suppressed 189:20; 207:17 suppressing 170:19 suppression 22:18; 25:14, 15, 22 sure 62:22; 64:18; 81:15; 32:7; 153:2; 160:9; 164:4; 172:19; 183:21; 185:12; 188:18; 198:7; 199:9; 218:2 surface 41:12; 42:1 surprised 157: 1 surprisingly 9:24; 12:4 surrogate 122:10 surveillance 121:8, 21; 155:21; 202:24 survey 137:3 Susan 8:23; 9:7; 28:20; 29:13; 66:7; 218:10; 225:16 Susan's 65:24 susceptibilities 74:12; 153:7 susceptibility 8:16; 9:17; 10:15, 18, 21; 11:4, 5, 16, 20, 22, 24; 12:1, 3, 6, 10, 12, 16, 20, 22, 24; 13:3, 17; 14:2, 8, 16, 20, 25; 15:1, 5, 16, 22; 16:21, 24; 17:7, 18, 19; 18:14, 17, 23; 19:4; 20:9, 10, 15; 21:4; 22:22; 23:1, 8, 12; 26:22; 28:4, 10; 29:10; 30:1, 6, 10, 17, 21; 33:17, 20, 24; 34:3; 36:20; 37: 19; 38: 18; 39:25; 51:1; 52:4; 72:6, 23; 74:10; 77:20; 91:19; 92:7, 9, 19; 93:1, 11; 94:3; 95:11, 22; 96:1, 13; 101:5, 9; 102:14, 25; 103:2, 10; 111:17, 24; 112:1, 8; 115:5; 119:13; 122:21; 125:9; 141:8; 143:24; 144:5, 8; 147:5, 9, 21; 149:15; 172:10; 224:5, 6; 225:15, 18 susceptible 33:9; 41:11; 77:23; 81:20; 92:22; 96:14, 20; 98:22; 99:5; 102:22; 103:5, 22; 104:9; 105:11, 16; 106:3; 107:7,</p>
---	---	--	---	---

<p>19; 108:9, 12; 109:4, 21, 25; 110:4; 118:1 suspect 47:9 suspected 22:7; 138:4 suspicion 32:14; 138:7; 145:23 sustained 22:19; 52:9 swamp 114:19 swarm 42:11; 45:14 Swiss 19:24 switch 32:3; 162:20 switched 22:16 Symposium 214:21 symptom 11:12 symptomatic 11:12 system 31:21; 95:4; 210:20 systematically 81:2 systemic 118:8 systems 108:8</p>	<p>tease 130:13 teasing 175: 19 technical 59:13; 118:22; 146:22; 148:9; 215:16; 225:23; 226:4 technically 81:16 techniques 105:21; 112:7; 113:9; 202:16 technological 124:17 technologies 81:14; 87:19; 139:4; 209:16 technology 7:24; 43:25; 63:7; 209:24; 226:8 telling 113:12 tells 79:24; 109:4 temperature 94:17 tend 13:16, 24 tens 137:3 tentative 97:24; 98:1, 6 term 60:18; 136:25; 153:21; 159:24; 161:16; 173:21; 201:20; 223:17 termed 216:16 terms 16:8; 18:16; 28:9; 30:6; 43:22; 83:22; 84:5, 11; 92:15; 95:8; 96:3, 6; 101:4; 102:10; 106:17, 20; 107:15; 114:14, 15, 23; 116:2, 18; 117:24; 119:1, 3; 139:25; 146:5; 152:10; 199:14; 201:21; 208:19; 210:9 terribly 188:23 terrific 57:9 territory 56:7; 154:14 test 11:13; 36:11; 38:13; 49:6; 56:11; 71:11; 72:17; 78:25; 79:1; 80:10, 18; 82:5; 93:11, 25; 94:8, 10, 15, 16, 17, 19; 95:1, 5, 9; 96:14; 100:2; 101:1; 105:20; 149:7; 151:22; 155:8; 163:15; 178:3; 182:20; 185:25; 186:3; 188:21; 189:1; 190:13; 196:25; 197:5; 202:13; 206:6; 217:9; 219:7; 223:8 tested 64:1; 73:6; 87:6; 105:8; 119:16; 152:25; 177:25; 184:1; 195:13; 205:5; 211:18 testing 6:10; 7:15, 21; 8:4, 22; 22:2; 27:15; 34:16, 18, 23; 46:4; 47:7; 54:15; 55:4; 56:18, 18; 57:1, 4; 59:21; 63:3; 66:10; 67:11; 69:10; 71:7, 14; 72:23; 73:3, 8, 8, 13; 75:23; 79:5, 12, 15, 22; 80:2, 12; 81:2, 22; 82:20, 25, 25; 83:2, 11; 84:18, 24; 85:4; 88:14, 18, 24; 89:1, 22; 90:1, 6, 16, 20; 91:14, 19; 92:3, 7, 19; 95:11, 22, 23; 96:13; 101:5; 102:14, 21; 110:13; 111:18, 24, 25; 112:2; 115:12; 116:2; 119:22, 24;</p>	<p>120:7, 10, 12, 13, 25; 121:11, 19, 25; 122:9, 11; 123:8, 10, 14, 19, 22, 23; 126:19; 128:23; 129:5, 14, 18, 25; 130:2, 5; 136:20; 143:3; 156:15; 178:21; 179:6, 11, 13, 16; 180:15, 18, 20, 22; 181:2, 15, 21; 183:20; 184:2, 16, 21; 185:4, 12, 13, 16; 186:11, 13; 187:11, 22; 188:11; 189:4; 190:4; 191:10; 192:8; 196:15; 201:1, 2; 205: 19; 206:1, 5, 6, 25; 208:5, 8, 14; 210:3, 7, 10; 211:25; 212:4, 19; 215:3, 10; 216:23; 218:13, 21; 219:25; 220:24; 221:20; 222:11, 14, 19, 20, 24; 223:3, 17 tests 11:2; 35:18; 37:1; 42:14; 56:9; 58:5; 66:1; 90:3; 92:24; 93:20; 95:2; 112:9; 182:15; 187:5 Texas 4:21 Thanks 27:5; 91:25; 214:12; 228:18 theoretic 65:17 theoretically 25:24 therapeutic 93:3; 96:5; 97:4, 5; 122:12; 224:3, 19 therapies 34:8; 86:22; 175:9; 191:15 therapy 8:12; 25:13; 28:18; 36:4; 44:17; 45:22; 68:7; 69:11; 95:24; 96:2, 7, 7, 9; 108:16; 110:1, 21; 111:12, 21; 125:19; 133:18; 137:8; 151:10; 161:7; 168:11; 170:17; 181:18; 182:9; 191:20, 24; 205:3; 207:1, 3; 217:24; 218:3; 221:13; 224:15 thereby 44:22 therefore 41:14; 125:2; 128:8; 181:16 thinking 52:16; 71:6; 107:15; 192:19; 217:1 third 83:8; 95:8; 97:6; 99:14; 136:13; 142:5; 144:10, 22; 166:25; 180:4; 196:8 third-party 222:11 Thirdly 109:7 Thomas 5:8 thorny 129:8 thoroughly 39:1 though 60:24; 69:1; 77:25; 152:7, 16; 165:13; 173:13; 193:5, 21; 195:19 thought 46:23; 64:25; 66:23; 74:9; 89:18; 116:12; 118:13; 136:21; 150:7; 161:11; 170:7; 175:3; 213:6; 221:24; 222:1 thoughtful 227:20</p>	<p>thoughts 181:2; 203:8; 207:2; 222:2 thousands 137:3, 3 three 14:6, 9, 14; 18:1; 29:4; 41:13; 67:4; 87:5; 96:11; 132:7; 176:1; 185:8; 206:2; 209:5; 210:1; 221:9 threw 217:12 throughout 105:9; 108:4; 122:21 Thus 22:2, 22 times 8:9; 33:13; 48:2; 88:19; 134:5; 145:4; 152:24; 163:15; 184:17; 189:6; 206:24; 208:22; 209:20; 216:13; 224:4 timing 36:9, 12; 54:7; 80:11; 82:23; 85:13, 22; 88:4 tiny 183:8, 14; 187:17 tipranavir 138:3, 8, 19, 20; 139:23; 140:6, 22; 217:19 tissue 96:18, 25; 99:16; 118:17 titled 101:23 Today 8:3; 10:23; 34:20; 41:16; 46:3; 57:24; 67:7; 192:8 together 40:22; 41:2, 18; 45:15; 87:1; 112:23; 122:2; 136:17; 150:7; 176:25; 209:17; 212:8; 214:1, 14; 221:7, 9; 228:1, 4 told 22:19; 47:20; 82:19; 150:19 tolerability 64:20 took 165:15; 171:24; 176:24 top 51:10; 139:10 topic 58:3; 207: 14 torpedoes 192:2 total 42:13; 66:3 totally 161:9 touch 36:14; 92:8; 94:2; 101:7 touched 8:9; 73:19; 194:24; 195:3; 197:9, 25; 198:21; 224:17 tough 131:3; 155:1 tougher 172:12 toward 26:11; 117:15; 221:12 towards 83:2; 228:11, 13 toxic 222: 13 toxicity 64:20 toxicology 98: 11 track 35: 1 tract 97:2 tradeoff 43:7 traditional 220:14 trajectories 223:7 trajectory 160:3; 190:12,</p>	<p>19 transcriptase 11:17, 25; 12:13; 13:1, 14, 23; 14:10; 15:17; 18:10; 19:16, 22; 20:22; 124:22; 135: 12; 148:12; 167:8 transcriptionist 62:8 translate 116:22; 127:17 transmissibility 23:16 Transmission 9:7, 10, 13, 21, 25; 10:3, 6, 7, 8, 10, 10, 15; 21:25; 23:18; 24:7, 15, 23; 25:11, 23; 26:16; 121:23; 222:9 transmit 26:6 transmitted 23:23; 24:2, 3, 20 transmitter 24:22 transportation 194:22 transporter 56:1 treat 183: 1 treatable 93:8 treated 27:14; 29:8; 34:4; 68:20; 96:15; 104:19; 107:11; 117:6; 150:15; 151:8; 154:6; 168:10; 201:16; 204:22 treating 71:6; 92:20; 104:1; 183:13; 188:4 treatment 8:21; 22:16; 23:11; 26:20; 27:16, 19, 25; 28:3; 33:8, 15, 23; 34:2; 35:6, 8, 9; 36:10; 38:13; 46:3, 15; 48:23; 53:6; 54:21; 73:14; 75:14; 85:14; 86:22; 94:5; 97:2, 11; 104:7; 106:5, 22; 107:5; 108:19, 21, 22, 24; 109:3, 8; 121:18; 124:2; 126:8, 11, 17, 22; 127:1; 130:3, 6; 143:19; 153:14; 158:2; 161:23; 167:24; 172:1; 178:7, 14; 180:1, 2; 184:6, 7; 189:3, 12, 13, 17; 191:24; 197:15, 21, 22; 198:2, 19, 20; 199:6; 200:16, 16, 19; 201:3; 203:6, 7; 207:16; 219:5, 17; 223:4, 6, 11, 14; 224:13; 225:21 treatment-experienced 167:21; 179:3; 220:23 Treatment-naive 18:25; 19:9, 19; 21:6, 10; 28:17 treatments 183:3; 192:19 tremendous 62:25; 228:4 tremendously 63: 11 trends 15:20 trial 70:7; 72:18, 24; 73:9, 20; 74:7; 75:11; 76:25; 78:23; 80:4, 6, 9, 12; 82:24; 86:12, 17, 21; 88:12, 12, 25; 89:12, 19, 23; 90:5; 91:15; 102:3, 10; 115:3, 4; 117:20; 121:17;</p>
---	--	---	---	--

T

T215Y 14:24
table 16:11, 19; 125:24; 144:17; 162:5
tables 177:14
tabular 99:10
tackle 195:16; 227:12
tackled 226:23
TAG 207: 13
tailor 206: 11
take-home 63:13, 18
talk 16:11; 28:21; 32:13; 34:24; 57:10; 65:8; 88:9; 90:25; 91:21; 92:2; 94:2; 100:16; 103:6; 116:24; 119:8, 21; 120:13; 136:17; 163:23; 215:18; 221:24; 223:14; 224:10
talked 74:6; 88:19; 90:4; 101:2; 120:19; 145:3; 148:2; 150:12; 152:23; 162:4; 181:7; 186:14; 195:10, 15; 198:24; 216:8, 19; 217:6, 11; 221:11, 25; 223:9, 16, 20; 224:24; 225:11, 23; 226:20
talking 79:18; 91:19; 92:5; 113:5, 13; 119:8; 140:11; 141:21; 147:10; 175:5; 181:24; 195:20, 25; 196:1, 2; 205:4, 5, 10; 211:24
talks 57:10; 93:6
target 72:10; 77:8; 79:23, 23; 95:6; 146:16; 168:24; 180:21; 187:14; 188:1
targeted 80:14; 117:14, 15; 184:6
targets 207:9; 213:4
task 92:4
taught 75:25
TC 10:1

<p>123:9, 20; 128:21; 129:6; 153:10, 10; 161:2; 166:13; 7: 24; 178:21; 180:5, 5; 187:8; 189:1; 193:18; 212:4, 22; 219:25; 221:5; 224:7; 226:14 trial's 226:16 trials 39:19; 54:14; 69:20; 72:21; 75:10; 77:14; 83:11; 85:25; 86:13; 88:22; 90:2, 7; 98:2, 4; 100:6, 9; 104:2; 114:25; 115:7; 117:15; 120:14; 129:19, 25; 130:7; 151:7; 156:9; 166:2; 180:19; 183:8; 184:10; 185:3; 187:6; 199:5; 207:3; 210:7; 212:1; 214:22; 218:5; 219:22; 220:25; 224:16 tried 27:17; 77:17; 177:19; 182:8; 224:19 Trip 54:23; 200:13 triphosphate 48:12 triple 47:24; 54:3; 112:24 trouble 71:8; 191:3 trough 48:6, 21, 21; 49:3; 50:2; 84:6; 223:24 true 126:9; 159:21; 161:1; 162:23; 182:15; 193:20; 194:14; 200:7</p>	<p>133:7, 7; 139:8; 141:1; 146:21; 151:19; 152:22; 156:24; 158:16, 25; 159:8; 161:15, 19, 21; 173:16; 181:25; 190:5; 195:3; 205:14; 210:1; 211:10; 223:18; 228:11 twofold 60:9 type 15:5; 16:24; 23:1, 9; 24:2; 28:25; 32:8; 37:21; 38:2; 39:7, 8; 42:19; 45:25; 49:15; 50:3; 51:2, 3; 61:1; 64:1; 65:20; 71:18; 85:16, 20; 87:7, 8; 91:3, 7, 11; 96:16; 109:15; 123:4; 130:15, 21; 135:8; 144:10; 149:16; 151:17; 154:6, 21, 23; 159:6; 161:22; 167:22; 178:5; 185:15; 195:7, 10, 14; 197:11; 198:13 types 10:23; 67:11; 79:11; 107:15; 145:6, 19; 159:5; 171:8; 201:11; 226:8 typical 22:10; 31:25; 151:13; 152:8 typically 33:13; 190:23 tyrosine 9:18</p>	<p>62:10 uniform 185:20; 186:7 uniformity 59:5; 220:3 uniformly 125:1; 155:23; 187:5; 220:6 unique 6:11; 28:25; 71:15; 76:7, 17; 192:5, 10 uniquely 222:5 United 6:14; 11:6; 21:14, 22; 72:20 units 84:17 University 4:14, 18, 20; 5:1, 3, 5, 8, 10 unknown 15:6; 23:12; 48:4; 128:9 unless 64:25; 77:14; 156:4; 186:24; 191:7; 194:16; 211:9, 14 unlike 71:13 unlikely 16:22; 77:16; 133:16 unmanageable 189:5 unpublished 63:16 unquantifiable 165:8 unreasonable 78:10; 207:8 unrecognized 10:11 unsuppressed 207: 17 untreated 29:23, 25 up 7:9; 19:18; 32:7; 33:20; 43:17; 46:25; 54:21; 57:16; 60:2; 63:9; 71:12, 13; 75:7; 77:1; 78:5; 81:11, 22; 83:5; 85:17; 86:14; 87:9, 15, 15; 88:16; 89:21; 91:1; 100:16, 17; 114:3; 116:2, 9, 13; 127:5; 129:1, 9; 132:8, 9, 11, 17; 136:13; 140:5, 20; 142:5; 148:14; 149:5; 159:8; 163:15; 166:15; 171:2; 177:16; 178:12; 185:9, 11; 189:16; 192:22; 201:7, 20; 203:4; 206:20, 24; 208:6; 209:8, 15; 215:11; 219:17; 220:2; 224:4; 225:11 up-front 73:25; 159:20; 166:13; 169:22; 175:9; 181:2; 182:20; 186:11; 191:22; 192:2; 201:25; 212:25; 219:6, 20 update 56:22 updated 122:15; 130:23 updating 56:20; 228:20 upfront 64:5 upon 7:4; 59:3; 83:3; 177:16; 182:7; 187:13; 197:25; 198:21; 218:8 urinary 97:2 Usage 103:12, 16; 104:6; 151:2; 167:5 Use 7:14, 16, 21; 8:18; 10:10; 12:4; 22:1; 39:5, 20; 47:6, 21; 53:2; 54:15; 59:23; 60:18; 64:5; 68:5, 7; 69:22; 82:4; 84:17; 85:11;</p>	<p>96:24; 97:1; 104:14; 113:17; 116:20; 117:8; 118:17; 119:24; 120:11, 24; 122:18; 123:19; 124:2, 13; 125:16, 19; 126:6; 127:10; 128:21; 129:14, 24; 130:1; 133:13; 162:5, 7; 163:8; 178:20; 179:13; 180:9, 15, 17; 183:20, 21; 184:6; 187:22; 193:9; 196:20; 197:17; 203:17; 206:15; 208:5, 8; 219:24 used 17:4, 13; 19:3; 20:4; 39:24; 47:15; 53:18; 60:22, 22; 62:14; 70:22; 78:4; 84: 15; 92:7; 95: 10, 12, 17; 96:12, 12; 98:1; 116:5; 119:5, 11; 120:13; 123:7, 22; 124:7; 125:15, 20; 126:4; 129:7; 137:18; 139:3; 168:16; 169:14; 191:16; 209:18; 216:2; 221:17 useful 48:8; 67:12; 71:25; 79:12, 15, 22; 83:24; 92:21, 25; 121:12; 124:18; 133:24; 134:3; 135:4, 22; 141:19, 24; 161:17; 163:10; 179:1; 181:11; 183:18; 196:24; 199:24; 211:8 uses 120: 13 using 11:4, 11; 14:5; 15:25; 16:4, 12; 17:4, 15; 18:4; 23:3; 27:15; 32:5; 44:5; 46:20; 49:23; 56:17; 76:12; 88:24; 123:8; 125:7; 129:21; 130:12; 134:19; 138:6; 215:22, 23; 219:23 usual 97:7 usually 96:18; 98:25; 100:10 utility 8:2; 101:12; 141:7, 7; 183:11; 206:7, 12, 16; 208:18; 210:25; 211:13</p>	<p>varies 40: 1 various 69:19; 196:14 vary 58:12; 88:11 venn 161:10 venture 195:19 venue 214:18 verbiest 18:25 verified 204:8 verify 172:6; 205: 11 veronica 20:23 versus 65:1; 71:6; 102:17; 118:11; 126:3; 151:22; 155:8; 158:17; 161:20, 22; 219:3 vertical 10:9 vet 227:9 vetted 214:4 vial 209: 14 VIRADAPT 48: 19 VIRADEP 130:4 viral 10:16; 13:24; 14:3; 22:12, 18; 24:18; 25:3, 18, 20; 26:2; 31:2, 9, 9, 11; 35:12; 36:12, 13; 47:20, 23; 49:1; 51:10; 56:12; 57:5; 58:19; 61:9; 62:11, 16; 66:9; 81:11; 91:9; 114:15; 116:2; 134:13, 23; 135:25; 145:15; 151:14; 172:15; 176:6, 15; 180:11; 187:5; 190:6, 11; 208:7, 8, 20; 209:11, 11; 210:3, 19; 224:12 Viramune 125:2, 3 Virco 18:5; 19:3; 84:16; 134:18; 136:15 virologic 10:18; 11:4; 17:4, 15; 22:9, 13; 25:14, 15, 22; 31:21; 50:6; 52:7; 34:16; 127:11; 129:16; 134:18; 136:6; 145:21; 151:7, 12; 159:16, 17, 24; 160:13, 16; 164:8; 170:20; 178:16; 181:24; 188:22, 24; 189:18 virologically 76:1; 145:24; 219:16 virologist 146:11 Virology 91:24; 121:4; 160:21; 164:13; 203:16 virtual 222:22 virtually 69:22; 71:11; 85:5 virulence 60:11; 61:7, 12 virulent 108:13, 15 virus 6:11; 10:15; 21:15, 19, 19; 23:2, 5, 9, 11, 18, 23, 24; 24:2, 3, 7, 20; 25:11, 16, 20, 23; 26:16, 18, 21, 22; 33:18; 35:7, 23; 36:1, 6; 37:2; 38:7; 41:8, 10; 42:9; 45:24, 25, 25; 46:17, 18; 47:1, 18; 49:11, 15; 50:3; 51:3; 55:6, 8, 11, 12, 18, 22; 57:25; 58:1, 6, 9, 10, 21; 59:1, 4, 18;</p>
<p>U U.S 8:5, 16, 24; 105:9 UC/San 4:16 ugly 209:7 ultra-sensitive 81:19 unanswerable 189:14 unavailable 179:14; 187:23 uncertain 181:10 uncharacterized 38:20 uncharted 56:7 uncontrolled 151:5; 163:6; 166:4; 203:6, 14 under 41:12; 42:1; 64:23; 84:6; 95:10; 128:6; 131:3; 132:14; 158:2; 223:24 underestimate 19:17 undergoing 190:6 undergone 113:21 underrepresentation 141:14 understandable 67:20 undertaking 1 14:4; 204:20 undertook 49:22 underway 70:11; 114:15 undetected 176:8 undoubtedly 48:15 unethical 172:21 unfair 57:21 unfavorable 178:24 unfit 58:14 unfortunate 176:7 unfortunately 17:16;</p>		<p>V VA 5:1, 2 vacuum 141:18 validate 77:7; 84: 14 validated 216:4 validating 200:21 validation 216:2; 221:17 valuable 203:13; 223:7 value 183:3 variability 23:8, 10; 26:12; 32:22; 153:16, 16 variable 69:21; 164:2 variant 24:21; 26:3; 38:4; 39:10, 13; 62:5 variants 8:15; 29:23; 30:15 variation 37:3 varied 12:16; 27:25</p>	<p>trial's - virus (24)</p>	

60:14, 19, 25; 61:18; 64:1;
65:18, 20; 68:16; 73:6;
77:24; 78:9, 10; 80:7; 84:5;
118:18; 125:1; 129:13;
133:14; 135:3, 3, 7, 11, 17;
145:25; 146:16, 19;
147:23; 148:25; 154:6;
160:10; 167:24; 172:20;
173:7; 176:3; 178:7;
179:2; 183:1; 185:15;
196:9; 197:14; 202:17;
207:3; 219:4, 5; 222:10;
224:25
viruses 15:5; 33:10; 39:2;
44:19; 46:22; 53:11, 13;
60:5; 63:10, 15; 116:5;
133:7; 136:1, 4, 7; 139:2;
140:1; 158:1; 170:21;
173:24; 177:22
visit 87:18, 23
vitro 13:6, 9; 56:2; 58:17;
60:4; 77:5; 91:3, 7; 93:20;
96:1, 5; 97:22; 98:25;
102:18; 103:15, 19, 20;
105:2; 106:7, 11, 14;
107:18; 108:9; 109:20;
110:10, 21; 111:1; 127:20;
141:8; 143:16, 21; 144:23;
150:4; 152:23; 153:6;
159:7; 164:2; 174:8;
197:11; 198:13; 199:4, 20,
22; 200:6; 217:4, 5, 6
vivo 13:6; 33:12; 36:4;
42:2; 51:13; 61:4; 109:20;
144:23; 150:5; 162:7;
174:9, 11; 223:22
voting 77:25

W

Wahlberg 23: 19
wait 87:10; 210:22
waiver 6: 17
waivers 6: 15
walk 52:15; 163:11
wants 62:4; 86:4; 111:16,
25; 153:9; 168:23; 195:11
warning 38:9; 123:24;
124:23, 25
warnings 123:25
warranted 138:9
washout 186:16
waste 208:20
wasting 222:12
water 192:3
way 47:2; 62: 15; 70:7;
71:15; 80:17; 81:15; 86:4,
5, 17; 90:24; 94:21;
122:18, 24; 132:24;
133:22; 135:15; 140:4;
146:8, 18; 154:19; 157:23;
158:10; 159:17, 20; 161:5;
164:7; 166:14; 170:4;
173:10; 177:8, 25; 182:12;
185:6; 188:17; 195:13;
197:5; 207:24; 208:9;
209:9; 211:2; 220:4, 6, 7,

12; 221:4, 9, 24
ways 75:25; 108:6; 133:3;
162:10; 178:17; 185:22;
226:24
weak 174:12, 15, 24
wealth 214:17
web 177:16
week 51:7, 7, 15, 19, 23;
52:2; 56:21; 82:9; 151:15;
157:9, 9; 161:22; 169:6;
170:7; 176:11; 220:22
weekly 210:14
weeks 45:20, 23; 50:6,
12, 14; 52:21; 82:12;
85:15; 87:5; 125:10, 25;
129:2; 157:14; 160:1, 9;
161:19; 164:6; 166:8;
173:19; 174:18; 190:25;
192:6; 210:1
Wegner 17:25
weighted 32:23
Weinstock 18:19
welcome 142:22
well-characterized 13:7;
15:2; 152:25; 156:11;
217:10
well-controlled 104:2
weren't 145:11
West 5:2; 32:24
Whereupon 131:20;
228:22
white 13:21; 14:12;
32:20; 66:17; 70:4, 16
whole 48:12; 103:7;
133:5; 138:14; 139:14;
164:6
whose 7:3; 70:4; 113:16
wide 51:9
widely 26:23; 66:15
wider 30:21
widespread 6:12; 12:5;
222:25
wild 15:5; 16:24; 23:1, 9;
24:2; 28:25; 37:21; 38:2;
39:8; 42:19; 45:25; 49:15;
50:3; 51:2, 3; 61:1; 64:1;
65:20; 71:18; 85:16, 20;
87:7, 8; 135:8; 154:6, 21,
23; 159:6; 161:22
willing 76:12; 177:11;
210:22
wise 129:4
wish 7:4; 70:10; 79:1;
132:11; 144:16; 190:7
wishes 142:7
withdraw 89:3
withdrawal 45:24
withdrawing 207:3
withdrawn 62:14
withhold 180:24
within 19:10; 24:21; 34:2;
35:25; 38:7; 45:23; 77:23;
89:6; 97:25; 98:8; 100:6;
102:3; 104:13, 19; 106:1,
15; 110:25; 130:20;

150:24; 192:6; 207:8;
218:4
without 38:25; 54:4;
60:14; 61:1, 1; 131:14;
153:14; 155:21; 163:19;
173:6, 10, 16; 174:16;
179:25; 185:20; 188:8;
189:11, 23
women 24:25; 25:5; 29:8;
204:11
wonder 27:11; 41:25;
61:20; 207:1
wonderful 114:12;
227:21
wondering 81:1; 175:25;
183:14; 204:3
WONG 5:2, 2; 55: 15;
61:14, 15, 23; 62:18; 69:5,
6; 77:10, 12; 111:16, 25;
112:1, 14; 163:19; 170:3,
4; 182:14, 15; 191:4;
192:1; 195:18
WOOLSON 4:13, 13;
75:6, 7
wording 103:13, 20
words 27:14; 113:15;
206:3
work 55:12; 57:18; 63:1,
16; 82:7, 7; 112:20, 23;
116:11; 135:16; 136:2;
137:22; 183:3; 185:14;
187:19; 192:12; 211:4;
213:1; 227:15, 18; 228:13
worked 99:22; 214:6
working 59:12; 82:3, 10;
122:10; 133:12; 206:10;
209:22
works 75:3; 183:5
workshop 42:17; 49:21;
207:13; 227:17; 228:4
world 193:21; 226:11, 12
worried 185:15
worries 62:21, 22
worry 115:24; 149:2
worsening 188:2
worth 162:12; 210:23
wound 215:11
wrestled 201:14; 217:11
wrestling 110:19
write 32:7
written 6:18; 120:23;
191:5
wrong 78:21; 184:4;
212:22

X

X 82:3; 103:20; 145:3;
159:10; 177:22; 178:24;
179:3; 190:4

Y

y 46:18

Yale 5:3
year 15:9; 55:13; 63:9;
86:24; 177:15; 194:13;
206:22; 209:21; 222:23,
23
years 18:1; 32:5; 38:22;
46: 11; 78:4; 92:7; 93: 10;
118:13; 160:14; 161:13;
166:21; 193:22; 218:15;
223:19; 225:14
yellow 14:11; 51:21;
140:13
Yerly 19:24
yesterday 8: 10; 10: 17;
13:20; 23:8; 27:10; 34:23;
44:3; 47:17; 48:19; 49:24;
50:17, 18; 57:23; 70:12;
73:19; 127:14; 227:24
Yesterday's 7:23
YOGEV 4:23, 23; 63:22,
23; 64:23; 65:5; 67:23, 24;
81:25; 82:1; 87:3, 4;
112:16, 17; 118:5, 6;
156:13, 14; 175:16, 17, 24;
192:4; 204:2, 3; 205:4;
213:5
York 218:14

Z

ZDV 174:2
Zerit 126:20
zero 159:3
Zhang 25:17; 26:1
Zhu 24:8; 31:14
zidovudine 150:3; 167:9,
25; 173:8; 174:2; 178:8